var title_f0_13_208="Drug induced exfoliation";
var content_f0_13_208=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F62321&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F62321&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Drug induced exfoliation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 237px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from vaibhav parekh, MD, MBA. Copyright &copy; Vaibhav Parekh, MD, MBA.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_13_208=[""].join("\n");
var outline_f0_13_208=null;
var title_f0_13_209="Triamcinolone: Patient drug information";
var content_f0_13_209=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"11\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Triamcinolone: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <div class=\"block note\" id=\"F12804749\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <p>",
"     Information for this drug is presented separately based upon the following methods of administration:",
"    </p>",
"   </div>",
"   <div class=\"sec_xr rmolist\" id=\"F12804750\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <ul xmlns=\"\">",
"     <li>",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?16/10/16548?source=see_link\">",
"       Triamcinolone (nasal): Patient drug information",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?19/31/19955?source=see_link\">",
"       Triamcinolone (ophthalmic): Patient drug information",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?5/49/5910?source=see_link\">",
"       Triamcinolone (systemic): Patient drug information",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?35/46/36580?source=see_link\">",
"       Triamcinolone (topical): Patient drug information",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11891 Version 25.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-190.111.122.2-74CF0474CE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_13_209=[""].join("\n");
var outline_f0_13_209=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   DRUG INFORMATION",
"   <br/>",
"   [by method of administration]",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?16/10/16548?source=related_link\">",
"      Triamcinolone (nasal): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?19/31/19955?source=related_link\">",
"      Triamcinolone (ophthalmic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?5/49/5910?source=related_link\">",
"      Triamcinolone (systemic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?35/46/36580?source=related_link\">",
"      Triamcinolone (topical): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f0_13_210="Patient information: Gangrene (The Basics)";
var content_f0_13_210=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?0/43/692\">",
"         Patient information: Type 1 diabetes (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?32/44/33475\">",
"         Patient information: Type 2 diabetes (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?42/38/43618\">",
"         Patient information: Foot care in diabetes mellitus (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?40/1/40980\">",
"         Patient information: Preventing complications in diabetes mellitus (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Gangrene (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/gangrene-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H27200634\">",
"      <span class=\"h1\">",
"       What is gangrene?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Gangrene is a condition in which body tissue dies from not getting enough blood. It can cause changes in skin color, numbness or pain, swelling, and other symptoms. Gangrene is a serious condition. It can be life threatening.",
"     </p>",
"     <p>",
"      There are several different types of gangrene:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Dry gangrene &ndash; In this type, the tissue dries up and falls off. It is most common on the ends of the fingers and toes.",
"       </li>",
"       <li>",
"        Wet gangrene &ndash; In this type, the tissue swells up and gets blisters.",
"       </li>",
"       <li>",
"        Gas gangrene &ndash; This type happens when bacteria infect tissue and cause gas bubbles inside it. &nbsp;",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H27200649\">",
"      <span class=\"h1\">",
"       What are the symptoms of gangrene?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Symptoms depend on the type of gangrene.",
"     </p>",
"     <p>",
"      Symptoms of dry gangrene can include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Hard, dry skin and tissue",
"       </li>",
"       <li>",
"        Changes in skin color &ndash; Skin might look pale or very dark",
"       </li>",
"       <li>",
"        Skin that feels cooler than normal &nbsp;",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      It can be easy to tell the tissue with dry gangrene from healthy tissue. The area with dry gangrene looks very different from the healthy tissue.",
"     </p>",
"     <p>",
"      Symptoms of wet gangrene can include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Tissue that looks wet",
"       </li>",
"       <li>",
"        Swelling",
"       </li>",
"       <li>",
"        Blisters",
"       </li>",
"       <li>",
"        Skin that looks dark",
"       </li>",
"       <li>",
"        Bad smell",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Symptoms of gas gangrene can include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Severe pain",
"       </li>",
"       <li>",
"        A numb or heavy feeling in the area",
"       </li>",
"       <li>",
"        Confusion",
"       </li>",
"       <li>",
"        Feeling sick, like with the flu",
"       </li>",
"       <li>",
"        Fever",
"       </li>",
"       <li>",
"        Changes in skin color &ndash; Skin can turn brown, red, or purple.",
"       </li>",
"       <li>",
"        Blisters &ndash; These can look clear or turn red, purple, or blue. &nbsp;",
"       </li>",
"       <li>",
"        Tissue that makes a crackling sound when you press on it",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H27200664\">",
"      <span class=\"h1\">",
"       Should I see a doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;See your doctor or nurse right away if you have a hard, numb area on a finger or toe. If you have diabetes, tell your doctor or nurse if you notice any skin changes on your feet or have a foot wound that does not heal. You might need treatment to prevent gangrene.",
"     </p>",
"     <p>",
"      If you had surgery or an injury, see your doctor or nurse if your pain gets worse in that area, the skin changes color, or you start to feel sick. These could be signs of an infection that could cause gangrene.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H27200679\">",
"      <span class=\"h1\">",
"       Will I need tests?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Maybe. It depends on the type of gangrene and your situation. The doctor or nurse might be able to tell if you have dry or wet gangrene from doing an exam and learning about your symptoms.",
"     </p>",
"     <p>",
"      You might also have the following tests:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Imaging tests, such as a CT scan or MRI &ndash; These tests create pictures of the inside of the body. They can show gas in the tissue. This can be a sign of gas gangrene.",
"       </li>",
"       <li>",
"        Blood tests&ndash; These tests can look for signs of infection. The results can also tell doctors if gangrene or a different condition is causing symptoms.",
"       </li>",
"       <li>",
"        Tests to measure blood flow &ndash; These tests can show doctors where problems are happening in blood vessels and how serious the problems are.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H27200694\">",
"      <span class=\"h1\">",
"       How is gangrene treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Treatments include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Cutting away dead or dying tissue &ndash; This can sometimes keep gangrene from spreading. A doctor or nurse might need to do this every day for a while. &nbsp;",
"       </li>",
"       <li>",
"        A kind of surgery called &ldquo;amputation&rdquo; &ndash; In this surgery, a doctor removes toes, feet, or other body parts that have gangrene.",
"       </li>",
"       <li>",
"        Antibiotics given into a vein through a thin tube (called an &ldquo;IV&rdquo;)",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H27200709\">",
"      <span class=\"h1\">",
"       Can gangrene be prevented?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you have diabetes, you can reduce your chances of getting gangrene by keeping your blood sugar close to normal and taking good care of your feet. Having high blood sugar for a long time can cause nerve damage in your feet. You might not notice a foot injury, and then the injury can get infected. This can cause gangrene. &nbsp;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H27200723\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?0/43/692?source=see_link\">",
"       Patient information: Type 1 diabetes (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?32/44/33475?source=see_link\">",
"       Patient information: Type 2 diabetes (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?42/38/43618?source=see_link\">",
"       Patient information: Foot care in diabetes mellitus (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?40/1/40980?source=see_link\">",
"       Patient information: Preventing complications in diabetes mellitus (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?0/13/210?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 83287 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-61.234.146.186-DE6246C94F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_13_210=[""].join("\n");
var outline_f0_13_210=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27200634\">",
"      What is gangrene?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27200649\">",
"      What are the symptoms of gangrene?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27200664\">",
"      Should I see a doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27200679\">",
"      Will I need tests?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27200694\">",
"      How is gangrene treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27200709\">",
"      Can gangrene be prevented?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27200723\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?42/38/43618?source=related_link\">",
"      Patient information: Foot care in diabetes mellitus (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?40/1/40980?source=related_link\">",
"      Patient information: Preventing complications in diabetes mellitus (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?0/43/692?source=related_link\">",
"      Patient information: Type 1 diabetes (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?32/44/33475?source=related_link\">",
"      Patient information: Type 2 diabetes (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f0_13_211="Triangular fibrocartilage complex";
var content_f0_13_211=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F80101&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F80101&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 555px\">",
"   <div class=\"ttl\">",
"    Triangular fibrocartilage complex",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 535px; height: 444px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Nagle DJ. Arthroscopically assisted triangular fibrocartilage complex d&eacute;bridement and ulnar shortening. In: Operative Techniques in Orthopaedic Surgery, Wiesel SW (Ed), Philadelphia: Lippincott Williams &amp; Wilkins, 2010. Copyright &copy; 2010 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_13_211=[""].join("\n");
var outline_f0_13_211=null;
var title_f0_13_212="RA MTP erosions x-ray";
var content_f0_13_212=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RADIOL%2F85831&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RADIOL%2F85831&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 596px\">",
"   <div class=\"ttl\">",
"    Plain radiograph of metatarsophalangeal joint space narrowing and erosions in rheumatoid arthritis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 576px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The radiograph of the left foot in the AP projection demonstrates an erosion in the periarticular, marginal \"bare\" area of the joint of the 5th&nbsp;MTP joint and more subtle erosions at the 1st, 2nd, 3rd, and 4th MTPs&nbsp;(white arrows), characteristic of rheumatoid arthritis. Also present is joint space narrowing of the 1st and 2nd MTP joints (orange arrows).",
"    <div class=\"footnotes\">",
"     MTP: metatarsophalangeal",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Richard Waite, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_13_212=[""].join("\n");
var outline_f0_13_212=null;
var title_f0_13_213="Ergonovine: Drug information";
var content_f0_13_213=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Ergonovine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?38/51/39731?source=see_link\">",
"    see \"Ergonovine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F13690178\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Ergonovine Maleate Injection",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F166263\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Ergot Derivative",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F166247\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Treatment/prevention of postpartum or postabortion hemorrhage:",
"     </b>",
"     I.M., I.V. (I.V. should be reserved for emergency use only): 0.2 mg, may repeat dose in 2-4 hours if needed, up to maximum of 5 total doses",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F166248\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foccan drugH1Div\" id=\"F13690183\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: Canada",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as maleate: 0.25 mg/mL (1 mL)",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F13690182\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Not available in the U.S.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F166231\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be administered by I.V. or I.M injection. I.V. use should be limited to patients with severe uterine bleeding or other life-threatening emergency situations. I.V. doses should be administered over a period of not &lt;1 minute.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F166269\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Compatibility when admixed: Compatible:",
"     </b>",
"     Amikacin, sodium bicarbonate.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F166230\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prevention and treatment of postpartum and postabortion hemorrhage caused by uterine atony",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F166259\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Diagnostically to identify Prinzmetal's angina",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F166261\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Angina (transient), bradycardia, hypertension, MI, palpitation, shock, thrombophlebitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Dizziness, hallucination, headache, vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Water intoxication",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, diarrhea, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Hematuria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Dyspnea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Allergic reactions, diaphoresis, ergotism",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F166234\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to ergonovine, other ergot preparations, or any component of the formulation; ergot alkaloids are contraindicated with potent inhibitors of CYP3A4 (includes protease inhibitors, azole antifungals, and some macrolide antibiotics); induction of labor, threatened spontaneous abortion, pregnancy, toxemia; hypertension; breast-feeding (if &gt;1 dose is administered)",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F166219\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiac valvular fibrosis: Ergot alkaloids have been associated with fibrotic valve thickening (eg, aortic, mitral, tricuspid); usually associated with long-term, chronic use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ergotism: Ergot alkaloid use may result in ergotism (intense vasoconstriction) resulting in peripheral vascular ischemia and possible gangrene. Ergotism is usually associated with overdosage or prolonged chronic use; do not exceed dosing guidelines and avoid prolonged administration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pleural/retroperitoneal fibrosis: Rare cases of pleural and/or retroperitoneal fibrosis have been reported with prolonged daily use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with cardiovascular disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypocalcemia: Restore uterine responsiveness in calcium-deficient patients who do not respond to ergonovine by I.V. calcium administration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sepsis: Use with caution in patients with sepsis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Vascular disease: Use with caution in patients with obliterative vascular disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CYP3A4 inhibitors: Concomitant use with potent inhibitors of CYP3A4 (includes protease inhibitors, azole antifungals, and some macrolide antibiotics) and ergot alkaloids has been associated with acute ergot toxicity (ergotism); the product labeling for various potent  CYP3A4 inhibitors (eg, ritonavir, clarithromycin, itraconazole) contraindicates concomitant use with ergot derivatives.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use with extreme caution or avoid use in the elderly; due to vasoconstrictive properties and cardiovascular adverse effects associated with ergot alkaloids.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; I.V. administration: Use with extreme caution when administering intravenously; risk of inducing sudden hypertensive and cerebrovascular accidents.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F166257\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F166224\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha-/Beta-Agonists: Ergot Derivatives may enhance the hypertensive effect of Alpha-/Beta-Agonists. Ergot Derivatives may enhance the vasoconstricting effect of Alpha-/Beta-Agonists.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Agonists: Ergot Derivatives may enhance the hypertensive effect of Alpha1-Agonists. Ergot Derivatives may enhance the vasoconstricting effect of Alpha1-Agonists.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotics: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: May enhance the vasoconstricting effect of Ergot Derivatives.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Boceprevir: May increase the serum concentration of Ergonovine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Efavirenz: May increase the serum concentration of Ergonovine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Itraconazole: May increase the serum concentration of Ergonovine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketoconazole (Systemic): May increase the serum concentration of Ergonovine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lorcaserin: May enhance the adverse/toxic effect of Ergot Derivatives. Specifically, use of these drugs together may increase the risk of developing valvular heart disease. Lorcaserin may enhance the serotonergic effect of Ergot Derivatives. This could result in serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Macrolide Antibiotics: May enhance the adverse/toxic effect of Ergot Derivatives. Specifically leading to the development of ergotism.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Azithromycin (Systemic); Fidaxomicin; Spiramycin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoclopramide: Serotonin Modulators may enhance the adverse/toxic effect of Metoclopramide. This may be manifest as symptoms consistent with serotonin syndrome or neuroleptic malignant syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nitroglycerin: Ergot Derivatives may diminish the vasodilatory effect of Nitroglycerin. This is of particular concern in patients being treated for angina. Nitroglycerin may increase the serum concentration of Ergot Derivatives.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Posaconazole: May increase the serum concentration of Ergonovine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protease Inhibitors: May increase the serum concentration of Ergot Derivatives.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin 5-HT1D Receptor Agonists: Ergot Derivatives may enhance the vasoconstricting effect of Serotonin 5-HT1D Receptor Agonists. Serotonin 5-HT1D Receptor Agonists may enhance the vasoconstricting effect of Ergot Derivatives.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin Modulators: May enhance the adverse/toxic effect of other Serotonin Modulators. The development of serotonin syndrome may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: May increase the serum concentration of Ergonovine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Voriconazole: May increase the serum concentration of Ergonovine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F166236\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ergonovine is used in the third stage of labor for the prevention or treatment of postpartum hemorrhage and should not be used prior to delivery of the placenta. Prior to administration, the placenta should be delivered and the possibility of twin pregnancy ruled out. Administration causes hyperstimulation of the uterus and may cause uterine tetany, decreased uteroplacental blood flow, uterine rupture, cervical and perineal lacerations, amniotic fluid embolism, and possible trauma to the infant.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F13690179\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/contraindicated",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F13690180\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May cause ergotism in breast-feeding infants. The manufacturer labeling states that breast-feeding is contraindicated when more than a single dose of ergonovine is administered to the postpartum mother. Administration of a single dose of ergonovine does not preclude a mother from nursing.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F2984497\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Blood pressure, pulse, uterine response; cramping",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F5539854\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Ergometrina maleato (CN);",
"     </li>",
"     <li>",
"      Ergometrine (CL);",
"     </li>",
"     <li>",
"      Ergotab (IN);",
"     </li>",
"     <li>",
"      Ergotrate (BR, MX, PE, PH);",
"     </li>",
"     <li>",
"      Ergovin (TW);",
"     </li>",
"     <li>",
"      Erinmet (IN);",
"     </li>",
"     <li>",
"      Evina (AR);",
"     </li>",
"     <li>",
"      Malergo (DO);",
"     </li>",
"     <li>",
"      Mergon (TW);",
"     </li>",
"     <li>",
"      Metrergina (AR, PY);",
"     </li>",
"     <li>",
"      Mitrotan (GR);",
"     </li>",
"     <li>",
"      Neometrin (PE);",
"     </li>",
"     <li>",
"      UL Ergometrine (PH);",
"     </li>",
"     <li>",
"      Uteronovin (PY)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F166218\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Similar smooth muscle actions as seen with ergotamine; however, it affects primarily uterine smooth muscles producing sustained contractions and thereby shortens the third stage of labor.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F166233\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: I.M.: 2-3 minutes; I.V.: 1 minute",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: I.M.: Uterine effect: 3 hours; I.V.: ~45 minutes",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      de Groot AN, van Dongen PW, Vree TB, et al, &ldquo;Ergot Alkaloids. Current Status and Review of Clinical Pharmacology and Therapeutic Use Compared With Other Oxytocics in Obstetrics and Gynaecology,&rdquo;",
"      <i>",
"       Drugs",
"      </i>",
"      , 1998, 56(4):523-35.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fuster V, Topol EJ, and Nabel EG, eds,",
"      <i>",
"       Atherothrombosis and Coronary Artery Disease",
"      </i>",
"      , 2nd ed, Philadelphia, PA: Lippincott Williams &amp; Wilkens, 2004.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Soriano D, Dulitzki M, Schiff E, et al, &ldquo;A Prospective Cohort Study of Oxytoxin Plus Ergometrine Compared With Oxytocin Alone for Prevention of Postpartum Heamorrhage,&rdquo;",
"      <i>",
"       Br J Obstet Gynaecol",
"      </i>",
"      , 1996, 103(11):1068-73.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9415 Version 31.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.25.216.6-31B8A52DC8-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_13_213=[""].join("\n");
var outline_f0_13_213=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13690178\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166263\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166247\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166248\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13690183\">",
"      Dosage Forms: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13690182\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166231\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166269\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166230\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166259\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166261\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166234\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166219\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166257\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166224\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166236\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13690179\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13690180\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2984497\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5539854\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166218\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166233\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9415\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9415|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?38/51/39731?source=related_link\">",
"      Ergonovine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f0_13_214="Pityriasis tinea amiantacea";
var content_f0_13_214=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F58114&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F58114&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pityriasis (tinea) amiantacea",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Thick accumulation of scales that cement the proximal part of the hair in a healthy 10-year-old girl with pityriasis amiantacea.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Copyright &copy; Bernard Cohen, MD, Dermatlas; file://www.dermatlas.org.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_13_214=[""].join("\n");
var outline_f0_13_214=null;
var title_f0_13_215="Parasternal long axis echo aortic valve vegetations";
var content_f0_13_215=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F62352%7ECARD%2F53904&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F62352%7ECARD%2F53904&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Parasternal long axis echocardiogram showing aortic valve vegetations",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 372px; height: 277px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The parasternal long axis view shows a bulky vegetation (veg) arising from the aortic (Ao) valve; the vegetation is large enough to prolapse into the left ventricular (LV) outflow tract. There is also a left atrial (LA) vegetation (arrows). Both the Ao and LA masses were shown to be bacterial vegetations.",
"    <div class=\"footnotes\">",
"     RVOT: right ventricular outflow tract; MV: mitral valve.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Parasteranl long and short axis echocardiogram views showing aortic valve vegetations in patient with endocarditis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 358px; height: 277px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAEVAWYDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5dlYx7AO2eSOfrURfLZ2in3PAQdscVBVNsSjYk8zkkKMnPPPekU5IHT3plOXqMnAoTYWJSoLv0Kr70MAVB546kHOBSt9/Kk7zxz6+oP8AnrTFOQQuOex9far8yRSo5I3bPfBwcdK1dD0S+8QapBpmmRiS9mLFEllWMMQu4/MxAB4NZLvuH+fy+mMUN/rG3Db1OB29KUttBq5b1Cwn0q+urLUI/KuraQxSoHVsMDyMgkH6jNTaZdXNqrtb3bQFQDs3EbuegHQ9c8+lZwIJ5GeepPapg8Yhwq4cY5JyGqWk9x6nbaV4nvrjejQjeB8xUBlxjuG57HuB+dag1uJpQUsFDE4YiEAt198H6YxXnENysboVU8cH5uOtaVnq1mkRe6gubi5jOIR5uIwPp1B+lYSproJwW52s187Qs8EcqujYVbgqNreyrtJ/E8+9cZfpfXkzyX27eCeCuEUHPQ5wB9KhfXDI5c28RlwFWVyWKjufQn3NULm/urkjzp5HAGApOAB6AdulVCDjqCjY1tI8MX+v6qumaDayXuoHcREjKAyjqwLY4xzz69qxry2lsbqa2uY9ssMhjdG6hhwQajWZ1cMrMG6AgkGm5O7JJznr3zWieuo7M07fWNRXR20tb+8XTSxka285vJZuOdmcE8L1HarGm67qdjptxZWOo3tvZXRPnWyTkRydB8wHGeB27D2rLjZVyRgkfMePpx/n3qeEgOCcDHTHfp/T+VDjHawRu3c0dQ8Waze6NDo17q1/NpdvtEdo8paNQBxgE9uw7VjGdDztJJ6/5/8A1U29AW5cDtgH64Gar1MUorRFPfUtmaJjkhiRzkjJJ+v/AOuozIhOcMD1JHOfwqCiquybIeSpfJB29cZ5o+QjqwP0plFDdwsSMUxwGz700n0ptFFxrQcMngDmjtnHHrQuM80q4AII/GiwXDOCemR3ozjB4+lN70o680rDuWLS3uL24jt7KCS4nkbCRRKWdj6ADk/hS3VtcWNzJbX1vNbXEZw8UqFHU+hBGR1p2mX15pd7DeabczWt5CSY5oXKOhwRwRyOM0uoX93qV9JfancS3d1K26SWZyzOfc9fSjyC7uaega5d6Y4TIeAnHluSDgdcEdK7G38QWt9GJLyCYwg5zcLuGT2GzH4HHP6V5rE6hmZ0DK3AUk/L6EfStvTdWEHkCS5SONHBPlxfM3u3Yn65rKcE9UJq53bXOmRRg29qkZYhmK3DMSccZXHPT6Dt1qtqmqXEKD7EmVfPMUPloSP4TuJ4+hH9azLjWdFa4DRahfFeWwIU3EkcgnHP/wCv2rL1nVNGjuIzpMF3cLjLRXTlUVh6AHn3B9KzjFvcmxkanObp3muEVWVgpXfz7gY4/GqciBEVsF0PCnHQ+n6/nS315JfXRmlWJCeAsSBFA9gK1/D3iPXtK03VNN0a9e3s9Sj2XcWExMuGTBLDI4dhxjrntXRsiumhhOQQMDmul8WeM77xJY2VjLaabYWFmMx29jB5Ue7GNxySc/p7VzHofyxRn0//AFUrXaY7I9Gf4r6i+oeFrmXRNDK+H0aO3iW3IWYMgT9583JGM8Y55rnPHfieTxf4in1i6sbOxkmABhtF2KcE8nrknJyf8nnB2J6dTmnA89sHr+VCgk7i0EOOMD3OOaQfeHAI9M4oLZOSCfxpAeRWoD5AMjAx9f8AP0opmcdOKKTuholuv4eSeoOfWq9XbpGcKFU5UEn6ce9VzC46jB9MiluL0IqfFjzUznGRnFO8mT+7+VPjhkWZMryDnBPvSAlkXC8ALkc4AI9vbr3qJgBkng4xg8npip5AAGJ5XoeMc9fw/wA/St/xR4SuvD+ladqEt/ot5DfpvRbK8WZoz1w68YI9sgfWq5ktGQ/I5ba8mWVDtHUgcf54NOeEqiEsvzE8hgcfl/nmkdt7bm6kc+9JtAQnIBHY5yf0xTbRpyslKRqqh84PIcfxfnSNEFX5WzuHQjGe9EchACl2UZ7HoexxSwWsk0m2NWcHuFzmlp1FciVS2dvJ9j1puevHB561pW9rDsZ5GuEwcKwiyvpycg+nbqaXVILFbuM2l608bjc58raVP04z+ntmp0G5a2ZmHpnnFL06U8jBbaTgdA3U00DBwePUUNNFIQg57596OD60ZGOePXig8f0oQNGz4b0m916/FjpkUbzlGdVlmWJSFGW+ZiB3zULW8treT28ybZYGaKVcg4KkgjP1B6Z6VmqT93IAOM57e9dtp/w+8U3nhb/hJbPS2k0VQWN0JYs4BwTt37uD6D88ZpvfUhaehxl9n7S2c5wOv0FV6musee+3p/PioaQBRRRQAUUUUAFFFFAEsIJc4GQBz1wBnvjtTwjFztO9TySvzHHr61HHuBJTqBnpS/M8uYw2c/KAckelNeRLWozrnJqa3t5ZyPKjLDOCe30zWtdeG9esdIh1qbSdSh0uUKY717ZliYHphumD255qpYapNYl3VUffkHd3+o/rU77FeZLDot89lJdpGhhiba48wBgevTrjjr9Koz28sD+VPE8UmOkqlTj8a14b2SW1mWe4Zbl2DIhTIfOeCc9uMDB6mpmniubdku3UyKuESUkhT3Ykc546d8e9K7W4I53aSMqpxnGcfl+NA9T+J9/84rpdI0a2uRKvmi7DD93DHcCJi3PPzDHSsK9t/s8xjOVw20hiCVx9M5qlJN2ExIpZYt3lPIoYfMQMZ44/nVdz6nPvmrdpELq6iiEkcQdgDJIcKgJxk4zwM9geOg7Va8S6DqHh7UjZ6nAI3Kh43Rg8csZ6OjDIZT2INNaMZkdOtPIG4hskk84pMZzgYB6+1KhA27sEE9OKqwgK4wScdqVUZ1Z1Rii9WAJC0EbV9jnjv6Vo2evatZ6Nd6VaahdQ6beENcW0chEcpGOo9eB+VQ9QTM5RnsM8daVVDHAByemefoKTDLwwIzz060/OcEjoMD2FLUuxGc4zn0wDSLkZ4pzD5j6+w7030wMnr61aJDaxJUDkdaKkbacKSVGBnAzn0PX3oqrN7Boiwp+XIG0fe65zSKQBwcfj0z70E85/i9zyMep9f896NrDgbSOg4/zz+lJB1AEhh1J5IwMZHTFDOuX5UkDqO46cD/P8qktUjluYYZZlgikkVGlYEiNc4LEDsB6e9WvFmmW+kamLWx1e11i3ChkubUMEPtgjIYYGfwpXV7CfYxmdmJyeD2z0HpSk5HT8ab+tAoKSHq20NgKQRjkdPcUwnAx0pe3ekOMDik3coVGZHDocFTkH3rYh1p7eP91FA8jDG54+Y+nCmsYDFAoaXUlrmO90Px6lvax2uo6dDLbBsuUHLjA4IP485Fa11e+HtcWQ6dYW6oo5jddjBvbHOO/6V5b2/wDrU6GV4JVkhdkdTkMpwRWfs1unYh01e6OuufDElxeOttFJbgDd++jYfkADVWTRdQtiiXOnCZnPykdM8nr+PIPoPx0tM+JGpxRRR6pGt+IuI5C5SQD03DqPY12GifEGwuZFjL/2Yu0mTzUWVZCRzyfrn1qHKcd0TeUThG8NR311JDARYXiH95aSjIX/AHWycj/61YuraFqGkziK+hMZYZ3D5hj14r3+1vPD2pSfvYLa8k7PvWNgvX7y9OCOe9ZOv6JBEs82lRmadl+WGJzKsYxwSf6VMa7bsJVGjw6C2klZUghMjsM7RknHv6V0sfhLWJLZSP8AVvzIBIePqOmf8fxHpfg1vD/hqEaj4rhdo87ooEIYyn6+hJwe+K57x18RG1TUsadYLYaZj93b2+A7qFGGY+uMn8R6U/aOeiRV29jj7nwvqNtZGZV35/5Z4w+D3x9MVgq3IKZyO/ceua3dQ8Qz3YVbR54Mg7mL/wAPoB2q3ZeGbjxCZF0NLczW0fmzefdJGGGQARuIBOew5rRSa+MpSt8Ry4zt24GM9CO9BI2kkdemec/X24poIILZHIPP+f8APNGAScMCe/YGtC7hk9Oc9eTn/wDXSMckkLkEdu/+Qf1oPJGCc9iRj6YpWACnIbP3uRge2QeO5/OmjOSuI5IBO3cBznOR1qNnG3K4OP7w560rjChR2UdOrd/8/SmABsABQG49TQ2JJCEgYJyuCcYPf/OKYDk84OfSt3xV4W1rwrc29vr9ibOWeITRjerh0PcFSR+HWsQenp2qb31Ra7svT61qk2mR6ZPqV9Jp0ZDR2rzs0SH1CE4H5VNoOt3OhXM0losU0cq+XJHOm5XXryAcj8DWUeeSD9aOeQcfhS5V0Qb7mlb3ymRovKhgimkG5lydgOeBnPAzXda54dW2kivIrm0ubC5XC3EfyqPVe+TyvUY/WvMz9acwONuSQD26Dmk4t6g0er23ha80yNb2zj3oAWQXKrKknHPpjjuK57W9Ji1GVpFsxp04XiGGJzE59WZmwox6Vzej67faVcLNBIZAq48uUlkx9OlepeFvH+lalpa6Pr1qfmYHzTIVUE5+UgDkf/qrF80NWS09zzG+0vybGKYFFkBKsgJO7BAyPqSR+Fbmiasself2P4gt31Xw4CXV4SPP09z1eEnp/tIflbHY4Yeiaz4UtNWc3ek2kktruAWYoBA3bAA5HXqfUVp23wsuJryN9JlEcioDPEYso5zwD2b6imqw1K54l4n8NT6MILuCZL/RrvP2TUIAfLlwOVIPKOMjcjcjryCCcM4JLc5Ptn07/wCf1r6YTwZqWjW90G0GzvdNv8Ld28TuIWx0LLj5WHO11+Yfjg4qfBTSp7rzraXUJLMsN0ClWntySMJIB17gOOD6A8VXtlbUa1ep4JbwTXVykFtG8sznakcYyWPoB3rsNL8CeIYLm3ubiymt/KcPg/K6Ecg4Poa+iE+HulfDq0Gqzyx2ZRMeUyKJHBzj5+ctzjivPPEHxVmiu3t9PtZUt2GHluiD5g+p7f1rOVVt8sUJt9BfE66r42igi8X620kVsSI5ZLeNGiJ6gbAAfuryeteKa7pc+j6lJbS7iFY7HxjcPUV6GvjSOcLGsFtb27MTMoBCE54Yk9+TwO2faua8aeIk1iGOCPdMkeWWWQjcOmenTpinS5k+VrQSbuclnA54HtycUgwc5/XipXgljiSWWGRIn+47IQrfQ1Fgnp19OoroRdxWJYD5eBwKKUjOcjoemf60VSYnYunoCuOAMEdu+Of8ntUblQuOACM4HPH+fWl9ySAO/b61XkLSv8oIU8gE9fx7mhIqWhZ1G2WHyGiu7e581PMKwliYz6NkDB+mfrVIAZGR1pWTAOCDg4zn9aRcA8j8jVWZKYvPOOcUnOMHj60mc+go7+lS99CrnSaF4Tu9Y8JeJPENvPClvoZtRNEwO+Tz5DGuzjHBHOcfjWzpnwx1fVE8HSadcWs8XiZ5IoHUt/ozxtiQSccbRluM5AOKb8P/ABtp/hzw14m0PWdDl1aw137N5givvspj8h2cYOxs5LD06e9avhj4sN4b8K+IdB07Rl+z3s802mTS3G6TS/NRo32nb858s4z8vOT3qbjPN7+BLa9uII5o7hI5GjWaPOyQAkbl9jjNQL3B7+3+cUd844oA4BHTqKaAcU2EAjr3Bzmm4/8Ar0pBGDnqKQ8etGjDVCVJC3zKMjHoRxVzRNF1PW7wWujafdX9yRny7aJnIHqcdB7nivqb9m74c+GL/wAM6lbeK9M0bUNdtrrzGCXKTyQwuihVcxsQp3LJwefXFNNIlnlngbwnpEugLd3ISS9lwyiW6RUTjJ+QHJ7cHHORXQ3mm3VjaJbeHHa/WX5pIY12L1x2JOMepxW/498efDjwZLd6B4F0m3kuGBSe8jldreJvQAk+Z+HGe+enP23xH0CRLS30eN7bU2z599OuV9Dx2XHOBuriqRknrqYyTucp8QfDOoWlsk+r3FtZylPMjtfOWQuDn+JSV9e4xj6V59ZscsvlPOOp2kkjHfPpj+let64ujaheGGWRNVmYhQbYsQxJAXaTyxzjt+fAq3deF9J0LQHm1q4i015yGjsI2DSsDg7iQeB3x15XuRioVLKzCM7I8QnVvMdpRsDcAKnyg+n4D61KJIVVmwZ5+M704A46D8Paum1/VNJktYbXSbeRlj+/Iw4bjoD39z+IrkHmJzHCvc8LyPTjvXTF83Q0TvuOeZfMYAKD6g/p/Lr6U7k4GOCAu1v/ANWPzoj026adYzGxdhuKgZYD3/z3rUTw/fZZYUWVEGc4IBPpk9/8/QcktGUtN2ZJYg9SSeuBwfrT0AxhTtBGQ2On0HXj/J60jh0lZZMqysQwPUGhjtUKw5OD1wfb+f8AnpTHa4sihQwAbbwducY/+v8A4dM5wl/YXVpDbyXFvJDDcL5kJcYDj1/WrFpA11L9n3bWJyFI2kfj/P8AD0FVNRsns5mRzuAyAaV+hHKkysPVe1bHh3w7qXiIaodIhSUaZYy6jc73VdsEeN7DPU/MOBzWOpBIzxj8q7v4Q+KtI8Maj4iHiJdQNlq2iXOklrFEkkjMpT5sOyjACt364plGCvhXV38NWviCK3MunXV2bCOSNwzefjcEKjkEjnnrVPxJol74c1y90jVFjS/tH8qZY3DgNgZG4cE8/wA69T+G/wAQ/C3gy61qwmsdW1bw9JLb6hpi3EcaTR3kOCrOofaqlsgkEnCjjkgeSalfT6nqN1f3krSXV1K80znqzsSWP5k0EkAXOM8qO/8ASlYAOwXJXnHYkUZOOuT6f5/zzTT6856cVJfQTOVAIHrnHNAYphkJVh0IOKUkEnn39aOCMjqeeKYjY0fxRrWilTp+oXEOOg3kqB0+6cjv6V2Wj/E6a0jiaa1nkuk+YXAu33D1wM4Bx04x7d6824Yfnn/P+f0pDtwBjoTkjOWqJUoS3Qb6n0JbfG63+wtbS2+vRK+RI638LblPHIaM8/lium+Hfxh8MaPrQjXQ0jt3j2/aoSJLnOf42YjcMemB6V8sxTmMr3HrnJA9Kt6aHlvljtBLLOceTt4IbH1wPTPpmoVGMdV0FY+9fEsfhn4kaXFPYXEFzeWDEx5TDjOCyAMO+Ae/QV4x8VptE/sKWbToYYAQV+0NCWkkOOi+q+4X8K5a3i1/QdJS88SeIXs7U48uDYzjr1wCQPwHf0rPm8d6Y8kkmtXb6lbhSsaSBnkY/Un5V9hWLvN8yRDd9DySW7kcKCsaoh3BAo2n6jv/AJ6VXkYyM27lz3HQD8OwxV/Wr+LUdQlnt4BbQ5OyMMcDJz/n6VnNlmLcgHqen1rsiVc0tS8QatqmnWGn6hqNzcWViNttDI+5YRgDCjtwBWdkAZBU57ZphOSegz6dKUZAIbj2xTslsNErYU4+X8Sf85opCwAwpYDrx29qKTKR2N34e0+y0S7Go6jdR60jgW1pHb7oZUO3rJn5TyfyB71gRWpt7mD7ZEHt5uNwOBj2Pb6d69p1fw1PNFY30bQ+XOhEVwP9VJnOY3B6Ej19QPSuJ1jR2sZJI7Bi1nn9/aSKd0XrjP8ACetZRqNmMZ33Oem0qKTTp3jhVoVO5ZlOXXg8Edhx+tc5cLg4C7SM59Ovb/PauysZbayupIZYpFgl+V4SGQ89vr6Y9abeeHzdsZNOaG7iA3EE7XxnPI7fh1z2zxUZ2epV+5xJ44HahTg5FaVxZSLJ86lkB+Z1Unbj1AFUpIWU/KQy+oINa6PYpO5GeMA5zR2NB6UFSAMgjIz9aLW1Kv0E9TQKXGfpRg8E9+cnvSb1BCZ9K3NA1XTNKgle60KDVL4t+6e7nkEMY/65ptLNnPLNj/Z9cTtntXQP4L8Tpqt1pjaFqQ1C2g+0z25t23xxcfOwxwvI5pNDYa14x17V7T7HcXzQ6eDxY2iLbW4/7ZRhVJ9yCfes3S9X1HSku00y+uLRbuIwTiCQp5sZIJVsdRxVtfC2unVbLTF0i8OoXsIuLa3EJLzRkFg6DuCFY59jWO3DEHnHpQFhDw2RgjPHFTRSIf8AW/dByFHrUaRtI4jjG52ICgdzXb+H/h7Pebpdc1Cz0S1Qjc11IN5B7qmfm/Dmk5KPxMmTS3KXh/WdQ0OOQ2KWcUxzieT52UEAbR/LPvWfqWo6hrF0815ctO+7HmFj9AB3xgDH0Ar1/wAM+D/AFo6LPenUbsFgjTPtt5uPbBXHPBqPxRaeGLJm23dpA5J2x2jK2cZ+8x5xj06ZHvWHtYX0WplzK90jxO7aUMYuVwfur04H6V1HgjwfrWtXijTLFnfH33XAX3z26/zrfXVPClkDMd15Oh4JGI2b1x1/p3NX5fixdxWqWdjaLZWXLMqH/WDpg+uPSqdSTVood29kdr4b+HlvpcxfUpreaV8GWXdnB7qT9Qen9BWX4pMdtNJHpXy25X5p9nLZyMIvf/7IVy2o/EP7faiBGbIG04O3OfyOOB/nmqWnag95qYmubgzrHgJGOQDycjsMn19PUCsFGe8ieV9TN1/wjcWmjw60rw+RNMYjb+epnVyerR9eajg8N31poL67dpZvZo/ltEZ185WyBu8vqeXHPTGa7/w7ox13xPA+mCC+vSQCshCjaO244BP459hRqPgaa9vLiSK0ktZoztmDLh4GHZ+M8gj2/WtPa6WY7vY8+s0hnZSYNqK2chtxB6Z9/wAef0qedba9j+zyxE3GcIZEwOvQ+9bceg3ml6lcQzJArMM5J+U88d/9njvz35qLbPDIGaMRBTt8qVgx9sHvx3/lSctbodzkdX0OKKbyoP3VyFLPE5/l7VzzI0chjP3lOMe9el3zLfQmO4tVMXL48zBTjordR2zziuL12ygtiTbhyST82c7gM5yOoxx+R9K2pzvoylIxiAOT6cZ/pQBzjOaXOeCetIo3MOQueM9hWlyrC9yeSO4FHQ8j6joD+FaJ0bUP7MfUI4C9jG4jMyEFdxz07npWfnqMZJ4pX6oLDcnoADR+GcenSlA64H1+lfUnhn4dfD27vfAUl/FBHczaRaNeaYZmDX09zGvlygbs4BEzNjH3V9aq4mfLhI3c4H0H601icnPWvoTwx8PvDXijTrLUILSK0g8PaxdxeIMSHElkgaVHIJ4G1PL4wckn3rw29Uarrd3JpdolvbzTO0NuGysKFiVQEnsMDk0NoDOJyR1yfU/zq7o14bG+WbZG47h+RjNbEXgnWmtTdTQRQW/UPJMgDDuQCeelegfD/RNAEdz9p0Ka5YIMPdMNxOTk7eQFyPvfSspzikDkrHNnUZ9WvW8mKGdDysewMUz25479PbFZmp6Dqd4/720sLJFJLFNqMMeqg8fSvZ9H8O+EtPWeVDbwX8wBEb3gC45+7sDDrnqQeR74yrrw7aXj/wClanYM/CKio0rrk9gAM8+p4rCNaKehHoeGapZx2jokTFhj5mPr9KrwwS3DrHBFJK7cBVUsTxmvfBovw/8ADFxs1OUapq5AbMnEMeT02DggZI+8KuWviLwpphaOxhVpABnbGIgQTnaqckDoOp9zVvEaaIps8Zj8I3HkR5y9y5BZFBCxjvk929q0B4RkihSQLI8YJHzR45+vWvXrzXVlRZ1so1LYk8tG3SSk9N3ZFz049Oa5XxdLrq2/2i+cieQcRIATGOwwPT16dalVZSYuZnl2paG0dwLXT457u5wZHSJC2xe3T8Pzore1fULrQFtl0iS4sbxwxmuY3ZZZM44J7KcA49R9DRW0XNq6KVmfQfhq3WaBbW7MNzoV6eC2Nit03Bh05I4PQ+55wfGvhKW2eaOWK6SeL5rWdUyrp6Ejkgen61H4dtZWi+0QzTsA+6QRDDKRklmHrnIz/jXotrc2niKyayuJk82Bc7sEhvQ46g+prkWj1/r+v63Ob0PnPXrVJohJEY/N4XgkBvY5/wA9OtYiyS2dwhsLkyc5a2JLMMnqOM8/jnAznOK9d8ZaHc2jyXlo0V1ADiW3f52B6kZHJzg4NcFc6JHeMXtlaORRuC8MhHXAOPY/99D0rWEk0XGRSh0bT9ek3SsquxC7oMkp7kDr19yRWZ4m+H2q6TG93ZmLUNOQ5FxaOGdBjq0YOUHuQK15riz067SO/WaBum5X3D1x78nvXSwTWV7ZfatMuIpr0fxLhnVuxI6k01UcH5Du16HiDo0e7Odob5lxgjHrn6kf5GY2Kk/dPU9+3avXtX8Pprmbq4RWuSpzNCnlOCBgFh0Y+hHXFcLqnhS9t1ke1UXMCnG6MfMPqPw7V0xrRloyoz1Oc4G0YBOOTnINDALxkE46j1/z/nvT5Imiba+5So6N1B9qF+XsQuADg5GDVqxakR7HDEFSD3BGMV9X3fxn0W/8aa4I4G/s65tprePWEtpi1xCIm8qDZs3ACWWQ5I7L2FfPGgf8I0txbHUpdQi2t+8MeCPcgf54r2PSta+HkLRvp+u6+12owsKRIAD0/iH+NYzq20sS5NdLkvhnVpJvhTb3B07U38c6TY3Gh6ept3Ba3mZcS7yMKY0MigZz7HINeX3Hwp8S2mnJeXtnBBGwBCPL8/TPQfrz3Fe4weM7P7N5EumX+oRqAPMjd1lxng5GQf0rzn4geN4LtjFYxajYx4K+TdMzDj2Ppz/k1mq05bRJ5nc8+mabRbPFukLsrZMphVvbgkcd+vPpXNXN3LcSvLIcux5JOfwqbUL6W6YmVju4zmqZxgHit0rb7lxRZhvZoVk2MV8wc4PX0GeuKY9wzLk4LE+57dfr75qbStL1DVPtR0y0nuTaQPdzmFS3lRJjdI2OijIyfepdF0LVdde5TRtOu79reIzzC3iL7EHVjjoOafUqxSinkikDxuVcdGXqPpSGeQsXdi5bru5zUQ6U9AWVsdAMmmLQt2UzqTLhWdT1cZHJ6np39/5Vq2N7F5uSv7tsZOcE5PPPbk9//rVgQECVWYEqvJxVqEHcmQFUHA7cjtmlKKYr62Pbvg3JqB8a2E8ap5WQFj45PpyOp7c17+YrPxCGmtYjZ69bKEkEhLHGehIxu6nk4I6+mfljwXczXWt2y6jI0UcePLcfdjPqccGvctN1K9sZbVxJPdSQruJVQXZeTkZ6qcHjrwfavOqXi9v6/r8ejFtoznfGmgXVrdP5lsEfO1/kA2r0652nIA546rx0rhbvR3ctF5u1toK+dGQCB0G8HGPp+lfRttLa+N7KW0uN8F8i9RlS49cHoOT+PNcDr+gXuiTLGT5ikYO8ja2fr0p35VzLYVrHiOpxzwK8F3aTyW0YyJV+YxnqMMvOM9+gzWGttZamr/vRb6gceX8+5ZvbHY4Knqe/QV6zJ4evVu5Jogv2fBVoGGRz6Y7nPoRXO+JPD+m7YwLOd2JICDnPU54+taxmr2BM8k1C0mtrllmhMbckqBwPp14/SoGjdV3YBX1BzXWX/hm6EMU1tIJvO5SPkucc5PHHXOPrWJqFpPYOEvIHjcjKkrhWHftzXTGSkWmZ0MrxSh4pHRhyGU4NLLK8srSTu8kj9Xdskn1OaR1TdkNx1weDQyEDcBhRjJz3NOw7oTjpg11+l6X451BrPV9Ni1yaSyjSC1u0kfdAijCqjZyqgZwBwBXI2081vJut3ZH9VrrLH4geJ4rb7PLqks9uq7QlyxdR6cH6fpUy5lsguafhDSdYln1S1u77V7SC7AF7HBK6efyeJBnDDJYYbuT34K6lqKeFQtrpAs5omGG+1xK0q89CVIz9PWuZ1fxTqmqoEvJt4X7hXjA9PpWJ1yScnPU1PK27yJs3udtZX9nJI0mq6wzxtyVtoshT1xtbAx9Kml1ya4SSG0Yw6eOBJgIfT5gpJGQfp1x0rjdKvZNOu/OhaRDjadoGSOOK3tX8WR3dskNro9jbsmM3JXMzH3bjPr9alw12C3Q56eVvPkMb45PKk8/oDSw3dxD/AKiaWNh/EjEHHpVfJHXOTzSHkDI6cVtvuO49jI7b3ZifUnmpVmmRQEkYYOfvZHvVdec5/SnfjyBj8Kdgvc6rwp4km0693yzxxOzFjM6biqn+6OgPfpXora/Bq1sIrcSQ2wH727GTcSY6ncfuL24B69a8NLZ9Se+T1rX03U7lNlvawq5zgAjd+lY1KV3zILXJfFckcurSCGJo4V+5vGGI9STy31PNFbU/g6+uEWW+mEE7H7hXex9SccDtj1oqoyila4Kx6/4Vu72Ax6pY4N5AAJDDhgyHPLL6Hnn+td+18uoWz6hpsf2K7jQ58sEhiP7vH/jprxfQpxZ3EbQSyQSK3yTxr90YPBx68+3HXjFej6J4i063DJeyeRdSjdIpYmKQ9Bg+vuM59q45qzOdrU1bK7bXEl82zs5L7hZfLfynk46ntkelcb4k0DUbG5jmW1mhTJ2b4sBGz2PQ8/pmr09wH1aO9094kdSNriMq3uQCckj0HfGfUdqdQ+3abJFcSXYkOQd0TCMdhkEfLx35AB/GoTsLzPI76a3vbSaDVdO2Tfd+0R4kUHnBH68Vjv4N00W/2qzufs0uMBhJsWT12kf5711txpDw3bPbQ3EUkedkszblcH/a49hgA8isfUL0xRGK+hjjQnaY5EDR59Seq89sZ961Tlstik77GJNAtnE2Lh2kXLHzGJVTyPlx6Y/PFY0+tW1o2+eQSsrEkDrnufQ//XzXUX/h7TdYtZJLKeeK5ixnac4OeME9s8dT7Z7cLq/hS+RWcP8AaDy20kiQ/gw/lnr2zWlNRe7GrPc1ovGPhuTyzd+G1eTOGYtuJHse1X7bUfhfqJf7boupabNjAaKQum7PUqO3TivM5IzGcMpQjn5hj+eKb0xk8jjB7f4fStvZdpM0su35noV2nw6imiezn1CeLALYiZSMZ654J/z2psnijQ7ecGytJJUX+CVRhfU8DJrgABvKkDH1yQf6/wCfSmMfRj9e+eoPt+HvT9lfdsVvmeuN49unhjOmatbWaoBmCMrE230DHv8AXpXM+Jrm41VFuDp+pyscHzmkD7++Tj145rj7GRoblJFERdGBAkUMnPqDxiu2s9Y1fUtkaS2VphQn+i2iRse2DjH198cisnTVN3QuW1mjg754yVEdusJUYbDMcnpnmqxxjA9e9dFr2nSQTs9wAjMSCX3ZY9hkjt0/DtWK9uUZfmVgcfNn5cV0LVXLTO/+COtaLo9/4rg8Q6oumW+reHrvTIrhoJJQsspQLlY1J6Anp2rtPhp4y8HfC6znW11q51u+vNRiaaewt3hX7LGgIVhMgJVmkcEDk7B7V4M6ggldxx144A+tJjPQj05NFhpm143i0iLxdq6+GroXWim4d7OURsn7onKrhgCMZ28gdKw/xp4RmcoB8wOMVcgtmXcfJaTB5ZgQEx/9ajbcd0RWsXzYlIVRxz9eRV1ZFaHyYlJB5yOCv1z61NY6bc6lJ5drCJGyFGzj/wDVx/8AX6V1cfhn+ybYS67NBFzkQKxzj346c8jv7ZqJTS3FdIk8FXHk31s0u6G0jYbpAu4fX2A9a9Z0qa3jkG55fKySLq3+YxkY+8ncdP1rzbTtXitJp2VJjbGEpIIyAAh69uB3z1PrXQWd3JYyR3umzs9i2AJAqjYM8hjkgjOOvr2Ga46iuzN7npNs1/BqFtN9uhaLOYn3bHByefx9/evRrEf2hbNY6nsmlxgeeo+f64rzXSdY0fUoBaarmCZ22eaEBV+wD9Sp4HzD26c1ftbk6beQ2jXUFzDEw8t2kKzw57K2CCPqM1ipcr5v6/r0KjotTa8Q+HrLyXiRvst1Gp8sqcYA/mOo/wD1V5P4gtLnR5JFvJZfncMoI3NjkqeO/Tgete66Trttqb/Yp2Dz7TmKRQQ/fP0468VjeKPBCTn7RpTwxKTue3kTKE4b7hGCrZ/AZ7dDpZSXNEco9Tw+MyiQXJuMwn52dwBGrHnBA5BqPWTPfoYtR06G8Vh8lzFyBjng9M10viTwza28KOEeKRV4EuSjcdccuM9evH0Oa44JqEFw0lmslr/CGZ28nHoCTjB96ce6JPPtY8OGImSxSSSEfKSASF4P+f8A9dYhs0ER3iVXxlQ2FH5Hr/n8PdZdQv4rNQyo8hwwIYxxoADwirx3565Jz71astbtjfma+023kndSC9/arcZ5ySN2Tnjr/wDXrZV2lqhp9z59ezkTJeBtmTltpAH0PpV7w/eGzudqWdlcGTtPAZfrgdele538vhZ3Laj4SszIxyDbsIB075AUAfXisE+G/DtyJJLe3toT02rcrJx/wAnPYYBxT9umtR3PLvFEe6QS/Ylty2c7ITEnU9AenTpWAD+Neu3ngi1urFntNQimZD8yRRONpPqGHsOD/LmvLtV02bTrh45CrgHllzj9QD+lawmpLQa7FPjOeopdvQ54+lNJ47U8E8DAyPWqKsdDrfhW70jwf4a8Qz3EL22u/avJiTO+PyJAjbuMck5GCa1PEnw11jQPAej+KruS1e01EoPIjJ82AOpaMyDGAGUZH1FX18eaHe/D7QPDWu+F7i9m0Vbpba8h1QwczybyTH5TZwdoxnnB9eNbxJ8Z5PEOl+JdKvvDlgml6pFHHbRwMI5LRoiPJJfZ+82gYxhcjPQUIm1jyQggdMDHekYEZBGCPU807PBOevYDH4U9twGSBgnGT34/wqlLQLakTDOPTt2rX8OtLHdI9lzdlgo43EKepA/rVGC58kHYTuzkfKpx+ftWr4ftZLqdjaCQsTjrz6kk9KmT0GbPiK/uI7OM3V2VkaQZWHOWwvVj7dKK7rStD0Gwt/N1W1Ou3cmAqJIoiiTHXlhyeO57+vJXL7aMNCLRe5k6DcqN4gjETgjGeh4AyMHpwOOn9Oqiee5j2wyLFKMF4AoZZD0ztPXPtivN9AkuLZ3kt5Aqo5AEmGUnJGDjpnrj3rqodUVkEREhmUZ2luB9COlOUbMylHU7bSpI5k+xXFokig7TDEPLnTp93PX6Gt7SNetbS5FhKvmRLyrAmKUA4xkDgkdj7/nyOmazaT20aajp8yztyjsCNw749zjr6UaizXqRKsc0jZP7p2yyDI5Vv97JA9QRWLjfT+v6/qwloesX+q6HPbrvu4jIBtHnIvmMSPlxjKt+JFcLrvhu41LNyITNHjJnb5CPTkDB5/wrmDp2oRyxwzNeNa9laHfGvPHv6dK3dIuV0e5jj1BWdHf/AFkW/v0+U8ZHpSfNHUej2OJn0y6t0la3n81EOAI5T+QPbuD6Y4ANQ2urQ3ObeeIuittcux3NgeoBwB0xn09cV7DJ4PsfEcz3Gha9ZRzMvzW7xCNgehZsc56f5FczrHwh11XmltbcuWXDtbSrzzngH3z+VaRtLYNeqOLe28LSxTb7G5imJ6QkSKBnupGf8ao2XhnQbxZtkMiKOh3H5Rz0GOf8+oq6/g7xDaSOZLHUHnUkFpLdg4/EcVWm0+7s4d0tvc2ZIy0gjYsT3z7dvxqrSXUatfc56/8ABcyzoulssynG0zfLn8+PU1f0bwtKL0LqttaTSA8x+UpVvoUcdfXH5V1llf30FuJtP8y5iGdzsFPP8QKn/PSrEmr3V7NtvraWBn+4Ut4w3TgjHOcfpih1ZNBzS2MbUvBmiSwq88FnZHnC2ruC3HozN/Uk8Gjw54VazAlkkmjtzjYBGNz+n54I6/0x2+h+Fxb3Av5rqSMuQcS2vnlsjgegro/7H1LUPK/syzvniOCHuIFMR5HbsODWftJPRahrszzfxbBazwmM2jQMgYZnd2Y8+gYj+ma8u1fR2t2k2xfuc8TGPoPdh/8AXr6VuPh3r8sIEVvpqScA+agVTwBkHrzj9aqW3wukt3H9qa7o6s2R9m8ky7fYHINXCfIrPT8AimtT5bksZlVW8lxGfmBI44OOn+NRLatlQsRJzgfITk8/gRwa+rx4N8IwQhZTJqN6gwqqoiQgddo+gxzznHpWDeeG4syLBoU6QI3yy3XyqoPbj5cela/WV0KcraNHzrb6deSuUiglbjLcE4HrXaaP4Rj8pLjV7jKdfLjX5mGM45wBjHY165pPhhsFUgtrdz0EKZz7AtxgYqzP4QsrC0+0aoqNNnO6aYKV742r97jnPSs5Yi+2guZ9DhdH026hctounGBy2FIUySYzkDA6Hp+PcYzVHWNJubW5aTWRNHORnJIZ1xnIx/CAf/rYrrrm7vLazmj0uYxJj55iPLUnJ/Pr35/I1w1xZatNMwt4XupJmyJJATk5/MHNTFt6giO1kR5ubBZUxuPHr3HqfcfrWpbLaWX723N1bbs8lGZDkEbTkc+5BB+vFS614N8QaV4YudX1C1WJ4F3mHzf3ir3bA6LXNad4tltwoV96Ekld2THzzjPUdDVWbWg7XOsa6jaPfY4jdD8sZYFG9fLIwVBHY/TnvBHr9yLkm5KeWOQJBv2H0cDk+nPtWFDe22qTFoY1WbkFUby2GcEEevU8expt1dNG/wDp8SMpI/f/AHGA9M9B9DU8oJNHcaX4ito7nzo4LlXXGYo5tisR6AY7kcNnjP1Hr3g7x1bXFqn2y5wMAFDEV6nr6AYHPHYmvmlisUaSQlfLJBEYPUH0I7Gun8K6nK7bYFiklQf6sD5h64JPB/wqHFxfNEq9tT6gvbK01i1A8tX8weYrSRqcgn72CMHPPX1rzvxJ4IvEiLRQIEVyQ8L5CDH90g4J9sfh1rl9J8ZXlsv2cTTaZDnb5is0hYj1LfKPw/CvT/D+uapPbW4ml0/Ud4BLRzeXJ046cGn7ROymtS1ZnhWpaXPFO+ySVFBK/aJAVY84yMcrzg89wPSoPM/0UtqN/qayDjEkgdCf4jznpzyOn419KS2tnqD7bnT2hlHJEkY5zgHno3PH61z178OdHuixaOItgDzY4VDE47D7vXNVyPoTyPoeBXK3M8CbW2wJgxuFOfTkjj6/zrEkurpQz/aMzLyAFUIOuc8frxXvUnwvaOSb7LeSqnRFaKMq2fUf1rAufhXJFKJoJGc55DW5cZHqOgos1o0HLZnnGl+H7nWB5l1fQgY7efJ16jCdSeQc8dPU55Lxf4Kn06WWRXYR4H3beUA/iw6V9JaB4O1CztzHDftb5OAot3VVHPOPzH4+tY2ufDXxRqLuIZ7WeBuf3zFPbjFOEpKWwWZ8mNbHzMZwmcZ6/QUwRMxOznHOP8/56175q/wA1uIPKssES9Tly65PpjnNcnqfwn1izV5DcxTYI3AxvHng889e9dPtF1HdI8tIJH65zQoZuB/hXaz+DbqI+UkM01zgHy1Q8jvz/nt6Uth4N1a9uRa22l3krfxokZyh7bj/AFquePQOY4yIDcwPA246Z/LNTyQsGAcO2zgK3YccZ9P5V7j4Z+CN9dzr/b+p22lMSf8AR4wJrjGM9Blcc9+1ewaL8LPDnh20RdK0ZbzUE4F3ffMVPTdjt647fL61DrLoM+R9D8LalrE6/Z7No4GGRJIu1dvqM/eH05r0DR9Gg0n/AEcQXF46gAiO0AJb/e5yPcnHtXvN54Zvrcm81ER3U5/1cMeAoA6DjhT7iuX12DUovN/erpsY/wBXBbESydOcBev9K5qlVvRoTTZ5v58/k/Z/sKWkKENtwpZiR1yAQf59OetFWbbw3d61NN9ijlKIcktKTk+7evI4HrRRyxlqyNP6/wCHPM4dYaGaVSjPbhzu2gbSM8Ejsw9T6n2rqNJ07TNRSN9I1E/bxz9nuG8sH1UE4/KuCIUldyqzfmP88/1+on7v5kBC8EY69f8AH1rrcL6obV9j1y1l1S1BiklaAqNz291HuTHY56j1z0/Oul0ppbOOO4nKPb7juKfvI8DjIxyv48Z55xXiMeuamixr9snKxn5RkMQe/wDnpU1v4l1mzlZ7bUJYpG4ONvpjuO1YSoS6W/r5E8h77qmrme1KW91DJGf4ZGDbG9j8pB6/w8Vi65NdLpeZ79mTcFjMTCTaDweoPPuRmvGD4h1MFwt5IN2f4VyeenQf0qMa3qQJP2uZflwcEAc+uAB0qVQa7CcPM950GWSWwCPDDfRtgkq4jdTnu2Qd2SODXaaVdyzxxql3qemopOzD7oyeSRjGT34J7nNfK6eItTWFIFvmCq2QAFB65POM9fXvitKHx54hWBIk1OURj+DapB9vu89uP/r1MsNJ7WK5bH1RqXjLW9HZdpgvbVU4lmAhD+hzk8+xx+FT6Z46j1YuZdNgiuo8Bhs83OfQ8fl9a+Vbr4j+JDaGCTUEZOpXyIuT6n5fT/61afhTx1dp8lxPAsjj5RLGuzPbBxlT6dfXHApSpVUr3/Fh7yPo1b/wpqySLqfh0xPnBkjtXVDxjIKc+vvgCsWODwbb6qyaba30vOfLhgk3J77nzx7Z/SuEsfFV1aRTS2OrSWjyYYghWAIGOSAOMDvnr7cvXxrrF3Luu/EWnynnaJbOO4GemeQOP15rNqTvf9P8hXPTNQ8Y2+g2Yis4njfGP9PjCtnryfp69q4XWPirq7TAR3kCjLfJGcDAxnO3J/p35rm9X8QG6fN/c29yEAZmggWFGyPTsO3SvPtY8SRxPu0nzIGGCNsjYz7fTn9KuFJy0eoK7PatJ8W3V1qCHW7h/s75RllDEdSTwvzc+3H5ceijW7MWUUNrp08u/wC7FPbsuR/ssRu/Svkyy8aatHAPntnK4/1kCuT0HX1+vfp7dRa/FzxLDam3P9kzxcEedZq564654/HHNL2EofCv6+ZdmfT9ul7fIiQ2UNpCerXce1hx0GcHHPp7Z5xU91Np0FuRd3ljcTqMFW+ZAT2K5wOvc85r5/tPjlqH9g3C6ggm1Xd/o+yBI4UXIwxIyS3LcdD0461mxfFT7ZoepLr0dxJqpG6xks0SOFWxjc43c/x+o9utChLon8/+AKzseqa3rFrdRoY7hZmHyBrfKoi9PkzhR9N7GucuNf0K3xHaWqXep8gvcM0mz1wvGPoCR1NcNrfjbw5J4NtU0y0v18WbVF3NOB5Ep6t8u4j6YXjv61wf/CS329mUxSdQCVOR+R/D1pxoyav/AF+IWZ7VZzWd1cRS65ew246iJVHmMcZACD5QcE8nceatSeJrOC9J0yGQkDG/OCCO545P0xjvXiNn4tv7OOT7LDZxu2MSiM71x6Hd79OnQd8HPl1y8LtOzYJIJK5yT+n+fY1XsG2Ll1PX/irr3n+CZjH5izPKkTuzEttYcoTnoe4/lXhgeOVc5WOTnK4+UD/D+ta+r+Ibu/s1tLmK3MWd2UVgR6kDO0Z9QP8AGsTygVP3ucfMR7+vPOCD/nnopU+SNmOKaRctr2RXXYgyDuCjjB9jnPTPWtT+23dAsys6gYDHG5R6H+E/X+tc+sIzgMwPJbrjI/mf0pxyWB87Pc5bBI+v+PNU4RZWj3Ogt9TgJCuRGD8o+XCueckkcfl+daltqFohCxJDGy42EbvlHufx68de+a45HYgSB2V85LDGeOv1IHtVm2upbZ90ZUvjguBgHPU4xnvz6GolTEz1ew1vUEMUdxqKyMDkQ3MJ2g4+7nuP/riu98P3hSdZmtJba5KfvJLUtGF9MkgJ+AP1rwHT/E97Z5CpE8JODDjap9QQAAfyrqtP+JptWjDaBYPHGAUh86RY89jsBIz74zXPOjJ6JAk1qfUdpfztbxm2uxO7jAV5AzEjucDOeoyOP0q3LcRhc3EUs06dRBKpJ5/uKc+o/Cvms/GrU5LiKafSrOWJSQqGZgD1wCe/U+v0+8C/U/jhcTyM50OziLcgRXDJ68kAfN269x71KhU2UfyLufS8WomUqsNq/IJPmnYR7beufwq7KjOqrKv3h90gn/DpxXytofxDW/uxcLbxxXDfM6+azgZ6Aq/B/DNd5afErUNPtTDZxaY5PQE7C3XoOgPT2HpTU5J2nH8h8/c9W1WV4GzFp0Fxjhs3hhPtjJx6nH9a878V+JL2GCVbS/mhYfK6W+o72TnAyrQD/wBCrndW8aa9q67NRhjgtSTjFwCq9uVwD7dSPzyOFmvdsdxP9pdF/wCWhgjDAHPr0Uj1zU2cn2Jc77Fi88U6lZX26HV7qWZXOBJOwx/wHgD6/wBK7Twr47u7+ZU1CVLZiMqzr9pzyAQAScZOO3t614NqOry+YZFaeQk489k27h6Hjn16/lWjonig6a+9ILhmxlttwFPI9l+X6DpnjrzpKhpdL9ATZ9XQ6rpTotveWuoCJvmCSW6Q9B1U5BB579u3rdsLLSbidZIbW/ZJFxuklaHP5bSx+pP9a+brL4mWkckcs2iXU5wNzXF+XXt8yjZx9eeK63xJ8XF0sW0Wm31vqszqDM0O7yYT2UOwG76eWp96z9nO9mr/AHf5DTtuj3OfUtN0S0byFt7PjLYGM89T69+Sa4+/8fP5jM9/sjydkVvEAdw7bmz8ucj8zxjA8/1rX9G1bxDomnXni6CS1vI/Nub0bo47NwpPllcgNk4AJxivOPHGtW2la1eabo91b39rGQqahbsT5y8YIyWAI6ZHHDYNNJ1LJP5LsNuS6Honi34jX0swgB8tnyD5bl3I7YUZNY/27VfsaJdyNBZytjYTtLEnqe/4DrXmtl4na1mLJaJtbBJ3fOPoew+v1q+PGNm1z50+mTNIOhNz82O4J6gey7fxq/YW2RDTZ7hF49t/CmmW0eiJHGzgCSaVN4Ixwqhe3U59vpRXz9feLBekCSBYYl6CH5QPQZAyTj19KKXspx0X6CfN/TX+Rzl8T5CAnJyDgDA5B6f5/lVCrt5/qFBGOQcdsHPSqVd7GFFFFIDS3fNwQAOcDtSZ5zgEnk5GeaGzsQY4zke//wBbOaaDkZ5YiqSKJt5aQgNweF+vY5/rWpodsj3ttcahZ3FzpglCzJu2F1xyA38P19s1jlQBkgHtt6Hvz7Y6596el/KLWRFnmCtgEB8A8dMfhUNXVkSy14m+wjW7ltFga2sZCDBE03m7R6b+/rVW0H8ScsOkZXBYZ4A9s5rPZySe3GMCpIpZIWV0ZkbOQw46dD+GKuztYlROut57iMuVe4h6ERCMlSeCc7hggkZx7CtD7c7IJ2mmSccNEIsKR9fyrijq98U2PdTMnHBc+3+AqMX9wHRzI529AW4rH2bYcp0mvXU5VTI0TKcMoHzSEn1PT/8AVWQIon/eNcKrY5jZSABjPB/L86z3vJnb97K5IJxz0z14ppkYxgDJAXGDyF59/U/zq4x0sPY9H8NeD7EGS+8SC6fToF/erZSLHIhx8pywIJ5GfYiuT1OOCK8nNks/9nrIfKaUAPszgBscbvpTvD+tyQSJBeSSNp+75kOSAK1tZiVRugXzLEgiMscGPI5/D+dZrmjK0mJNpnPiZxkbsqDnB5B79PwpEZk+7jptB9+n5c4oeN1Tequ8QGA+MLn601gF3MeOq9eox0Hvx+FaDB2IQnr05b9Ka7ghyxYg5G7+9z0H+NMYZGRt+ZcDv36Z9aaTxjGCCTgcCmkUkPaRwx4IPfJyaYXIGWJJxgc/54pc9eM7h0Hb/P8AKmlcZPGCcZ7E/wBapWHYefmkwh4PBbP3qc+5o3cEk7CQccgc9/8AP5VHkDBGcnhgePy+oqVwFjkwFGUJODnt/n+dJ6CZm+bIf425680GaQ9ZHP1Y1HRSEPDuvRmHOeDWgp2rlSc4xkjgd8Y7/wD16zKv8Yxxx7/5/wAinuNakzSDbjDYOcsMEUokcAlgc9+ev9KhJ6cHjse1M3xoQJMsBkYQ45/pSsOyRt6EdNa9STW/tTaWmROLRgJmyDgLuGOpGc9ge9VNVigW8vJtLS5bTvNYwG5IMwTORvxwTg5yOPw4qjd6hLPHFGNiJH0VFwM+v1qpvYjbngnP1pJPcVze0eaQRKMGQA7ljRuRz+g+ldnaai9w+TdXMD4AcXEO4MOuDnqeP5V5fDK8LB42KsDkEcVqR67fkq73M5Mfyq2/O0Gs5w5thM765uoQpeKaSWU/dQQ7VHoDnv29qnhktfNf+0jLI4PmSNAMKcdScc1wp8TX0qJDNdGWCMkhGUDd+I74GKgtb+CRyTD5cnZmmbnJ5/yaj2cluFjq/EWqabLZNa29oJYQ/mIudhb3yOce1ZMcnheXQ72SWbUbbV0IFrbwxK8EgA53ufmB5PI7Vm37W0c8cUZHk/ccryxz178/h2rOeIvdMYtyR4+Q47E9/wAzVwhZbhaw5gwJD5LZ5x3IP+fzpQ53DJ2kjGRkjHX8PwqKfMEzK8olBP3l53fnSk4HGcHov+fT9K2KuiQM3TOOvX9efypC245U9evy/THH5D05/JoH9wEnvhckcDA59Mniod/73cCACOR1HI6YpWvsF0BkyuGIPU5HvUfmc5wCPTtTGIPA6Z4z1pR7ZxQxXYhJPU570U5Rzx+WcUUXsIsXOBBgKMFgc49uRn8fxqnWgcZyVyO/GcCkKIeNgHbgfr/n9KbRTRQorQARc/KpPbKj/P8AP+tG1SMFF69NoByaLC5QI5wDj8KONuSwGeNvf/8AVUU0xBK8MT1P/wCquhufF5ufCFvoDaDoMflH/kIR2YF2/JPzSZ56/oKLsHJ9DDuGQxdlDdsZ79Afy/X1xVM8L160rMWJ3H6DtSZxxTukCXVidKcCDnJPHSm/Tj3pcjHAOfXNJtlKwoAGOAePypo6+9LnnjFKThiCO/bpSYaDevpijB27sHGcZpc88Uv3h8qjgdBRsLQXeVbdwWPfrXY+EXilVYbuRjEOi5wo5xyeo+lcfDlpBk+xLNjjp1r0vwH4dTULaRpdQjht0bMnnKNrYHr1PtioqtcpnKyR0/gjw79peSFtCW9tjuDxTzGKPBHBDLljj73A5ORXHfEjwZc+E9THmG3e3uDvjEXzJDkZEZJOeASBnk4PsT7Ro2of2PZFLN4fP+7FM8hikVSMZAHTuevT8xDd61pzaLeWN9Y2mp3cxLyXNxKXPLZBKn5dw4GQB79TXJCs0yE3ufNLnkkt82OCBgsPw9feo+/H5Vu+JtGfTLmT7NvnsTkpKATjno2On41hsME4KnHZTkD613RaaujaDTFweTwQO47+/wDn/GkIYE5B6YP585pytj7vXqvPfpn9T+dNY8AKBjHTHI/D/P8AOmVcTB9PypzHFvKQV6H5R2zxn+Q5/wAKaCABnnHzdPekOCp3dPrQLcoUVdMMeFO3jHXJ5prRIvVefrxRYVipWmByBlfpn/GoPKiGNykZ4/zzTppgqkcEnuMfj24//V0xQg20JMopBcEx9DTL1Fd2liw8a4BZcke2c8/pW/rvijTtS8OWenW3hfTdOvYABJqNu7iWYY53DODnqc59sVywwORnPT/9dTe+trBqORQeuMY7mgpgjr154qaA22xlndlK5AMY+8P85/T8ImG1OcdcEc8f/roHcYw6c0gTOQTjH6VLEkknMYLHPQdTQ8UsZ2yxvGwHRhjApiuNEZ3cnGDg5FI6/N0x2x/OlJwcj6/T8KCR+XQD+lCHoaOkOiNHsgXzVO4yuSQR1xjHH5j+tdBIkeoCRLSzWKaLGS7lcj6np0461yVqyediXlG4POMcf5FehaBJarCVt1iwhBEYiDgE4G4568HufQE1nU0dyX3MWw0by7jzpnthuAVBKpKluOOAOnrwP69nL4Gj1bRrmQ2tvY6rEDM941wwhdAf9WsQUnPbOatwJGhdmN+0shDE44TPIz6Z/wBnH6VttrVw0sVvewfaLAFFktBJs3KPXHKcdSPzrCdSV7k3voeCTwukjxuuHRWBzxjHt2/TrVJ1wxVfmA5yBjIr1r4oWuma1qhufDloto0EA86B53mV8ZPyu45I9B/WvKrhCBglvl6q3UdB/wDW/D6V1RlzIadyED6U7GDg8ZHFMBxQMjpTH1HZUL060U4Hg8En8/0ooYi1tOM9ePTimnGORgH37+lOHTPGSPWjGO+G6c/56VZo9hOBnPAGckc0Xkc8CxebFPEXG9S6ldw9QT1onSVbdZRFIImO0SFTtz6A96s614i1fXLbT7fVr+e7gsY/KtUkOfKXCjA9sKv5UnfQm99jKJyeepo4xz1o7+1BHY5z6Uh2F4I9DWhcWy3NsLm3UIVA86MdF/2x7eo7GqCqz52jOKs2d69nIrLnjOQRxz1B9vb3NS02rrdG1GpCLcKnwvfuvNenbr9zUMttNAEaaNkV/ulhgH6U61tpbqYRQKXdunH51qlIJAlxA8ggc7ChGQjf3SxyQCOhA/ka6ixs5o9NS5s7G5jiDDMrJhU/2lfH6HPQ/ivaaaIyr05UZcr+T6Nd/wCvnY5JNEv8kNb4LZxngZxnA/PP5U678N6tbwGd7CbyRxuAyK9M0m1N2B9tu7ya3f5W8i13huvAJ29Np59u+c16VZfDlZdOinsI9SdGX92Z7sBV7fMp6dOlZuu72OfnaZ8sfY7gMN8Ev/fBFXbDR7i7mAIWCMj5pJDwvHX+f0r6XsvB+k2bvceJNbEMIUbYIUDng9M7en41zWsx+GoLw32nLJcooxtkhyEx9DjOME9uPrS+sp6R/wAx87POV0XQtOgWaOW6v7wZO14CIuRwMdTyCeKZa3627slzhUByYtnA74C9RXQ+J/HJktZobDT7SNZBte5XLOvPI59PbpnPrXnV3cPLOjnc7NgEOxy35URTmveGk3uemSeK5WsRbpZxSQzrgcYKr67j3HH6DvUBtxK0Q8+QWgDb/JXaCPYn73fnv24rE0G2edBO0csk+TuKrgLjuSf1J/uiuz/ercQpM++GMYfyAGboeCTwvUdexPTFZtcuhFki3ZTQz6euk6Vb2zWb/wDHwHGJ5B2yTxnJJ/GvM/FvhK80KWSVYQ2nFuCrbjEeu1sdOBXbnVbOzuZ208G0LL80khEjkeoI4H171jW3i690++ufsa2N6LhfJlF7F5qAE53ckLu49elOm3F3Q4p30PNxyBzxj/P+fajkjjOePw961tZ0k6djyrgXURALPGCQvAHP5/T8ORlEA8jk/XiutNPVHRdNCZy2efU/X+tIGKr05Htj8f8APv604g7mC/fHXnk5FCruU4yQABgnkHof89uPaghhyFGOM+n4/wCfypoOCQdpweQOBwKewbJ7AdQSATn1z0H9SKg88xyq0TDcpBDY7jkce1DHe+gPL1UE985GM+/+fao14PHXtWx4r8S6v4rv477XrpLq6SIQrIIo4vkBJAwgAPJPJ/OsfaCc9aXQNhpOQOD/AEoAyeOTSnrnGaBkEbcg47UAt7Fq2sZpY3McW9h/Dnnv2656Vdjt96G2Uu8wIC7xsA6+v8vrVOO7lmmTz5SCSP3n8QA9D2raMC/bh57LggNvCl9wHcN9Pp1NJtpCZBPpjrcILiAxRj5nMDbgx9QP8Olas9lNd7GY6jbxSKJVluGDI4HA+btnA611ml+FBLsl0+aKVwoZJp4WiP8AwEEnn9a7HR7ZLG5hf7AJZRkzfaJUMbYHQ8dew69RXPKqlqyXLseVf8I1I6Otza/aLf7wnswpdQBxz0xyTWdc+DNQkV5dMtrmeIH7jRnevJ68fT8a941OLV7y4gu9K0q40yxjOfOszGqjqMb88Dkj3ycZqja61pmoa3O9xdSrdgsv2lpGlCnODtbp2xyf5VPt3ugu+p87CwuobpkubWcFM+YuzkfWu08KCK6SOGZJLMp9x2J+f/ZAP8/bivUtV1HQdHhW51uxuNTLsfLP3ApPQs3Qj2rldfu7W6iSeN5YY9wdESPgL0AJPBwB2J5P4VTq82lhklkkaTOXnkV04VoVJG4dyOvQH9e1OluZTcRxxMjtIAiRspLSE8ZYDpntmm6ddxG2NzLLLCFUeUwBJbPPpjB9zyD9a6zwpfypcIdI0lnuLniWSTAcD+937c+1ZN26E2KEnhefSZYZryVru/dN0dhFD5ix8EBpCenTgjpiuf8AiD8OpBaTaqPs9hdhSWtQvyzY7rjoeD1r1fV9S0zwrOuoW96dQ1DqY1lEkKN6uR95v9kHt715VrviCbUHu57jUZo1Jw0LAJyQBxnj264/PFEJtO6/r+v67DtZnijLh2BOKQdc113jTUf7dljuRZ6ZZeQnkgWNv5Ky85BIydzYPXjjHWuQ9q7YvmVyh5xj3ooA47Ee54oqtA5rF0EYHYn9Pf8Az9KhklABULh+Pw/H/P4Vr+H/AA9q3iGS8j0O1Nw9tCbiXMiJsQDOfmIz+HPArD2EjKnOAMg000HNfQuXOrajPpVvpk95cNp8DF4rVnYxxsc8hTxk7j+ZqgSe34U54ZEGWVhkZ5poVhzjGelCtayGnYXtg9P88UmKCCOCDk+opAcn60nuO49HKNkYOCDyB2+tXJ72OeJI5ItjKNpcZyR71SB6AgEA9P8A69X7fTpJ13RmKRf72/G3nuDRdLViexf0NniuRHFBHcvN95eSQue/YHv7V17Q3dtbmTzXuGV8rBkRxgHjoOPc+uK4Q209hOHQuVU/LIpIBIHqK2NP8Uuitb6ohliI2lx97HfPrXDiqdVyU6Wq6+Z9Bk1XLqlKeHx+jaahLpG/prvrrdelz0DwKfEdxLcRWU0EdxOT5cVy4RZASPlR24bkdj06+ldFDoHxF8P6lHdzFtOsZF/eSJcC5UA9R0O316f41xHhT4g6jLPFpWoX5awGRGxiyxwflxkcc8/hXZXsp1Ly7a5u9VgRyAtxJvKKAMZZfTFDW6lH+vuPmpqUJWRpal408/Sm01ltbqZD/rbmdP3h5GSBtP48n9a87huNZvppLOy0prhoxlTbq5HfnCnbxx17Y7AV2Uesy/DiXzNM8Y6Nfl1x5NvakEY9c54wa4rXfG13qeuvqeo67P5rrhTDAEXb6YH559SPWnGL1SV/n/lcSXYS50S+MZl1OFEnY/edljII4A2ggnGMDI5rPl8Ly/Z/tJSe5gc7sKFiX0wWx39hUFx4ivNTvI2yUicBdzIAOe/Pv/KtqKW6aGOIXaO6MSqbgpPuCf8AOKvmlHceqMm2vHsg0RidGjAVY5ydqgdN3r1PQYq1d+JpmtCsMVtFDF8qALsU9t2BjdjnGeMlumABi635sd1Its5kk583PK/gW4zg9eOlc9d3EhK7izKM4yxI5q401IpK+psyaxLfyeXOHkfO5tyAl/XOf65x/On9uaSQLNGpERIjiONi888f0/GstpGlfDgMxP3egrREdrDGd0juxHRVzjPp6fQ9a0skM031GKO8aTUFWaRuAhQHH5f/AFuAPoM/UbKW1kJ8mWOHqBKQGHr2/pVO2ncMXXeFDZZlycA9/r/9b0rQ1Sd5YYg0gKKC3lync7E9z2B4oS5XYe2xlcdwMHgAA/l/nH9KcPlOc5JHJ4AHOOSenXp/9Y0rQXPlJPLbypBISEkKEKzegJ4q2+gao3h1tcSxnbR1k8lroKNgcYGOuf4gK1JZn+axkCIykHHYgen8v61Z1q4vpDbQX00kqQR7Yd/8KegqnC4ScF1DKeo9Qfp0rcXTJNR0sy28nmyRcrD95wOM49RWbeuo7KOxz+OOf8in/NjaT1bHQ1dubWZEWKe2Mco5DBcHHvxzVA8cHI9v6H9adx9Ab2J9aQYI5zj1FITyTQepIzkd+hp2EWbOETXCksgG4D5jtHPvXcW2sadoMSMsCXE7LlWgJCqRg4w2cH164571wke9E8yIYGdpP17GoyxOC2TkZ57iocebcbV9zqtQ8daxd2rW6TLDbEY8hV+Uehx0/Hg1hXGrXtwA11cSTSDgM7EnH1qhknnuST0pRg8GhQith6F+PWL2N0ZbiUFOVxIwwc9v8/1rf0bxKZr6GTUGkLIc/IR859wR19zkD09ORznnqKUBd6hyQmeSOSBSdOPYL3PaNT1LUPEMcbDTZkijAMe7MkZx3IBx78H8Kglv41UpdC1Lq20GFmck9QFz07DgDHPXpXMeFr66EkFnZf2lNasP3ka3WIz7gAdPY+9dVPClxK1u1nb2skYGY43PmHpyGP1H61hbl0/r+vvM2rGbBq4imjjnjW2Dk+XKSPOfPB9cZ5744PHTHS2/i59NRobOO3tbOZAshaX5245LHqAT2BFcH4iSG3uBGGtkBA3gMZHYjHLHqD0yBjoKz3vXDZ3ElV4VQFBB4Oc5P+NDhzFLyOs1DxHqOYYrLy0jiBbzAdsQycntkkd8eg+h4m7LHUEUxNM0gyS4yWJ7gDr26Z6mtIiZESWWcLaOMMm1mYDpgY7d/oKi1TT5I/Jn1JfIt5GPzNJudxnOAvbvx1Bq4JRBaFRdKlZndsvIBvQMchEzxnH8h/8AXrBkjZmlkX5kB5Yjbz7VuvHJLNJCFMUDfMEkkwzD1YD0qhdPbgDfEss0a4JQ5R/Q/QVpFspaozlCqvzY5oqWK3ub+Vza2kkxHJWCMkL+AorZQnLVIhyS6lYFsFhuwOCR2rW0LaupW/2iESwsdg9wT0rJUjIB9a3dJljBaKSRPnOdsw/dt269QT6//rqZfCU9Gb+v6ZZabfJIttdmyYAlM5A5wD7jtj2qjbWumJO4gu454HHyRvgPu6dT/wDqx71fju7q4hmh1K3F7axjhg2W6dRxkn346fTHF3kISQmN9ygEEkbW9DkevNZRvLS5CvsafiCOycq1lKDKvDq6lSfz/wAmsKnFiQATnHQE9KaePrWnQ0SsTRmHywsqMrD+MHqPpU4tZXRDDIsqsfug856DiqfXHfFLnbkKSO2KEx8pv2+hTXWIYmUTZxslfacjsB6Uy/0fULBNs8G+HBIcR7gfx7EVL4c1OS1AxLAkQPMTJw/1OOnua9d8N/Eh1tVtdSutOMAGI47i3W6wf9nn+Q7+9ZTnKD1WhlK6PH9Kn1W0LNp8k0XQOxQErz3yOT/9Y104+JPiq2MFrHrE9zFEQBE0SEA+nTPavR7+fT/GMWyWGyYRjANhZrGe/HH4nHT06Zrjj4CEF3vEN7kncEjgBz6nHbsRmo5qc7uS19Be0X2kO8beMrzxDoKR3Og3dvOM77piFBbGMhQnp2zxXmkl1cqHRZJFhYDcpX5T1zgmuv1+GFYmhe/uI9oJMTDbx07+/wBa5vRF0szyf2u8yqnMYVchiOx5+nP19BV00lEa20RBbXSogd4syM2UZwSuO+PxretLd5jHPMbVWYgjeCTL6DB4x710WmadYTQpOLWbO4COaWI+UxA4JHQH8eM/XGNrsFvFvYwSzIDhnWT9ynp8o44+tJyUtEHNd2C8itrS1c386XV1LjCA5jiGeAQeO3qe9cjK0QSQxKzhj94fKoXB49z0rW1JrGG2jMcqzvwdjsWVBxwB0wc+vGPqKxb6WRo1UvleAqgAZHY4A5/M1dNdhrYYly8KB4iqkngkcn/61T2jzTRS5kVUP3izAbj9fp2rOAHrSqOCatspKxP9pkRPKibEW7dhRtJPuael4yJhU+bGMk9B6VXKcZ5A60jYBwOfxpXTKsjSfXtWuNDg0WXULl9LhcvFaFyUVic8D6k1XtPMmiNurTsM7jGp+XHdsevAqopKsGxnHNWcySxh32A4yjMcFuf/ANf+c0KKWxNiU2kkUiNGQVbjGQpGCRjnvx29a0dBuWtNdhktZmikTIAYENj0yM03Sp1e2eG+DNEeUZQDtb13evyjr79KgtwXvis53lT8uV6jHQKT/nFJ63TA9GtJYb7zvOK3qMCZEkwGi455HIzg9eOTXn/iGxhg1UpZb3RjkKww2fQHoetKsUn2oz2UzxXKfvAp+XOO4B+nQ1ttq2ma9EseqiKxvUG1byCLasnoHUfzP1z6ZxXJ6E2scc9rLvZVSQsMZUj5h6cUtl5RkKTQPLuwAUbay/TtW7fwX0LBzL55hHySIDwvqCBgg59ffvWfNqm8lJIFLjgMDsbI7kjqfetN1Y0hPklzK3z1Fm0WcyMlofPIGSjDZJ/3yev4Zqnf2F7p8qx31rPayEBgs0ZjJB5zz25rctmt7hrddXv5reNH3b4IwxB7EEZ9V59/xHYR+EdO1awM9v4rtL+3UFlWW3nSZBgnG/ZtJ7YORWfO4b6/19x1JUcRJRXuyfq4/wCa/wDJvkeUHgcdO9O56+gr0PU/Ddrc6fHBbhYpYlwjkdfXd65rMs49E0kmO4iF5qIfHlyRnYD24OOO+aihjIV17u/Y7s4yHE5RKPttYy2a2v1XqvxWve3IlSVA5x65yCe/+fpW74a8Ia34knMWm2yjYCWeeRYlAHuxH6V1WkWmvX8jT2qHyEXd5NraecFXI/ug4A45PHAGBxWX4317WXI0y/VII1AJj8ho8Y7YdQfX1/GteaUtEeJfojrfDyjwlZSQWlzYxakCYriaXGADwQT+fNW7zRtIlt3ubnW5ZbqUM5FgxfJPPP8Ad6nj0FcX4N1nw/BFGNZhk+0ISBJtzkf7xzj0+7xWlr/jnTFglh0CweFmwQ7uHzgjnIA9B0A/OsXGXN/wBNHNa3C8U4FqzsTn9+M5b2PuPwrFtBNNdKySZYsdrYyT9B/SptU1e81GQyXcgYEgmPkICBjOPXvnvk9cmqtrKsMm5gxVScJnIJ98EV0RWha21OrRJ4YFSaVYlxubY437T3z+f+RiqjSzuz3Eqt5Zynmp8xDf3QTwDgjken1qul5E6ZuIIWlzkLgnj0HXk88/Q5PNVb2ecFTPM4VQQqGTO0HgjHTnnI9jxUKOuoirc3J8vykEaK/LBckn/eP+FUwuRnIx6Cpn8jzFBMm3d88h5LevH1z19ajbYWIUYXoP4jWqGaWg+JNZ8OzzS6Dqd3YSTKFka3kKlgOgOPSisogKfb3opOlBu7QFm2VVy0nJxkAdfX/PenxvbxygTKGQ8MOfl9/881H5UjRBh0GDnPT0+ppk00j7Fm+YDnkcn8etW1cleZ2GmXNjp0x+0TxzK6gCUElZACMg88H881ha5Pp9zN5lr5sbD7yMdyuc9cj8axzgZ29D0B6ikx6VCjyu4KN9RWIP3RgY6ZzikHtQeOv4YpV6kkdqr1L2FH3hzj3FIQQSCDnpSDjt+de9eJvCXhzQP2j5NI1HQXj8HXM0FkmTII43lt0w6yE9RISTknvSHc8Gwu3JPP0q3Y389o2UbPsQGH5H6CvQfir4Qs/AGgaNoN3AjeKJp7i8vLgMcpbhzHCgGcYYIz+vIrzIdKPUnc3E8R3i3K3G8LImAAFHPv09h78CthfiDq7zo93M1wq4wrHHJHXpyfeuLP3aOTz/AFqHTi+gnFHpuj+IvDmu3AbxhcavCo6LaOG3nPQk10yeHfhiGimjvNSndvuwpIiqeMfMxYEDJHQ9AfpXhu4j7pI/rTt7ZHPQ59B1qXTf2XYXJpoe8SRaHEjhJ5IxGMxou0sV69ehPXOOf0ry/wAX6naTXRWxmd4t3IxtPv8AQ/nVPRWnvYhZ7LZ0bgPMu50/3efb9at614bS1tzcpcO44JV1Cvn6elTCCi9WSlZ6nMO5bKgttzwpOa9j8NeDb/xX+zy50DRjqGsR+KTueKJfOEAtBkbuu3cy8ZxmvIVtZHkCRhnJGRgdeO36/ka3YrG3is3kumhhZMfuWbcWPqP1yPetm7GnMe56f4G0iT4TnwcU0k+MJtLOtKCP9OE+fNWEDbwphAXGepNfNAOD94iug0rw/f6pLi1g8uNv4yvJ/wB0D+legWHwZksLU3/jHUU0qzI3RQEbp5unRR29+2alziupLklueQRo8jhI1Z2PQKMmnyRlGYNnKkZHpXYeJ9StLANaeH7QWtvyGdgGkbPTLfTniuM6jJOSTTTvqNSGg8/MDip0uGEPlMqsvOAScc9/r05/A5qD6VNFh5AGT5QOdo5qrDuT2N6bZHidFeJxg5HT/OM+vA6U9ImmmMcLo5C7kVuGx6A+tRSRxiRVeOWMHI9e/b8MVb03Tjcu7ITNEowTGMlfcr1/Gh6aiIJJLgM/nNOMffz82T1HXv0pxWGZF3pMJSflkdsgjrlj/wDqq2XMihGjme4j+VXQgrjpg+o/+vV+3Nl5Wy8R4HCD/SbZ8qx770PTjGf/AK9S35BfuZcwvbaTy2V3XGd54I/4EOlVrcFJPntGm3H5twIwc9iOa7bQoLe5jSGa6Cxk/LOAAGI7jHT8fetCDRLXT7rfIySpKcebvKIPUVHtLXFfWzOTVDCyy2JNttO6Ni6uVOOfm6468D0PFWtb1DUv7FQ3lrpRDttMyAfaGPJ+bBz2PX+WK6zWtDi+yPNHDFMu3KttVRk45z9en/168qv1kW6kEhJIOBlgcAdv5U4WkJajhqN2oIFxJ7EtyPoa6PSLbVdbsDAkOnTrj/XTzRiYY56s2f8AP1rkcEHnjHvR2GelW6aeq3NXVm4cnM7HVJcXHhs5iuIjcbVBiMhcqOvGxsen4H14rn9QvZr24eedizuckEkjP4596q9R0waQnP1NCgk79SL3HA45OT269qeG4zg9R0/z7VF34pwB46fhVtCHkkYPTGfbmmrjf3H4U9Yi4yWRV55Y+n61ESAx28j3FIPU0bSRTKIQjmQ8KzNnGeDgDGePU9qbfLGkwCTNIpHLnnB9B6n8vwqiBx3FTQyeXMrqiybeqkZXFTazK9BsilAPkZA3ILcEjH+fz71GAWA5GB6npVqeK4kP2m6BCOepIBPsKqPjPAAH1qkwGmiiihiNKxmCHf5Suo7H+vp9a2orfRtThEW97G+xhQylkznpkD19ayNOW2uSqzMsMnCh9uFHbn/Gumk04wWqrIUa0ZvkuRtLIfXPf/Com0noS30OX1HSrnT3xcRlcnhgQVP+HeqYjO7DAYIz94f5616tpUaW8qreW8NzbugR1ZOq8DBJ/PIx+FdK/wAGtN8RW7TeENVWGcqSdPvBhw3PTnB4HbI57cVMa8dpCUmeBeWwbDKQRzgg5NMHv16V2nijwP4i8NTtb6vp9wkSNtDqm9DnuBx/KuWng2Y+VlPJwRz09O351omnsWpIqjHIOK29a8W+I9ctkt9a8QavqNujiVIru8kmVXAIDAMSAcEjPXk1Tj09pl3RZYg7T1z+I/T/AB61VkglVpNytxyc9fxosUpXJ9X1TUNZvWvdXv7u/u2AVp7qZpXIA4BZiTx2qn0OSRQRyd3BHtSgbcHr7ihpjVr2EPv60h4FLkfj6ig+1FgdhBntTjj1BHHapIIpZ8qhBx/eYDGe/P0qSO2MjACROTg89OQOvT/9X0ot3Emjc8FeX/aCCSNnOcgbwg79677V7ezay8yR7aJyuC8CmZsH1Z+PyrlPDem6MJR5+rIW4LReTluPQAnPftXpum3NjY2bSR2NmYnBBnmieWYY6fIWTH4Fvxrlqy966MZvW5w2heCrrWLkRaNptxqMrMcmRsRJ05ZhgA8jgkDmu9m+HNppOlmfxdcxx3AbJ021kVZMcgDjPHvuPHpnIz7rxVe6fDLawGKOFvlY5dZH/i/1a4x1HLbh161z0usahfX7gXKLFnLRwxqZc4GTyg7epHbrUuU2LVnpVh47s9B03y/CWiWumlUC+fJ+9kOBjO88cgdABXmniTUtQ168ee+1OaV5iWwvTB7A9M12MWjeHrfTvtWpXktspGQ88gDSZ7KoyFP0I/CuB8Sa+11K9poFsYLWInzJGXBbjqcnPQdyaIK7BavQ5PUbMIrgq/lodrSzcfN1/wAePc/UYeVHAYkfz/Ct6+t3mYvPeNPKuF5Yrt6/Ko59OAMDtjpWU9mxlb754JbOCR9ef8/rXXHVWNUVVO1gRjK9Kljn2zlioAfhvXB6/pUTrg/eBPTjoKVTjpx9eab0Gkjo9HBdzaXFn9rjJ+V1ODzyMHp/eOM9/wADpTaDLKWubETeZHnqAsqn0bHGMd+9cpGY/OUBHYHkY+XHqQM9fYHGRXW6Rq8UAhaGeTzY+FDZ3pjsQOW+gGKzmmnoZ62uiCy063nuZFZ7mDUAv3T8hx6g8/j/AFqSXTnksyV3SqrfO7IFUcH7xBJU8Dr3/DHaWFz4a8UWZs9RlfTdQUFkkmh+Rn7ZzkD39q1bPwvrkdxFLpmoR3EkZxEiPmKUc/KCM44H6Ad6ydS27Bt3PIntrnTL2NrsTwg4AdUDcDoynpjHfFd1EJLnTFf+1LO4hUgp5sQilBP+83OPoRXpkelaNq0I07Wyug6jt/eRzjy0LbeNh+6c5yevOe/Tzvx/4C8Q+FIVmijgudMc5intlGTnkHd3/DtRzKfqPfc5jWtXuY4LizvLuQqoPl/KNrDg7doGccdc8VxEpEk5ZAApP+TWymnS3kxLebgjBCg56dMnGfXnH8qztRtRBPIsaSIyn5lYg4z6kflW0Eloiij0FOA+Ug9fXtSZyD2HoKepHAYA88YA/wA/56VrcTEIG7DcEce1Mbknp09alP3ccfMAM9eP8/y/NhI+UdSB159KegrDVA6+npn/ADmpoY92W3bUXliOcen+c1Fkd88e1aem6XLeyYSMSdMIJVQn25+o7dalyS1ZSRSluC67WjQkcFyoyfrWt4b8Lal4hmCabCZOdpOOAfqeB+P8ua7Lwx4K0+1K3XiFp4wcmOFNj89iWD8847euRXW3Gv3Utk0GnwvFDEChlR0iXGf4+jD6Yb8awlVt8Im77HJ/8K9sNJhd9ZvXklj4ZUwqRn+6xOCD9Mg+tc9qOr6NY74/D+nIHPW6nG9sD+6rcY9j7e9aHihuHluL5rh48BUgBKYHrI2G7jgAf4cTMgj/AHkWTE3AJG3B9MZ6U4Jy1kwS5tyK6kklmaaWQvI5yWbqag+tSudpwOBjBpmN3T+VbK1hjaKU9eRRRbzAcGYDAYj2BrpPD2sR2YZLwtJCw2llPI9gPSub6Yzj15705G2kFQCO+6iSTWoM9TtPE1rPGI43WTbkq4G1054JHQ4/WteOS+t4vtdkz3GOVmtJPQDl+46DHrj1FeS2V2bdgbbaM8uj/Mh9z3FdZpviC2sWV57R7WVeR9nbKMAeCQOuDxg9/wAa5pUraJX/AK/r/gEcttj17w78QdYldYbx01KxYiMw3Ue4np2Pp+vNdo3w/wDAXijbPNajTbpuGSKXaM+2eK8a0nx1Y3Vwpu7JrqT7qyQyCF2PoDjAGT3HrzzXT6NqVtFmeLULmwBO6RZyGA+mQQa53zU9tCba6o6TVfgBbxqH0HUEcHKiGdAUCnPQ+uCfyrzvxl8HtdgUtbWF4RHyXA3Rj3G3oP8A6/avW7XxJFDDnU1njtThYzbXHlmU5OTg5znj0rb0jV7BZPK0vVdYtJD87LcbblE7YzuIHTGP61Sr2f8AX+VvxGt9z5BvfCWrWCPJPbqEj42u2D9cVgxwSSs+1QQRgjGOv9O/4CvtrV9a1U74IJ/DOtwkYMD27rI31wSoNcH4g03S3ZrjX/BEUC4AIsbxIhz3PU962jie/wCn6Njk0j5aeIqDxkLknjkf5NBL7sKSE6fkOn+etfQt34Q8FXtistrouqaYcA/JdrMQOR91uvb8TWJY/DXR9R1KMx3l/HZ5xmSMKRznjGR/+urWJgF0eLbVCrkMuOc9R78VZsIZ5WWKBTIxySB2HtXv2ofCPS4d8qwpOiSFN4usHI/hI79c8Vf0jwP4d0hDNNBYlx/DNK7sep4UKOO+PcewMvExtoHMjyDw/wCHtYZma1glluC3+rDKuCAMZJ/E1uzW2p21ud11aw3YbElvExlmH1BGPbOa9ti0X7dbpJb2Wo/Z2AVEtLeO3XHHOWyxPTn0981na14VvbxljsrLUBdKcB7sgRgem4Abs/8A66x9pzO7/UltnjkVk9zvjuYJjcqcRhELOMHOPb610Z0U2Wlxyag7xROoKzNOqN9ABz17H0ruT4RTTbYzahqVpZ3oXBiibJY+7Z+nPTp6Vzt34fhmSaeW6XEYyolIl5zjdhffnBpc9xXPJdTkYiSa0t3NivInl6Seny/1ArHVbiaN3ml8iM/dQnqvsD2rudfsombemrPJOn3Y40DMh9lHI/DpXFG2l8yXzgEiwWdJJMuwz1x2PeumDVjWLTRbs47eGHdazwCRuiRnMj4HUsfuZ68d/oKzL268pnihjiEfTkHngZPr6f5zWjp2nX+otmytYnhzz0TcO3165qPUVs9P3pPOkt8SQ4tiSAR2LHjv254qlqwRzsiYkIDBif7vrTc4zTkJe4TbtUkjGTx+NaTxw/ItxF5T4OWX7p56j09OatlJ2MxWIdW3sCOhB5FbGkSW0s6tfuwyQMuflHbtzmqhtUV0KYLYDFJDtD56hf1//XTdqySMrsYzuGQ6k4Y+hH8qW6FodbPHeedbz2T+bbqPlMYDmMepxyOnPr0rpND1fU7O6jZ7S3MisrCZRslz15x1+tc1o6XUHktaJ+6bAcROoJ57rnPTt3rrYrmKKaOTy45liwxhlynf5sMemff/AAFcs1oJ9j2PSviTDf2a6f4h0drtNo8weUJARgY2rjj/ABzTJYfCk/mTaNqc+iS7W32MhVkPvhs4+grl9MtdKv1gmtv7R098EyLERc5O7qGU8c+ta2raXqP2UILtZMZfdc2qblHrvAwD7daxettf6/NfeK5yk2iy6jfyWlnJaLahsteTQ7cEdsD+EkYx9fWsfWPhhrkkLCG3jv4QARcW1xnHU52nk969F8PWWpiFbWXUUNu/S0itWAf1JLgZ554PY/St6TTrS3s9rzGyl8s5UQ+UCB/eZWYn7vp1P1qlUkhpWPle88EarA8jvaTm3Q4Mkabl5Pt0rDvNJvLR+YJinY7CO9fVWsG9i8q0ku7W5hYA/uFZUAx1J7jnHPeqU+kSyKjR29iEwEjk2+ZnPYhe/wCvFaLEdGO58svbzqgLQygc9UOPz/Gnx2Vy67xBL5eOGC8HivqZfBMGo2yPJdW1iDlWYWrIG5PGST3B7dvXNV5/APhvSow15ejYeQMErk+jZ46en1q/rCW6D5Hy4IZGLKAMr1BIFdR4Tt0mv1ili+2O7DbCygB2wO+eufx6179Z+G/h5ZQi61q3/tPLZVZXCAZ6DjGR+XFZ2pT6Xp9vN/wi+hadY2bNuWd1WZoyOu3rnP8AjRKumrLcaZkaV4b1hAjSWUelWJO7yZCGyP7wGcj/AA4Ap2oJZW0kn2lIQQAB5cvyuo/unH3vYir2n6va3Eok1C7a4lUdJ42SNsDgjHI6fmKzbzxRpVz9ohfULfS4c/NHa2LTl/cOQSvvzWCcm9iXHqeZeL7uG6u1isLSZmRcLIykFRkDBXv1/HNZx8NX7L9ouhsQjO4nluemO2eTmvSYb/QbEGaxtYzKSG+2XzZz16EdPoRXF+I9Vk1qeTy7ySderMIiiY6fl/8AWwea3hNvRDXkcleQxw/LHuLZIO44wfpVUt2FS3Sqk7qjmQLwGI56c1Cfrz0NdKHcSiggkbu1FN2ELkEdKXdkcjgUUUuZjBWwdy5BHTnpUoncEgbQPQDAooph0EW7kXO3aARggjOa1LLxNqVrGsKyrJACD5co3Kcfr+VFFS0nuItr4z1lXykyKh48oruQD0wxP1rStfiDq1pKBFb6eCFKkiJl3Y7nDD/PtxRRT9jBpaESRf0/4t+JtNkzamzWMscxeUSv/oWf1qe6+MniC7b9/ZaQ0aj/AFYgcLn14fNFFSsPT0dhJInj+MlwEAn8IeFJyMfM9rKT0x18z0/Olk+MtxI3PhPw2q54Ea3CfniWiirdKFrWKsNT4y6hHIrR+HPD649EnJwOgyZePwrc0/8AaH1ayK48N6G+DuyfOJz65ZzRRUOhBK6Q7Ivv+01r5DH/AIR7Q94OQ22T8P4uvXn3rJ1T9obxLqkckd5Yae0TdERpUA+u1xn8aKKbowe/5sVrmBd/F3WZlTybHT7d1GCyK5DD0ILYIrI1H4h6tqDEXEVqIOnlRqyDoRjg+5/M0UVLowjokCgjPn8W30sbRRxW0MbdAiE45znknJ+tMtvE8sC5NjaSSn7zsGBb8jwfcYNFFCih2RbuvG+pSQvbiK1jjLZbylKFjz1IOT1Pv/OuckmV3LLDGowQF5OOtFFEUorQEQj7wxx6Vo2Wqy2yGKRfOgI+4zYxkdiOlFFMZVlud5/doIgMHCsev4/54qzb6iiQlbi2SUEEKwO11PH8XPHtRRTsBe0vxH9kVUntBNGOMpIY3A7gNg4+taqeNolmDtpCMFYEEznf/wB9bce3TpxRRUunFvULXNC0+JKWkgeLSG3dCxu8Ejv91Bzx6VtRfF6yC4Phy5RtwOYdVIHH+y0bKfxFFFQ6MG7tAootL8bJJkMdzpN1KpO1c6iBt/KL37Y/pUsXxittkwTw9PnGVEmpbxnHfMWSPoR0H4lFZulBbI0UI2ZHp/xxvN6RHRYIIhuAFtKM4P8A11SRen+zVxvjldWF4Dp2kmKOReVaaHdz/tLAv45zmiihwipcq2CME4tv+ths3xsvpZmM9lcyY6Kb75R0H9zPv1/+tgal8WJ71ikulRiJeFCShWXnn5gmTn3oopQpx3sDhG7RQPxLu1cL9kaSMjAimuneNQfReB+dVx43d5FlFtPHkbgEuRwef7yHjjp9M9Bgoq3TildIXKrkOp+Oru+t3iuI5HiJ+4bhtvXuBwenp3NZ8ni68MSKplSJc/u1lwpJ9QBzRRWkaULbCklF2RmXGszTyb2XaT2DcD6elV5ryWaMqzuIsn92GOMkcnnrRRVqKsK5VZvmJHB/lTT60UVSEAoooouB/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The precordial views from the transthoracic echocardiogram shows multiple bulky venetations (white arrows) and abscesses (red arrows) of the aortic valve and root. These images were obtained digitally and are displayed in quadrant screen format. In spite of insensitivity for smaller vegetations, precordial transthoracic imaging is often effective for imaging vegetations.",
"    <div class=\"footnotes\">",
"     LV: left ventricle; LA: left atrium; MV: mitral valve.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_13_215=[""].join("\n");
var outline_f0_13_215=null;
var title_f0_13_216="Metoclopramide: Drug information";
var content_f0_13_216=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Metoclopramide: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?33/45/34517?source=see_link\">",
"    see \"Metoclopramide: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/47/759?source=see_link\">",
"    see \"Metoclopramide: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F8117624\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F195600\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Metozolv&trade; ODT;",
"     </li>",
"     <li>",
"      Reglan&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F195601\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Metoclop&reg;;",
"     </li>",
"     <li>",
"      Metoclopramide Hydrochloride Injection;",
"     </li>",
"     <li>",
"      Metoclopramide Omega;",
"     </li>",
"     <li>",
"      Nu-Metoclopramide;",
"     </li>",
"     <li>",
"      PMS-Metoclopramide",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F195655\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antiemetic;",
"     </li>",
"     <li>",
"      Gastrointestinal Agent, Prokinetic",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F195605\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Gastroesophageal reflux:",
"     </b>",
"     Oral: 10-15 mg/dose up to 4 times/day 30 minutes before meals or food and at bedtime; single doses of 20 mg are occasionally needed prior to provoking situations. Treatment &gt;12 weeks is not recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Diabetic gastroparesis:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: 10 mg/dose up to 4 times/day 30 minutes before meals or food and at bedtime for 2-8 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.M., I.V. (for severe symptoms): 10 mg over 1-2 minutes; 10 days of I.V. therapy may be necessary before symptoms are controlled to allow transition to oral administration",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Chemotherapy-induced emesis prophylaxis:",
"     </b>",
"     I.V.: 1-2 mg/kg 30 minutes before chemotherapy and repeated every 2 hours for 2 doses, then every 3 hours for 3 doses (manufacturer labeling); pretreatment with diphenhydramine will decrease risk of extrapyramidal reactions",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Alternate dosing:",
"      </i>",
"     </b>",
"     <b>",
"      Note:",
"     </b>",
"     Metoclopramide is considered an antiemetic with a low therapeutic index; use is generally reserved for agents with low emetogenic potential or in patients intolerant/refractory to first line antiemetics.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Low-risk chemotherapy (unlabeled):",
"     </i>",
"     I.V., Oral: 10-40 mg prior to dose, then every 4-6 hours as needed (NCCN Antiemesis guidelines, v.4.2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Breakthrough treatment (unlabeled):",
"     </i>",
"     I.V., Oral: 10-40 mg every 4-6 hours (NCCN Antiemesis guidelines, v.4.2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Delayed-emesis prophylaxis (unlabeled):",
"     </i>",
"     Oral: 20-40 mg/dose (or 0.5 mg/kg/dose) 2-4 times/day for 3-4 days (in combination with dexamethasone [ASCO guidelines, 2006])",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Refractory or intolerant to antiemetics with a higher therapeutic index (unlabeled; Hesketh, 2008):",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     I.V.: 1-2 mg/kg/dose before chemotherapy and repeat 2 hours after chemotherapy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Oral: 0.5 mg/kg every 6 hours on days 2-4",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Postoperative nausea and vomiting prophylaxis:",
"     </b>",
"     I.M., I.V. (unlabeled route): 10-20 mg near end of surgery.",
"     <b>",
"      Note:",
"     </b>",
"     Guidelines discourage use of 10 mg metoclopramide as being ineffective (Gan, 2007); comparative study indicates higher dose (20 mg) may be efficacious (Quaynor, 2002).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Postpyloric feeding tube placement, radiological exam:",
"     </b>",
"     I.V.: 10 mg as a single dose",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F195630\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/47/759?source=see_link\">",
"      see \"Metoclopramide: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Gastroesophageal reflux (unlabeled use):",
"     </b>",
"     Oral: 0.1-0.2 mg/kg/dose 4 times/day (maximum: 5 doses/day); pretreatment with diphenhydramine will decrease risk of extrapyramidal reactions to this dosage",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Chemotherapy-induced emesis (unlabeled use):",
"     </b>",
"     I.V.: 1-2 mg/kg 30 minutes before chemotherapy and every 2-4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Postpyloric feeding tube placement:",
"     </b>",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &lt;6 years: 0.1 mg/kg as a single dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     6-14 years: 2.5-5 mg as a single dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &gt;14 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F195606\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Initial: Dose at the lower end of the recommended range. Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F195607\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;40 mL/minute: Administer 50% of normal dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Not dialyzable (0% to 5%); supplemental dose is not necessary.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F195570\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [preservative free]: 5 mg/mL (2 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Reglan&reg;: 5 mg/mL (2 mL [DSC], 10 mL [DSC], 30 mL [DSC])",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral: 5 mg/5 mL (0.9 mL, 10 mL, 473 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 5 mg, 10 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Reglan&reg;: 5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Reglan&reg;: 10 mg [scored]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, orally disintegrating, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Metozolv&trade; ODT: 5 mg, 10 mg [mint flavor]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F195554\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes oral-disintegrating tablet",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F8083407\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Metoclopramide oral solution:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM244086.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM244086.pdf",
"     </a>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Metozolv&trade; ODT:",
"     <a href=\"file://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022246s000lbl.pdf\" target=\"_blank\">",
"      file://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022246s000lbl.pdf",
"     </a>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Reglan&reg; injection:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM176362.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM176362.pdf",
"     </a>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Reglan&reg; tablet: file://www.alavenpharm.com/downloads/ReglanTablets_MedicationGuide.pdf",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F195574\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Injection solution: May be given I.M., direct I.V. push, short infusion (15-30 minutes), or continuous infusion; lower doses (&le;10 mg) of metoclopramide can be given I.V. push undiluted over 1-2 minutes; higher doses (&gt;10 mg) to be diluted in 50 mL of compatible solution (preferably NS) and given IVPB over at least 15 minutes; continuous SubQ infusion and rectal administration have been reported.",
"     <b>",
"      Note:",
"     </b>",
"     Rapid I.V. administration may be associated with a transient (but intense) feeling of anxiety and restlessness, followed by drowsiness.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Orally-disintegrating tablets: Administer on an empty stomach at least 30 minutes prior to food. Do not remove from packaging until time of administration. If tablet breaks or crumbles while handling, discard and remove new tablet. Using dry hands, place tablet on tongue and allow to dissolve. Swallow with saliva.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F195662\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W, mannitol 20%, LR, NS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Acyclovir, aldesleukin, amifostine, aztreonam, bivalirudin, bleomycin, caffeine citrate, ciprofloxacin, cisatracurium, cladribine, cyclophosphamide, cytarabine, dexmedetomidine, diltiazem, docetaxel, doripenem, doxapram, doxorubicin, droperidol, etoposide phosphate, famotidine, fenoldopam, fentanyl, filgrastim, fluconazole, fludarabine, fluorouracil, foscarnet, gallium nitrate, gemcitabine, granisetron, heparin, hetastarch in lactate electrolyte injection (Hextend&reg;), hydromorphone, idarubicin, leucovorin calcium, levofloxacin, linezolid, melphalan, meperidine, meropenem, methadone, methotrexate, mitomycin, morphine, ondansetron, oxaliplatin, paclitaxel, palonosetron, pemetrexed, piperacillin/tazobactam, quinupristin/dalfopristin, remifentanil, sargramostim, sufentanil, tacrolimus, telavancin, teniposide, thiotepa, tigecycline, topotecan, vinblastine, vincristine, vinorelbine, zidovudine.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Allopurinol, amphotericin B cholesteryl sulfate complex, amsacrine, cefepime, doxorubicin liposome, furosemide, pantoprazole.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Cisplatin, dexamethasone sodium phosphate, haloperidol, midazolam, propofol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Aminophylline, ascorbic acid injection, atropine, benztropine, bleomycin, butorphanol, caffeine citrate, chlorpromazine, cisplatin, cyclophosphamide, cytarabine, dexamethasone sodium phosphate, dimenhydrinate, diphenhydramine, doxorubicin, droperidol, fentanyl, fentanyl with meperidine, fluorouracil, heparin, hydromorphone, hydroxyzine, insulin (regular), leucovorin calcium, lidocaine, magnesium sulfate, meperidine, methotrimeprazine, methylprednisolone sodium succinate, midazolam, mitomycin, morphine, ondansetron, pentazocine, prochlorperazine edisylate, promethazine, ranitidine, scopolamine, sufentanil, vinblastine, vincristine.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Ampicillin, calcium gluconate, chloramphenicol, furosemide, pantoprazole, penicillin G potassium, sodium bicarbonate.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Methotrexate.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F195573\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral: Symptomatic treatment of diabetic gastroparesis; gastroesophageal reflux",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     I.V., I.M.: Symptomatic treatment of diabetic gastroparesis; postpyloric placement of enteral feeding tubes; prevention and/or treatment of nausea and vomiting associated with chemotherapy, or postsurgery; to stimulate gastric emptying and intestinal transit of barium during radiological examination of the stomach/small intestine",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F195664\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Metoclopramide may be confused with metolazone, metoprolol, metroNIDAZOLE",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Reglan&reg; may be confused with Megace&reg;, Regonol&reg;, Renagel&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - moderate; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F195653\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not always defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiovascular: AV block, bradycardia, HF, fluid retention, flushing (following high I.V. doses), hyper-/hypotension, supraventricular tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Central nervous system: Drowsiness (~10% to 70%; dose related), acute dystonic reactions (&lt;1% to 25%; dose and age related), fatigue (2% to 10%), lassitude (~10%), restlessness (~10%), headache (4% to 5%), dizziness (1% to 4%), somnolence (2% to 3%), akathisia, confusion, depression, hallucinations (rare), insomnia, neuroleptic malignant syndrome (rare), Parkinsonian-like symptoms, suicidal ideation, seizure, tardive dyskinesia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dermatologic: Angioneurotic edema (rare), rash, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Endocrine &amp; metabolic: Amenorrhea, galactorrhea, gynecomastia, hyperprolactinemia, impotence",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gastrointestinal: Nausea (4% to 6%), vomiting (1% to 2%), diarrhea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Genitourinary: Incontinence, urinary frequency",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hematologic: Agranulocytosis, leukopenia, neutropenia, porphyria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hepatic: Hepatotoxicity (rare)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ocular: Visual disturbance",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Respiratory: Bronchospasm, laryngeal edema (rare), laryngospasm (rare)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Miscellaneous: Allergic reactions, methemoglobinemia, sulfhemoglobinemia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F195578\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to metoclopramide or any component of the formulation; GI obstruction, perforation or hemorrhage; pheochromocytoma; history of seizures or concomitant use of other agents likely to increase extrapyramidal reactions",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F195558\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Depression: Mental depression has occurred, symptoms range from mild to severe (suicidal ideation and suicide); use with caution in patients with a history of mental illness.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Extrapyramidal symptoms (EPS): May cause extrapyramidal symptoms, generally manifested as acute dystonic reactions within the initial 24-48 hours of use. Risk of these reactions is increased at higher doses, and in pediatric patients and adults &lt;30 years of age. Pseudoparkinsonism (eg, bradykinesia, tremor, rigidity) may also occur (usually within first 6 months of therapy) and is generally reversible following discontinuation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Neuroleptic malignant syndrome (NMS): Use may be associated (rarely) with neuroleptic malignant syndrome (NMS); monitor for mental status changes, fever, muscle rigidity and/or autonomic instability; discontinue use if signs/symptoms appear.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Tardive dyskinesia:",
"     <b>",
"      [U.S. Boxed Warning]: May cause tardive dyskinesia, which is often irreversible; duration of treatment and total cumulative dose are associated with an increased risk.",
"     </b>",
"     Therapy durations &gt;12 weeks should be avoided (except in rare cases following risk:benefit assessment). Risk appears to be increased in the elderly, women, and diabetics; however, it is not possible to predict which patients will develop tardive dyskinesia. Therapy should be discontinued in any patient if signs/symptoms appear.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Edematous conditions: Use with caution in patients who are at risk of fluid overload (HF, cirrhosis). May cause transient increase in serum aldosterone; use lowest recommended doses initially and discontinue use if signs/symptoms appear.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypertension: Use with caution in patients with hypertension.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; NADH-cytochrome b5 reductase deficiency: Patients with NADH-cytochrome b5 reductase deficiency are at increased risk of methemoglobinemia and/or sulfhemoglobinemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Parkinson's disease: Use with caution or avoid in patients with parkinson's disease; may have increased risk of EPS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment; dosage adjustment may be needed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Surgical anastomosis/closure: Use with caution following surgical anastomosis/closure; promotility agents may theoretically increase pressure in suture lines.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Avoid use in older adults (except for gastroparesis) due to risk of extrapyramidal effects, including  tardive dyskinesia; risk potentially even greater in frail older adults (Beers Criteria). In addition, risk of tardive dyskinesia may be increased in older women.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: EPS are increased in pediatric patients. In neonates, prolonged clearance of metoclopramide may lead to increased serum concentrations. Neonates may also have decreased levels of NADH-cytochrome b5 reductase which increases the risk of methemoglobinemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Discontinuation of therapy: Abrupt discontinuation may (rarely) result in withdrawal symptoms (dizziness, headache, nervousness).",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F195649\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP1A2 (minor), CYP2D6 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2D6 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F195563\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anti-Parkinson's Agents (Dopamine Agonist): Metoclopramide may diminish the therapeutic effect of Anti-Parkinson's Agents (Dopamine Agonist).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotics: Metoclopramide may enhance the adverse/toxic effect of Antipsychotics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Metoclopramide may increase the absorption of CycloSPORINE (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the adverse/toxic effect of Metoclopramide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: May enhance the adverse/toxic effect of Metoclopramide. Management: Seek alternatives to this combination when possible. Monitor patients receiving metoclopramide with metyrosine for development of extrapyramidal symptoms.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Posaconazole: Metoclopramide may decrease the serum concentration of Posaconazole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prilocaine: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Prilocaine. Combinations of these agents may increase the likelihood of significant methemoglobinemia.  Management: Monitor patients for signs of methemoglobinemia (e.g., hypoxia, cyanosis) when prilocaine is used in combination with other agents associated with development of methemoglobinemia.  Avoid lidocaine/prilocaine in infants receiving such agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Promethazine: Metoclopramide may enhance the adverse/toxic effect of Promethazine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinagolide: Metoclopramide may diminish the therapeutic effect of Quinagolide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: Metoclopramide may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors.  Management: Seek alternatives to this combination when possible. Monitor patients receiving metoclopramide with selective serotonin reuptake inhibitors for signs of extrapyramidal symptoms, neuroleptic malignant syndrome, and serotonin syndrome.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin Modulators: May enhance the adverse/toxic effect of Metoclopramide. This may be manifest as symptoms consistent with serotonin syndrome or neuroleptic malignant syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetrabenazine: Metoclopramide may enhance the adverse/toxic effect of Tetrabenazine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tricyclic Antidepressants: Metoclopramide may enhance the adverse/toxic effect of Tricyclic Antidepressants.  Management: Seek alternatives to this combination when possible. Monitor patients receiving metoclopramide with tricyclic antidepressants for signs of extrapyramidal symptoms, neuroleptic malignant syndrome, and serotonin syndrome.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trimetazidine: Metoclopramide may enhance the adverse/toxic effect of Trimetazidine. Specifically, the risk of extrapyramidal symptoms may be enhanced.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Venlafaxine: Metoclopramide may enhance the adverse/toxic effect of Venlafaxine. Specifically, the risk of serotonin syndrome may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F195595\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ethanol: Avoid ethanol (may increase CNS depression).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F195566\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F195581\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects were not observed in animal studies; however, there are no adequate and well-controlled studies in pregnant women. Crosses the placenta; available evidence suggests safe use during pregnancy.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F195613\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F195582\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk; may increase milk production",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F195580\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Metoclopramide HCl Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg/mL (2 mL): $0.54",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Metoclopramide HCl Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg/5 mL (473 mL): $19.25",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, orally-disintegrating",
"     </b>",
"     (Metozolv ODT Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg (10): $26.40",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (10): $13.20",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Metoclopramide HCl Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg (100): $32.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (100): $27.75",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Reglan Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg (100): $248.44",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (100): $248.44",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F195568\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dystonic reactions; signs of hypoglycemia in patients using insulin and those being treated for gastroparesis; agitation, and confusion",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F195583\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Afipran (NO);",
"     </li>",
"     <li>",
"      Ametic (ZA);",
"     </li>",
"     <li>",
"      Anausin (FR);",
"     </li>",
"     <li>",
"      Balon (TW);",
"     </li>",
"     <li>",
"      Carnotprim (MX);",
"     </li>",
"     <li>",
"      Cerucal (DE, EE, HU);",
"     </li>",
"     <li>",
"      Clomitene (PH);",
"     </li>",
"     <li>",
"      Clopamon (ZA);",
"     </li>",
"     <li>",
"      Clopram (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);",
"     </li>",
"     <li>",
"      Dart (BR);",
"     </li>",
"     <li>",
"      Dibertil (BE, LU);",
"     </li>",
"     <li>",
"      Dirpasid (MX);",
"     </li>",
"     <li>",
"      Emeliv (SG);",
"     </li>",
"     <li>",
"      Emetic (BR);",
"     </li>",
"     <li>",
"      Emperal (DK);",
"     </li>",
"     <li>",
"      Enzimar (CO);",
"     </li>",
"     <li>",
"      Gastro-Timelets (LU);",
"     </li>",
"     <li>",
"      Gastrobi S.R. (KP);",
"     </li>",
"     <li>",
"      Gastronerton (DE, LU);",
"     </li>",
"     <li>",
"      Gastrosil (CH, DE, LU);",
"     </li>",
"     <li>",
"      Imperan (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, TW, YE);",
"     </li>",
"     <li>",
"      Itan (CN);",
"     </li>",
"     <li>",
"      Legir (UY);",
"     </li>",
"     <li>",
"      Macperan (KP);",
"     </li>",
"     <li>",
"      Malon (MY);",
"     </li>",
"     <li>",
"      Maril (HK, SG, TH);",
"     </li>",
"     <li>",
"      Maxeron (IN);",
"     </li>",
"     <li>",
"      Maxolon (AE, AU, BB, BF, BH, BJ, BM, BS, BZ, CI, CY, EG, ET, GB, GH, GM, GN, GY, IE, IQ, IR, JM, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, NE, NG, NZ, OM, QA, SA, SC, SD, SL, SN, SR, SY, TN, TT, TZ, UG, YE, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      MCP-Beta Tropfen (DE);",
"     </li>",
"     <li>",
"      MCP-ratiopharm (LU);",
"     </li>",
"     <li>",
"      Meclomid (MX);",
"     </li>",
"     <li>",
"      Metamide (NZ);",
"     </li>",
"     <li>",
"      Metlazel (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Metoclamid (LU);",
"     </li>",
"     <li>",
"      Metoclopramide-Eurogenerics (LU);",
"     </li>",
"     <li>",
"      Metopram (FI);",
"     </li>",
"     <li>",
"      Metsil (PH);",
"     </li>",
"     <li>",
"      Movistal (LU);",
"     </li>",
"     <li>",
"      Nausil (TH);",
"     </li>",
"     <li>",
"      Nilatika (ID);",
"     </li>",
"     <li>",
"      Norvom (ID);",
"     </li>",
"     <li>",
"      Paspertin (HU);",
"     </li>",
"     <li>",
"      Perinorm (IN, RU, ZA);",
"     </li>",
"     <li>",
"      Perone (TW);",
"     </li>",
"     <li>",
"      Pharmyork (GR);",
"     </li>",
"     <li>",
"      Plasil (AE, BF, BH, BJ, CI, CO, CY, EG, ET, GH, GM, GN, IQ, IR, IT, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, MX, NE, NG, OM, PY, QA, SA, SC, SD, SL, SN, SY, TH, TN, TZ, UG, YE, ZM, ZW);",
"     </li>",
"     <li>",
"      Polcotec (MX);",
"     </li>",
"     <li>",
"      Pramidin (PL);",
"     </li>",
"     <li>",
"      Pramin (AU, IL, TW);",
"     </li>",
"     <li>",
"      Primperan (AT, BE, BF, BJ, CH, CI, CO, CR, CZ, DK, DO, EC, EE, ES, ET, FI, FR, GH, GM, GN, GR, GT, HK, HN, JP, KE, LR, LU, MA, ML, MR, MT, MU, MW, MY, NE, NG, NI, NL, PA, PE, PT, RU, SC, SD, SE, SG, SK, SL, SN, SV, TN, TR, TW, TZ, UG, VE, ZM, ZW);",
"     </li>",
"     <li>",
"      Primperil (AR);",
"     </li>",
"     <li>",
"      Prinparl (JP);",
"     </li>",
"     <li>",
"      Prokinyl (LU);",
"     </li>",
"     <li>",
"      Prowel (TW);",
"     </li>",
"     <li>",
"      Pulin (MY, SG);",
"     </li>",
"     <li>",
"      Regelan (PK);",
"     </li>",
"     <li>",
"      Reglan (BG, HR, IN);",
"     </li>",
"     <li>",
"      Reglomar (PH);",
"     </li>",
"     <li>",
"      Reliveran (AR);",
"     </li>",
"     <li>",
"      Setin (ZA);",
"     </li>",
"     <li>",
"      Sotatic-10 (ID);",
"     </li>",
"     <li>",
"      Vitamet (PH);",
"     </li>",
"     <li>",
"      Vomaine (PH);",
"     </li>",
"     <li>",
"      Zudaw (TW)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F195557\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blocks dopamine receptors and (when given in higher doses) also blocks serotonin receptors in chemoreceptor trigger zone of the CNS; enhances the response to acetylcholine of tissue in upper GI tract causing enhanced motility and accelerated gastric emptying without stimulating gastric, biliary, or pancreatic secretions; increases lower esophageal sphincter tone",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F195577\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Oral: 30-60 minutes; I.V.: 1-3 minutes; I.M.: 10-15 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: Therapeutic: 1-2 hours, regardless of route",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: Rapid",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : ~3.5 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: ~30%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Oral: Range: 65% to 95%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Normal renal function: Children: ~4 hours; Adults: 5-6 hours (may be dose dependent)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: Oral: 1-2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (~85%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;American Academy of Pediatrics Committee on Drugs. The Transfer of Drugs and Other Chemicals Into Human Milk,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 108(3):776-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/13/216/abstract-text/11533352/pubmed\" id=\"11533352\" target=\"_blank\">",
"        11533352",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Geriatrics Society 2012 Beers Criteria Update Expert Panel, \"American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2012, 60(4):616-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/13/216/abstract-text/22376048/pubmed\" id=\"22376048\" target=\"_blank\">",
"        22376048",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bruera E, Seifert L, Watanabe S, et al, \"Chronic Nausea in Advanced Cancer Patients: A Retrospective Assessment of a Metoclopramide-Based Antiemetic Regimen,\"",
"      <i>",
"       J Pain Symptom Manage",
"      </i>",
"      , 1996, 11(3):147-53.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/13/216/abstract-text/8851371/pubmed\" id=\"8851371\" target=\"_blank\">",
"        8851371",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Desmond PV and Watson KJ, \"Metoclopramide - A Review,\"",
"      <i>",
"       Med J Aust",
"      </i>",
"      , 1986, 144(7):366-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/13/216/abstract-text/3515136/pubmed\" id=\"3515136\" target=\"_blank\">",
"        3515136",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      DiPalma JR, &ldquo;Metoclopramide: A Dopamine Receptor Antagonist,&rdquo;",
"      <i>",
"       Am Fam Physician",
"      </i>",
"      , 1990, 41(3):919-24.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/13/216/abstract-text/2407079/pubmed\" id=\"2407079\" target=\"_blank\">",
"        2407079",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gan TJ, Meyer TA, Apfel CC, et al, &ldquo;Society for Ambulatory Anesthesia Guidelines for the Management of Postoperative Nausea and Vomiting,&rdquo;",
"      <i>",
"       Anesth Analg",
"      </i>",
"      , 2007, 105(6):1615-28.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/13/216/abstract-text/18042859/pubmed\" id=\"18042859\" target=\"_blank\">",
"        18042859",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Harrington RA, Hamilton CW, Brogden RN, et al, &ldquo;Metoclopramide. An Updated Review of Its Pharmacological Properties and Clinical Use,&rdquo;",
"      <i>",
"       Drugs",
"      </i>",
"      , 1983, 25(5):451-94.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/13/216/abstract-text/6345129/pubmed\" id=\"6345129\" target=\"_blank\">",
"        6345129",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hart J, \"Pediatric Gastroesophageal Reflux,\"",
"      <i>",
"       Am Fam Physician",
"      </i>",
"      ,  1996, 54(8):2463-72.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/13/216/abstract-text/8961846/pubmed\" id=\"8961846\" target=\"_blank\">",
"        8961846",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hesketh PJ, &ldquo;Chemotherapy-Induced Nausea and Vomiting,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2008, 358(23):2482-94.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/13/216/abstract-text/18525044/pubmed\" id=\"18525044\" target=\"_blank\">",
"        18525044",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Karadsheh NS, Shaker Q, and Ratroat B, &ldquo;Metoclopramide-induced Methemoglobinemia in a Patient With Co-Existing Deficiency of Glucose-6-Phosphate Dehydrogenase and NADH-Cytochrome b5 Reductase: Failure of Methylene Blue Treatment,&rdquo;",
"      <i>",
"       Haematologica",
"      </i>",
"      , 2001, 86(6):659-60.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/13/216/abstract-text/11418378/pubmed\" id=\"11418378\" target=\"_blank\">",
"        11418378",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kris MG, Hesketh PJ, Somerfield MR, et al, &ldquo;American Society of Clinical Oncology Guideline for Antiemetics in Oncology: Update 2006,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2006, 24(18):2932-46.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/13/216/abstract-text/16717289/pubmed\" id=\"16717289\" target=\"_blank\">",
"        16717289",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Martindale RG, McClave SA, Vanek VW, et al, &ldquo;Guidelines for the Provision and Assessment of Nutrition Support Therapy in the Adult Critically Ill Patient: Society of Critical Care Medicine and American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.),&rdquo;",
"      <i>",
"       JPEN J Parenter Enteral Nutr",
"      </i>",
"      , 2007, 33(3):277-316.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/13/216/abstract-text/19398613/pubmed\" id=\"19398613\" target=\"_blank\">",
"        19398613",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mary AM and Bhupalam L, &ldquo;Metoclopramide-induced Methemoglobinemia in an Adult,&rdquo;",
"      <i>",
"       J KY Med Assoc",
"      </i>",
"      , 2000, 98(6):245-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/13/216/abstract-text/10870338/pubmed\" id=\"10870338\" target=\"_blank\">",
"        10870338",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Matok I, Gorodischer R, Koren G, et al, &ldquo;The Safety of Metoclopramide Use in the First Trimester of Pregnancy,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2009, 360(24):2528-35.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/13/216/abstract-text/19516033/pubmed\" id=\"19516033\" target=\"_blank\">",
"        19516033",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      McGovern EM, Grevel J, and Bryson SM, &ldquo;Pharmacokinetics of High-Dose Metoclopramide in Cancer Patients,&rdquo;",
"      <i>",
"       Clin Pharmacokinet",
"      </i>",
"      , 1986, 11(6):415-24.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/13/216/abstract-text/3542335/pubmed\" id=\"3542335\" target=\"_blank\">",
"        3542335",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Multinational Association of Supportive Care in Cancer (MASCC), &ldquo;Antiemetic Guidelines,&rdquo; Updated April 2010. Available at file://data.memberclicks.com/site/mascc/MASCC_Guidelines_English_2010.pdf",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Comprehensive Cancer Network&reg; (NCCN), &ldquo;Clinical Practice Guidelines in Oncology&trade;: Antiemesis,&rdquo; Version 2.2010. Available at  file://www.nccn.org/professionals/physician_gls/PDF/antiemesis.pdf",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Parrish RH and Bonzo SM, &ldquo;Use of Metoclopramide Suppositories,&rdquo;",
"      <i>",
"       Clin Pharm",
"      </i>",
"      , 1983, 2(5):395-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/13/216/abstract-text/6627864/pubmed\" id=\"6627864\" target=\"_blank\">",
"        6627864",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Patterson JF, &ldquo;Neuroleptic Malignant Syndrome Associated With Metoclopramide,&rdquo;",
"      <i>",
"       South Med J",
"      </i>",
"      , 1988, 81(5):674-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/13/216/abstract-text/3368821/pubmed\" id=\"3368821\" target=\"_blank\">",
"        3368821",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Quaynor H and Raeder JC, &ldquo;Incidence and Severity of Postoperative Nausea and Vomiting are Similar After Metoclopramide 20 mg and Ondansetron 8 mg Given by the End of Laparoscopic Cholecystectomies,&rdquo;",
"      <i>",
"       Acta Anaesthesiol Scand",
"      </i>",
"      ,  2002, 46(1):109-13.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/13/216/abstract-text/11903083/pubmed\" id=\"11903083\" target=\"_blank\">",
"        11903083",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Schulze-Delrieu K, &ldquo;Drug Therapy. Metoclopramide,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1981, 305(1):28-33.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/13/216/abstract-text/7015140/pubmed\" id=\"7015140\" target=\"_blank\">",
"        7015140",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Van Veldhuizen PJ and Wyatt A, &ldquo;Metoclopramide-induced Sulfhemoglobinemia,&rdquo;",
"      <i>",
"       Am J Gastroenterol",
"      </i>",
"      , 1995, 90(6):1010-1.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/13/216/abstract-text/7771397/pubmed\" id=\"7771397\" target=\"_blank\">",
"        7771397",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9642 Version 43.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-200.131.240.2-5115C1355F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_13_216=[""].join("\n");
var outline_f0_13_216=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8117624\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195600\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195601\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195655\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195605\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195630\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195606\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195607\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195570\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195554\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8083407\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195574\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195662\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195573\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195664\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195653\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195578\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195558\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195649\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195563\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195595\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195566\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195581\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195613\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195582\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195580\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195568\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195583\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195557\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195577\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9642\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9642|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?33/45/34517?source=related_link\">",
"      Metoclopramide: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/47/759?source=related_link\">",
"      Metoclopramide: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f0_13_217="Systemic therapy for brain metastases";
var content_f0_13_217=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Systemic therapy for brain metastases",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/13/217/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/13/217/contributors\">",
"     Jan Drappatz, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/13/217/contributors\">",
"     Patrick Y Wen, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/13/217/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/13/217/contributors\">",
"     Jerome B Posner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/13/217/contributors\">",
"     Deputy Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/13/217/contributors\">",
"     April F Eichler, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/13/217/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?0/13/217/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 7, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Metastases account for more than one-half of all intracranial tumors in adults. Brain metastases are being diagnosed more often, due to both improved detection of small metastases by magnetic resonance imaging (MRI) and a true increase in incidence resulting from improved systemic therapy of extracranial disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/58/6057?source=see_link\">",
"     \"Overview of the clinical manifestations, diagnosis, and management of patients with brain metastases\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The primary approaches to the treatment of patients with brain metastases include whole brain radiation therapy (WBRT), surgery, and stereotactic radiosurgery (SRS). There is only limited evidence documenting the superiority of these approaches compared to systemic chemotherapy in the treatment of patients with brain metastases.",
"   </p>",
"   <p>",
"    The roles of various factors that determine responsiveness to systemic treatment will be reviewed here, along with the efficacy and risks of such treatment in the tumors that most commonly metastasize to the brain. The use of WBRT, SRS, and surgery in the management of brain metastases are discussed elsewhere, as is the treatment of leptomeningeal carcinomatosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/35/44601?source=see_link\">",
"     \"Treatment of brain metastases in favorable prognosis patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/40/36486?source=see_link\">",
"     \"Treatment of brain metastases in poor prognosis patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/53/26458?source=see_link\">",
"     \"Treatment of leptomeningeal metastases (carcinomatous meningitis)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     FACTORS AFFECTING RESPONSIVENESS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Blood brain barrier",
"    </span>",
"    &nbsp;&mdash;&nbsp;The blood-brain barrier limits the passage of large molecules and hydrophilic drugs into normal brain. Whereas hydrophilic chemotherapy agents generally do not penetrate primary brain tumors because of this, several studies suggest that such drugs can reach brain metastases [",
"    <a class=\"abstract\" href=\"UTD.htm?0/13/217/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The observed contrast enhancement of metastases on computed tomography (CT) and magnetic resonance imaging (MRI) also suggests that the blood-brain barrier is at least partially disrupted in metastases [",
"    <a class=\"abstract\" href=\"UTD.htm?0/13/217/abstract/3\">",
"     3",
"    </a>",
"    ] and also high-grade primary brain tumors that contrast enhance.",
"   </p>",
"   <p>",
"    The responsiveness of some brain metastases to conventional chemotherapy also indicates that the blood-brain barrier is not always impermeable. However, there are only limited data on the potential enhanced delivery of chemotherapeutic agents via intraarterial infusion and blood brain barrier disruption in patients with brain metastases, and this approach cannot be recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?0/13/217/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/13/19674?source=see_link&amp;anchor=H18#H18\">",
"     \"Experimental treatment approaches for malignant gliomas\", section on 'Blood-brain barrier'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other factors that may affect the relationship between the blood-brain barrier and chemotherapy responsiveness include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The use of corticosteroids to treat peritumoral edema can at least partially reestablish a disrupted blood-brain barrier, thereby preventing drug penetration and a therapeutic response. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/26/39335?source=see_link\">",
"       \"Management of vasogenic edema in patients with primary and metastatic brain tumors\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Although the center of a metastasis may have a sufficiently disrupted blood-brain barrier to permit drug penetration, the periphery may still only receive subtherapeutic concentrations, preventing a clinically meaningful response [",
"      <a class=\"abstract\" href=\"UTD.htm?0/13/217/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The development of a brain metastasis after successful systemic chemotherapy does not mean that the metastasis is necessarily resistant to that chemotherapy. A metastasis that was sheltered from chemotherapy by an intact blood-brain barrier may become exposed once it has progressed and disrupted the blood-brain barrier.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Chemosensitivity",
"    </span>",
"    &nbsp;&mdash;&nbsp;The sensitivity of a tumor to a chemotherapy agent is probably at least as important as the ability of the drug to cross the blood-brain barrier [",
"    <a class=\"abstract\" href=\"UTD.htm?0/13/217/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. Unfortunately, many tumors that commonly metastasize to the brain, such as melanoma and non-small cell lung cancer (NSCLC), have limited chemosensitivity, although responses have been observed even in these less chemosensitive tumors. Furthermore, within a given patient, the chemosensitivity of brain metastases may differ from that of the extracranial disease.",
"   </p>",
"   <p>",
"    In patients who have not previously been treated with chemotherapy, the response rate of brain metastases is often comparable to that seen with extracranial disease [",
"    <a class=\"abstract\" href=\"UTD.htm?0/13/217/abstract/9\">",
"     9",
"    </a>",
"    ]. Thus, in patients with symptomatic systemic disease and small, asymptomatic brain metastases, initial chemotherapy may be an option [",
"    <a class=\"abstract\" href=\"UTD.htm?0/13/217/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Only a limited number of prospective phase II and III trials have examined the role of systemic chemotherapy in the treatment of brain metastases, and most evidence comes from case reports, small series, and retrospective analyses. These available data have a number of limitations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Many of the reports include a variety of tumor types.",
"     </li>",
"     <li>",
"      Death from progression of systemic disease frequently prevents an assessment of the effect on intracranial disease. It is unclear whether responses that are observed are associated with a survival benefit.",
"     </li>",
"     <li>",
"      Most patients with intracranial metastases have progressed on one or more chemotherapy agents; thus, the observed results are in metastases that may be resistant to chemotherapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     SMALL CELL LUNG CANCER",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both the primary tumor and systemic metastases in patients with small cell lung cancer (SCLC) are generally chemosensitive, at least initially. A number of individual agents and combinations are highly active in this disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/39/6778?source=see_link\">",
"     \"First-line chemotherapy for patients with extensive stage small cell lung cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The reported response rates of brain metastases to systemic chemotherapy in previously untreated patients have varied between 27 and 85 percent, with some studies suggesting that brain metastases are as sensitive to systemic chemotherapy as extracranial disease [",
"    <a class=\"abstract\" href=\"UTD.htm?0/13/217/abstract/11-13\">",
"     11-13",
"    </a>",
"    ]. However, another study found that although some brain metastases do respond to chemotherapy, the response rate is substantially lower than for systemic disease [",
"    <a class=\"abstract\" href=\"UTD.htm?0/13/217/abstract/14\">",
"     14",
"    </a>",
"    ]. Most of the regimens were based on",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    , but other agents studied included",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    . Patients had significant toxicity, while the survival appeared to be comparable to that of patients treated with only whole brain radiation therapy.",
"   </p>",
"   <p>",
"    Response rates in previously treated patients with brain metastases range between 22 and 50 percent and are comparable to the response rates with second line chemotherapy observed in extracranial disease [",
"    <a class=\"abstract\" href=\"UTD.htm?0/13/217/abstract/15-20\">",
"     15-20",
"    </a>",
"    ]. A metaanalysis of five studies with a single chemotherapy for pretreated patients showed RRs ranging from 33 to 43 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?0/13/217/abstract/15\">",
"     15",
"    </a>",
"    ]. Several trials with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/2/32807?source=see_link\">",
"     topotecan",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/55/4983?source=see_link\">",
"     teniposide",
"    </a>",
"    have shown objective response rates of 33 to 57 percent. One multicenter phase II study of topotecan in heavily pretreated patients showed a response rate of 33 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?0/13/217/abstract/18\">",
"     18",
"    </a>",
"    ]. Similarly, a response rate of 33 percent was observed after treatment with teniposide in a series of 80 patients, most of whom had received prior chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?0/13/217/abstract/17\">",
"     17",
"    </a>",
"    ]. In contrast, a recent phase II trial of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    for relapsed SCLC identified a 65 percent response rate in 15 patients with brain metastases that were either asymptomatic or previously treated with WBRT; overall survival in these patients ranged from 1 to 24 months [",
"    <a class=\"abstract\" href=\"UTD.htm?0/13/217/abstract/21\">",
"     21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/5/4183?source=see_link\">",
"     \"Treatment of refractory and relapsed small cell lung cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Adding WBRT to chemotherapy increases the response rate of the brain metastases, but does not appear to improve survival. In a phase III trial conducted by the European Organization for Research and Treatment of Cancer (EORTC), 120 patients with SCLC and brain metastases were randomly assigned to treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/55/4983?source=see_link\">",
"     teniposide",
"    </a>",
"    alone or with WBRT [",
"    <a class=\"abstract\" href=\"UTD.htm?0/13/217/abstract/22\">",
"     22",
"    </a>",
"    ]. Patients treated with the combination of chemotherapy and WBRT had a significantly higher response rate (57 versus 22 percent with chemotherapy alone), but overall survival was not improved (3.5 versus 3.2 months). Most of the patients in this trial had received prior chemotherapy.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/47/11000?source=see_link\">",
"     Temozolomide",
"    </a>",
"    , an oral alkylating agent that crosses the blood-brain barrier and has shown activity in treatment of glial tumors, was studied in a randomized phase II trial. Improvement in neurological symptoms as well as radiological response was observed when temozolomide plus WBRT was compared to WBRT only. However, this approach cannot be recommended since the study included a number of different histologies and the subgroup of patients with SCLC was small (n = 9).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     NON-SMALL CELL LUNG CANCER",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Systemic therapy",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Cytotoxic chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Non-small cell lung cancer (NSCLC) is less responsive to systemic chemotherapy than SCLC, although results combining platinum compounds and third generation agents are substantially better than with earlier regimens. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/54/34666?source=see_link\">",
"     \"Initial systemic chemotherapy for advanced non-small cell lung cancer without an epidermal growth factor receptor mutation or the ALK fusion oncogene\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Response rates of brain metastases to chemotherapy have been highest in patients who had not received prior systemic treatment or radiation therapy (RT). In a series of 43 previously untreated patients with NSCLC, the objective response rate to the combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    was 30 percent, and the median survival was 32 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?0/13/217/abstract/23\">",
"     23",
"    </a>",
"    ]. Other platinum-based regimens have given similar response rates in previously untreated patients, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/2/32807?source=see_link\">",
"     topotecan",
"    </a>",
"    also has activity [",
"    <a class=\"abstract\" href=\"UTD.htm?0/13/217/abstract/24-27\">",
"     24-27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/47/11000?source=see_link\">",
"     Temozolomide",
"    </a>",
"    has been extensively evaluated in patients with previously irradiated brain metastases, and response rates have ranged from 0 to 20 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?0/13/217/abstract/28-33\">",
"     28-33",
"    </a>",
"    ]. A study from the EORTC was closed early because no objective responses were observed in the first 12 patients with brain metastases [",
"    <a class=\"abstract\" href=\"UTD.htm?0/13/217/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/27/36279?source=see_link\">",
"     Pemetrexed",
"    </a>",
"    also appears to have activity against brain metastases in patients with NSCLC. In a series of 39 patients with systemic disease, a partial response of the brain metastases was seen in 15 cases (38 percent), and another 12 cases (31 percent) had stable disease [",
"    <a class=\"abstract\" href=\"UTD.htm?0/13/217/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patupilone, a novel microtubule stabilizer that crosses the intact blood brain barrier, is presently being studied in an ongoing phase II trial in NSCLC patients with progressive brain metastases. Of 25 enrolled patients, eight patients had an objective response, of which three continued treatment for more than 24 weeks (eight cycles) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/13/217/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite the responsiveness to chemotherapy of unirradiated brain metastases, chemotherapy appears to be less effective than RT. In a preliminary report of a phase II trial presented at the American Society of Clinical Oncology (ASCO) meeting in 2006, patients with multiple brain metastases from NSCLC were randomly assigned to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/47/11000?source=see_link\">",
"     temozolomide",
"    </a>",
"    (200",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    days 1 to 5 every four weeks) or WBRT (30 Gy in 10 fractions) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/13/217/abstract/36\">",
"     36",
"    </a>",
"    ]. After eight weeks, significantly more patients treated with temozolomide had progressed and were excluded from evaluation (49 of 104 versus 28 of 104 treated with WBRT).",
"   </p>",
"   <p>",
"    Chemotherapy may have a role in patients who present with disseminated lung cancer and asymptomatic brain metastases. In this setting, systemic chemotherapy rather than RT has been proposed as an alternative, using a regimen specific for lung cancer. In a randomized pilot trial involving 48 neurologically asymptomatic patients, no significant differences in response rate or survival were observed when patients were treated with chemotherapy (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/59/953?source=see_link\">",
"     vinorelbine",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    ) followed by RT rather than with RT followed by chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?0/13/217/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Targeted agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;The small molecule epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/13/36056?source=see_link\">",
"     erlotinib",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/12/19654?source=see_link\">",
"     gefitinib",
"    </a>",
"    have antitumor activity in patients with brain metastases [",
"    <a class=\"abstract\" href=\"UTD.htm?0/13/217/abstract/38-43\">",
"     38-43",
"    </a>",
"    ]. Responsiveness is seen primarily, although not exclusively, in patients whose tumors harbor an EGFR mutation [",
"    <a class=\"abstract\" href=\"UTD.htm?0/13/217/abstract/41,43-45\">",
"     41,43-45",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/4/31816?source=see_link&amp;anchor=H177151213#H177151213\">",
"     \"Initial systemic therapy for advanced non-small cell lung cancer with a mutation in the epidermal growth factor receptor\", section on 'EGFR mutation as predictor of responsiveness'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The spectrum of activity in patients with brain metastases from EGFR-mutated and wild-type NSCLC can be illustrated by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A series of 53 evaluable patients with brain metastases from NSCLC included 17 patients with known EGFR mutations who were treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/13/36056?source=see_link\">",
"       erlotinib",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?0/13/217/abstract/43\">",
"       43",
"      </a>",
"      ]. Eight of nine had an objective partial or complete response after treatment with erlotinib plus whole brain RT, while six of eight had an objective response to erlotinib alone. The remaining three patients had stable disease. In the entire group, the time to tumor progression in the brain was 11.7 months.",
"      <br/>",
"      <br/>",
"      In contrast, there were no objective responses among the 36 patients in whom EGFR status was either wild type or unknown (the majority of whom were male current or former smokers), and most received erlotinib in conjunction with RT. Although 78 percent had stable disease, the median time to tumor progression in brain was only 5.8 months.",
"     </li>",
"     <li>",
"      In a phase II study, 48 patients with NSCLC and asymptomatic brain metastases were treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/13/36056?source=see_link\">",
"       erlotinib",
"      </a>",
"      alone after progression with first-line platinum doublet chemotherapy [",
"      <a class=\"abstract\" href=\"UTD.htm?0/13/217/abstract/45\">",
"       45",
"      </a>",
"      ]. Complete or partial responses were observed in 58 percent, which included six of eight patients (67 percent) with known EGFR mutations, five of 15 (33 percent) with wild-type tumors, and 17 of 25 (68 percent) with unknown EGFR mutation status. The median progression-free survival in brain was significantly longer in patients with known EGFR mutations than in those with wild-type tumors (15.2 versus 4.4 months).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Additional trials with EGFR inhibitors, both as single agents and in combination with RT, are in progress. Neither",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/12/19654?source=see_link\">",
"     gefitinib",
"    </a>",
"    nor",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/13/36056?source=see_link\">",
"     erlotinib",
"    </a>",
"    has been compared directly with RT for treatment of brain metastases, either as initial therapy or at the time of progression. Until additional data are available, we consider using small molecule EGFR tyrosine kinase inhibitors for patients with brain metastases from NSCLC in the following settings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with EGFR mutated tumors, symptomatic systemic disease, and small, asymptomatic brain metastases. In such patients, delayed RT in lieu of a closely monitored trial of an EGFR inhibitor is a reasonable approach. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/4/31816?source=see_link\">",
"       \"Initial systemic therapy for advanced non-small cell lung cancer with a mutation in the epidermal growth factor receptor\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with progressive brain metastases from NSCLC after RT, particularly those with known EGFR mutations. In such cases, an EGFR tyrosine kinase inhibitor is a reasonable alternative to cytotoxic chemotherapy. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Cytotoxic chemotherapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The utility of anti-EGFR agents in patients with leptomeningeal disease is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/53/26458?source=see_link&amp;anchor=H25#H25\">",
"     \"Treatment of leptomeningeal metastases (carcinomatous meningitis)\", section on 'Other agents'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"     Bevacizumab",
"    </a>",
"    , which has activity against glioblastoma, may also have some activity in patients with brain metastases from NSCLC. In a retrospective series of six patients with brain metastases, including five with progressive disease, two patients had a partial response and three had stable disease [",
"    <a class=\"abstract\" href=\"UTD.htm?0/13/217/abstract/46\">",
"     46",
"    </a>",
"    ]. Median progression-free survival and overall survival were 8 and 14 months, respectively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Chemotherapy plus RT",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of agents have been used in conjunction with WBRT in an effort to improve control of brain metastases from NSCLC. The most extensively studied are",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/47/11000?source=see_link\">",
"     temozolomide",
"    </a>",
"    and the radiosensitizer, motexafin gadolinium (MGd). The use of MGd is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/35/44601?source=see_link&amp;anchor=H19#H19\">",
"     \"Treatment of brain metastases in favorable prognosis patients\", section on 'Radiation sensitizers'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Temozolomide",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/47/11000?source=see_link\">",
"     temozolomide",
"    </a>",
"    in combination with WBRT is uncertain although it has been studied in combination with WBRT in three small, randomized trials in patients with newly diagnosed brain metastases [",
"    <a class=\"abstract\" href=\"UTD.htm?0/13/217/abstract/47-49\">",
"     47-49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one phase II trial, 52 patients were randomly assigned to WBRT with or without",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/47/11000?source=see_link\">",
"     temozolomide",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?0/13/217/abstract/47\">",
"     47",
"    </a>",
"    ]. The overall response rate was significantly higher with the combined modality approach compared to WBRT alone (96 versus 67 percent), and fewer patients required corticosteroid therapy two months after treatment (67 versus 91 percent). A second phase II trial that included 82 patients found that patients treated with the combined modality approach had an improved 99-day progression-free survival compared to those treated with WBRT alone [",
"    <a class=\"abstract\" href=\"UTD.htm?0/13/217/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A phase III trial that was designed to include 550 patients was initiated to address the role of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/47/11000?source=see_link\">",
"     temozolomide",
"    </a>",
"    more definitively [",
"    <a class=\"abstract\" href=\"UTD.htm?0/13/217/abstract/49\">",
"     49",
"    </a>",
"    ]. However, the trial was terminated after 95 patients were enrolled because of slow patient accrual. There was no statistically significant difference in either freedom from central nervous system progression or overall survival between those randomly assigned to WBRT alone or to WBRT plus temozolomide.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Other agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other chemotherapy agents that have been evaluated as an adjunct to WBRT for brain metastases include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?0/13/217/abstract/50\">",
"     50",
"    </a>",
"    ], 5-fluorouracil [",
"    <a class=\"abstract\" href=\"UTD.htm?0/13/217/abstract/51\">",
"     51",
"    </a>",
"    ], chloronitrosoureas [",
"    <a class=\"abstract\" href=\"UTD.htm?0/13/217/abstract/51\">",
"     51",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/2/32807?source=see_link\">",
"     topotecan",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?0/13/217/abstract/52\">",
"     52",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?0/13/217/abstract/53\">",
"     53",
"    </a>",
"    ], and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/59/953?source=see_link\">",
"     vinorelbine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?0/13/217/abstract/53\">",
"     53",
"    </a>",
"    ]. None has shown evidence of significant improvement in response rate or survival.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17007278\">",
"    <span class=\"h2\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with NSCLC and newly diagnosed brain metastases should be managed with radiation therapy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    surgery. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/35/44601?source=see_link\">",
"     \"Treatment of brain metastases in favorable prognosis patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/40/36486?source=see_link\">",
"     \"Treatment of brain metastases in poor prognosis patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is not enough evidence to support the use of concurrent agents with WBRT. Patients with asymptomatic brain metastases and extensive systemic disease may be candidates for upfront chemotherapy and deferred WBRT. Chemotherapy with platinum-based regimens,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/2/32807?source=see_link\">",
"     topotecan",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/27/36279?source=see_link\">",
"     pemetrexed",
"    </a>",
"    or EGFR targeted agents as well as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    may be considered for patients with relapsed NSCLC brain metastases. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     BREAST CANCER",
"    </span>",
"    &nbsp;&mdash;&nbsp;The brain is increasingly being reported as the first site of relapse in patients with breast cancer. This observation is probably a consequence of both tumor biology and treatment-related factors. Higher rates of brain metastases probably reflect the greater effectiveness of newer therapies, many of which do not penetrate the central nervous system (CNS), in controlling systemic disease.",
"   </p>",
"   <p>",
"    The role of cytotoxic and targeted agents in the management of women with brain metastases is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/0/19464?source=see_link&amp;anchor=H12#H12\">",
"     \"Management of brain metastases in breast cancer\", section on 'Treatment of recurrent/progressive metastases'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     MELANOMA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Melanoma is the third most common cancer causing brain metastases in the United States, which appears to reflect the relative propensity of melanoma to metastasize to the central nervous system (CNS). The role of systemic therapy in the treatment of brain metastases in patients with melanoma is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/63/39927?source=see_link&amp;anchor=H12#H12\">",
"     \"Management of brain metastases in melanoma\", section on 'Systemic therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     GERM CELL TUMORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Brain metastasis from testicular or ovarian germ cell tumors can be present at the time of the initial diagnosis or subsequently as a manifestation of progressive disease. Isolated relapse in the brain after control of systemic disease is rare [",
"    <a class=\"abstract\" href=\"UTD.htm?0/13/217/abstract/54\">",
"     54",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/7/13432?source=see_link\">",
"     \"Overview of the treatment of testicular germ cell tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Metastatic germ cell tumors, including brain metastases, are very chemosensitive, and chemotherapy is the primary treatment for brain metastases that are present at the initial diagnosis. For patients with residual metastatic disease following induction chemotherapy, the current standard of care is to resect all residual disease (including the brain) if technically feasible. The initial management of patients with testicular germ cell tumors and the treatment of brain metastases in testicular cancer patients are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/63/24568?source=see_link\">",
"     \"Initial risk-stratified treatment for advanced testicular germ cell tumors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/56/2954?source=see_link&amp;anchor=H19#H19\">",
"     \"Treatment of relapsed and refractory testicular germ cell tumors\", section on 'Brain metastases'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     GESTATIONAL TROPHOBLASTIC DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Brain metastases from gestational trophoblastic neoplasia (most commonly choriocarcinoma) are highly responsive to systemic chemotherapy, and this is most often the primary therapeutic approach. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/15/42234?source=see_link&amp;anchor=H501922995#H501922995\">",
"     \"Gestational trophoblastic neoplasia: Staging and treatment\", section on 'Treatment overview'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     NON-HODGKINS LYMPHOMA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Non-Hodgkins lymphoma (NHL) can arise as a primary tumor within the CNS or can spread to the CNS as a manifestation of systemic disease. Chemotherapy is an important component of therapy of CNS lymphoma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/17/39194?source=see_link\">",
"     \"Secondary involvement of the central nervous system by non-Hodgkin lymphoma\"",
"    </a>",
"    .) Parenchymal brain metastases of systemic NHL are much less common than are leptomeningeal metastases or epidural spinal cord disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/17/39194?source=see_link\">",
"     \"Secondary involvement of the central nervous system by non-Hodgkin lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     OTHER TUMORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of brain metastases may be increasing in other tumors types such as colorectal cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?0/13/217/abstract/55\">",
"     55",
"    </a>",
"    ] and ovarian cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?0/13/217/abstract/56,57\">",
"     56,57",
"    </a>",
"    ], possibly due to the availability of active systemic regimens to treat disseminated disease. The management of brain metastases in these patients can involve the use of surgery, radiation, or systemic chemotherapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/35/44601?source=see_link\">",
"     \"Treatment of brain metastases in favorable prognosis patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/40/36486?source=see_link\">",
"     \"Treatment of brain metastases in poor prognosis patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For these cancers, there is only anecdotal experience with systemic treatment. Although there are little data to gauge their effectiveness in treating brain metastases, the disease-specific agents or combinations that have activity outside of the CNS are the ones most likely to be active. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Chemosensitivity'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     RISK OF CNS HEMORRHAGE WITH ANTIANGIOGENIC AGENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of angiogenesis inhibitors in cancer therapy is expanding. Several classes of agents are available including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    , a monoclonal antibody against vascular endothelial growth factor (VEGF) that inhibits binding of the normal VEGF ligand to its receptor, and orally active antiangiogenic tyrosine kinase inhibitors (TKIs) that block angiogenesis by inhibiting the actions of VEGF and other growth factors. The two most commonly used antiangiogenic TKIs are",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/10/44200?source=see_link\">",
"     sunitinib",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/45/9944?source=see_link\">",
"     sorafenib",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    All VEGF-targeted agents have been associated with an increased risk of hemorrhage. In particular, concerns have been raised about a potential increase in the risk of intracerebral hemorrhage in patients treated with these agents who have brain metastases. In general, patients with brain metastases have been excluded from most clinical trials evaluating these agents. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/54/34666?source=see_link&amp;anchor=H525779160#H525779160\">",
"     \"Initial systemic chemotherapy for advanced non-small cell lung cancer without an epidermal growth factor receptor mutation or the ALK fusion oncogene\", section on 'Chemotherapy plus bevacizumab'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, accumulating evidence supports the view that the risk of intracerebral hemorrhage in patients with treated, nonhemorrhagic brain metastases or with previously undiagnosed brain metastases does not appear to be significantly greater than that for patients with brain metastases who are not treated with these agents. As a result, patients with a history of treated nonhemorrhagic brain metastases probably should not be excluded from systemic therapy with a VEGF inhibitor as long as they are not on concurrent anticoagulation. In practice, however, antiangiogenic therapy is generally held during local therapy for brain metastases. This subject is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/54/43882?source=see_link&amp;anchor=H1651227407#H1651227407\">",
"     \"Toxicity of molecularly targeted antiangiogenic agents: Non-cardiovascular effects\", section on 'Intracranial bleeding'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;As better treatments lead to improved control of systemic disease in cancer patients, brain metastases are becoming an increasingly common problem. Surgery, radiotherapy, and stereotactic radiosurgery remain the primary therapeutic modalities for most patients.",
"   </p>",
"   <p>",
"    Intrinsic sensitivity of the tumor to chemotherapy is often more important in predicting response to chemotherapy than penetration of the drug across the blood-brain barrier. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Factors affecting responsiveness'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For highly chemosensitive tumors (ie, testicular germ cell tumor, gestational trophoblastic neoplasia, lymphoma), chemotherapy has been integrated into the primary management of patients with disseminated disease, even when brain metastases are present. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Chemosensitivity'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H15\">",
"       'Germ cell tumors'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H16\">",
"       'Gestational trophoblastic disease'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H17\">",
"       'Non-Hodgkins lymphoma'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with other small, asymptomatic brain metastases about to undergo chemotherapy for their systemic disease, radiation or surgery can be deferred until the effects of the systemic chemotherapy on the brain metastases can be determined. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Chemosensitivity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For other tumors (eg, small cell and non-small cell lung cancers, breast cancer, melanoma) when surgery, WBRT,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      stereotactic radiosurgery have failed or are inappropriate, systemic chemotherapy or molecularly targeted agents may be of palliative value. The choice of a specific agent or combination should be based upon the chemosensitivity of the specific tumor type and the ability of the drug to pass through the blood brain barrier. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Chemosensitivity'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/13/217/abstract/1\">",
"      Zhang RD, Price JE, Fujimaki T, et al. Differential permeability of the blood-brain barrier in experimental brain metastases produced by human neoplasms implanted into nude mice. Am J Pathol 1992; 141:1115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/13/217/abstract/2\">",
"      Stewart DJ. A critique of the role of the blood-brain barrier in the chemotherapy of human brain tumors. J Neurooncol 1994; 20:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/13/217/abstract/3\">",
"      Davey P. Brain metastases: treatment options to improve outcomes. CNS Drugs 2002; 16:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/13/217/abstract/4\">",
"      Fortin D, Gendron C, Boudrias M, Garant MP. Enhanced chemotherapy delivery by intraarterial infusion and blood-brain barrier disruption in the treatment of cerebral metastasis. Cancer 2007; 109:751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/13/217/abstract/5\">",
"      Fortin D, Desjardins A, Benko A, et al. Enhanced chemotherapy delivery by intraarterial infusion and blood-brain barrier disruption in malignant brain tumors: the Sherbrooke experience. Cancer 2005; 103:2606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/13/217/abstract/6\">",
"      Donelli MG, Zucchetti M, D'Incalci M. Do anticancer agents reach the tumor target in the human brain? Cancer Chemother Pharmacol 1992; 30:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/13/217/abstract/7\">",
"      Lesser GJ. Chemotherapy of cerebral metastases from solid tumors. Neurosurg Clin N Am 1996; 7:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/13/217/abstract/8\">",
"      Postmus PE, Smit EF. Chemotherapy for brain metastases of lung cancer: a review. Ann Oncol 1999; 10:753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/13/217/abstract/9\">",
"      Lassman AB, DeAngelis LM. Brain metastases. Neurol Clin 2003; 21:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/13/217/abstract/10\">",
"      Moscetti L, Nelli F, Felici A, et al. Up-front chemotherapy and radiation treatment in newly diagnosed nonsmall cell lung cancer with brain metastases: survey by Outcome Research Network for Evaluation of Treatment Results in Oncology. Cancer 2007; 109:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/13/217/abstract/11\">",
"      Lee JS, Murphy WK, Glisson BS, et al. Primary chemotherapy of brain metastasis in small-cell lung cancer. J Clin Oncol 1989; 7:916.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/13/217/abstract/12\">",
"      Kristjansen PE, Soelberg S&oslash;rensen P, Skov Hansen M, Hansen HH. Prospective evaluation of the effect on initial brain metastases from small cell lung cancer of platinum-etoposide based induction chemotherapy followed by an alternating multidrug regimen. Ann Oncol 1993; 4:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/13/217/abstract/13\">",
"      Twelves CJ, Souhami RL, Harper PG, et al. The response of cerebral metastases in small cell lung cancer to systemic chemotherapy. Br J Cancer 1990; 61:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/13/217/abstract/14\">",
"      Seute T, Leffers P, Wilmink JT, et al. Response of asymptomatic brain metastases from small-cell lung cancer to systemic first-line chemotherapy. J Clin Oncol 2006; 24:2079.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/13/217/abstract/15\">",
"      Grossi F, Scolaro T, Tixi L, et al. The role of systemic chemotherapy in the treatment of brain metastases from small-cell lung cancer. Crit Rev Oncol Hematol 2001; 37:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/13/217/abstract/16\">",
"      Kristensen CA, Kristjansen PE, Hansen HH. Systemic chemotherapy of brain metastases from small-cell lung cancer: a review. J Clin Oncol 1992; 10:1498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/13/217/abstract/17\">",
"      Postmus PE, Smit EF, Haaxma-Reiche H, et al. Teniposide for brain metastases of small-cell lung cancer: a phase II study. European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. J Clin Oncol 1995; 13:660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/13/217/abstract/18\">",
"      Korfel A, Oehm C, von Pawel J, et al. Response to topotecan of symptomatic brain metastases of small-cell lung cancer also after whole-brain irradiation. a multicentre phase II study. Eur J Cancer 2002; 38:1724.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/13/217/abstract/19\">",
"      Groen HJ, Smit EF, Haaxma-Reiche H, Postmus PE. Carboplatin as second line treatment for recurrent or progressive brain metastases from small cell lung cancer. Eur J Cancer 1993; 29A:1696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/13/217/abstract/20\">",
"      Kaba SE, Kyritsis AP, Hess K, et al. TPDC-FuHu chemotherapy for the treatment of recurrent metastatic brain tumors. J Clin Oncol 1997; 15:1063.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/13/217/abstract/21\">",
"      Chen G, Huynh M, Fehrenbacher L, et al. Phase II trial of irinotecan and carboplatin for extensive or relapsed small-cell lung cancer. J Clin Oncol 2009; 27:1401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/13/217/abstract/22\">",
"      Postmus PE, Haaxma-Reiche H, Smit EF, et al. Treatment of brain metastases of small-cell lung cancer: comparing teniposide and teniposide with whole-brain radiotherapy--a phase III study of the European Organization for the Research and Treatment of Cancer Lung Cancer Cooperative Group. J Clin Oncol 2000; 18:3400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/13/217/abstract/23\">",
"      Franciosi V, Cocconi G, Michiara M, et al. Front-line chemotherapy with cisplatin and etoposide for patients with brain metastases from breast carcinoma, nonsmall cell lung carcinoma, or malignant melanoma: a prospective study. Cancer 1999; 85:1599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/13/217/abstract/24\">",
"      Fujita A, Fukuoka S, Takabatake H, et al. Combination chemotherapy of cisplatin, ifosfamide, and irinotecan with rhG-CSF support in patients with brain metastases from non-small cell lung cancer. Oncology 2000; 59:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/13/217/abstract/25\">",
"      Cortes J, Rodriguez J, Aramendia JM, et al. Front-line paclitaxel/cisplatin-based chemotherapy in brain metastases from non-small-cell lung cancer. Oncology 2003; 64:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/13/217/abstract/26\">",
"      Wong ET, Berkenblit A. The role of topotecan in the treatment of brain metastases. Oncologist 2004; 9:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/13/217/abstract/27\">",
"      Bailon O, Chouahnia K, Augier A, et al. Upfront association of carboplatin plus pemetrexed in patients with brain metastases of lung adenocarcinoma. Neuro Oncol 2012; 14:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/13/217/abstract/28\">",
"      Ebert BL, Niemierko E, Shaffer K, Salgia R. Use of temozolomide with other cytotoxic chemotherapy in the treatment of patients with recurrent brain metastases from lung cancer. Oncologist 2003; 8:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/13/217/abstract/29\">",
"      Dziadziuszko R, Ardizzoni A, Postmus PE, et al. Temozolomide in patients with advanced non-small cell lung cancer with and without brain metastases. a phase II study of the EORTC Lung Cancer Group (08965). Eur J Cancer 2003; 39:1271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/13/217/abstract/30\">",
"      Abrey LE, Olson JD, Raizer JJ, et al. A phase II trial of temozolomide for patients with recurrent or progressive brain metastases. J Neurooncol 2001; 53:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/13/217/abstract/31\">",
"      Christodoulou C, Bafaloukos D, Kosmidis P, et al. Phase II study of temozolomide in heavily pretreated cancer patients with brain metastases. Ann Oncol 2001; 12:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/13/217/abstract/32\">",
"      Giorgio CG, Giuffrida D, Pappalardo A, et al. Oral temozolomide in heavily pre-treated brain metastases from non-small cell lung cancer: phase II study. Lung Cancer 2005; 50:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/13/217/abstract/33\">",
"      Siena S, Crin&ograve; L, Danova M, et al. Dose-dense temozolomide regimen for the treatment of brain metastases from melanoma, breast cancer, or lung cancer not amenable to surgery or radiosurgery: a multicenter phase II study. Ann Oncol 2010; 21:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/13/217/abstract/34\">",
"      Bearz A, Garassino I, Tiseo M, et al. Activity of Pemetrexed on brain metastases from Non-Small Cell Lung Cancer. Lung Cancer 2010; 68:264.",
"     </a>",
"    </li>",
"    <li>",
"     Abrey LE, Wen P, Govindan R, et al. Patupilone for the treatment of recurrent/progressive brain metastases in patients (pts) with non-small cell lung cancer (NSCLC): An open-label phase II study. J Clin Oncol 2008; 26:97s. (Abstract available online at: file://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&amp;vmview=abst_detail_view&amp;confID=55&amp;abstractID=36183, accessed on July 8, 2008).",
"    </li>",
"    <li>",
"     Wagenius G, Brodin O, Nyman J, et al. Radiotherapy vs. temozolomide in the treatment of patients with lung cancer and brain metastases: A randomized phase II study (abstract). J Clin Oncol 2006; 24:398s. (Abstract available online at: www.asco.org/portal/site/ASCO/menuitem.34d60f5624ba07fd506fe310ee37a01d/?vgnextoid=76f8201eb61a7010VgnVCM100000ed730ad1RCRD, accessed on June 8, 2006).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/13/217/abstract/37\">",
"      Lee DH, Han JY, Kim HT, et al. Primary chemotherapy for newly diagnosed nonsmall cell lung cancer patients with synchronous brain metastases compared with whole-brain radiotherapy administered first : result of a randomized pilot study. Cancer 2008; 113:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/13/217/abstract/38\">",
"      Chiu CH, Tsai CM, Chen YM, et al. Gefitinib is active in patients with brain metastases from non-small cell lung cancer and response is related to skin toxicity. Lung Cancer 2005; 47:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/13/217/abstract/39\">",
"      Ceresoli GL, Cappuzzo F, Gregorc V, et al. Gefitinib in patients with brain metastases from non-small-cell lung cancer: a prospective trial. Ann Oncol 2004; 15:1042.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/13/217/abstract/40\">",
"      Wu C, Li YL, Wang ZM, et al. Gefitinib as palliative therapy for lung adenocarcinoma metastatic to the brain. Lung Cancer 2007; 57:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/13/217/abstract/41\">",
"      Kim JE, Lee DH, Choi Y, et al. Epidermal growth factor receptor tyrosine kinase inhibitors as a first-line therapy for never-smokers with adenocarcinoma of the lung having asymptomatic synchronous brain metastasis. Lung Cancer 2009; 65:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/13/217/abstract/42\">",
"      Zee YK, Chin TM, Wong AS. Fatal cystic change of brain metastasis after response to gefitinib in non-small-cell lung cancer. J Clin Oncol 2009; 27:e145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/13/217/abstract/43\">",
"      Porta R, S&aacute;nchez-Torres JM, Paz-Ares L, et al. Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation. Eur Respir J 2011; 37:624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/13/217/abstract/44\">",
"      Jamal-Hanjani M, Spicer J. Epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of epidermal growth factor receptor-mutant non-small cell lung cancer metastatic to the brain. Clin Cancer Res 2012; 18:938.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/13/217/abstract/45\">",
"      Wu YL, Zhou C, Cheng Y, et al. Erlotinib as second-line treatment in patients with advanced non-small-cell lung cancer and asymptomatic brain metastases: a phase II study (CTONG-0803). Ann Oncol 2013; 24:993.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/13/217/abstract/46\">",
"      De Braganca KC, Janjigian YY, Azzoli CG, et al. Efficacy and safety of bevacizumab in active brain metastases from non-small cell lung cancer. J Neurooncol 2010; 100:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/13/217/abstract/47\">",
"      Antonadou D, Paraskevaidis M, Sarris G, et al. Phase II randomized trial of temozolomide and concurrent radiotherapy in patients with brain metastases. J Clin Oncol 2002; 20:3644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/13/217/abstract/48\">",
"      Verger E, Gil M, Yaya R, et al. Temozolomide and concomitant whole brain radiotherapy in patients with brain metastases: a phase II randomized trial. Int J Radiat Oncol Biol Phys 2005; 61:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/13/217/abstract/49\">",
"      Chua D, Krzakowski M, Chouaid C, et al. Whole-brain radiation therapy plus concomitant temozolomide for the treatment of brain metastases from non-small-cell lung cancer: a randomized, open-label phase II study. Clin Lung Cancer 2010; 11:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/13/217/abstract/50\">",
"      Guerrieri M, Wong K, Ryan G, et al. A randomised phase III study of palliative radiation with concomitant carboplatin for brain metastases from non-small cell carcinoma of the lung. Lung Cancer 2004; 46:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/13/217/abstract/51\">",
"      Ushio Y, Arita N, Hayakawa T, et al. Chemotherapy of brain metastases from lung carcinoma: a controlled randomized study. Neurosurgery 1991; 28:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/13/217/abstract/52\">",
"      Neuhaus T, Ko Y, Muller RP, et al. A phase III trial of topotecan and whole brain radiation therapy for patients with CNS-metastases due to lung cancer. Br J Cancer 2009; 100:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/13/217/abstract/53\">",
"      Robinet G, Thomas P, Breton JL, et al. Results of a phase III study of early versus delayed whole brain radiotherapy with concurrent cisplatin and vinorelbine combination in inoperable brain metastasis of non-small-cell lung cancer: Groupe Fran&ccedil;ais de Pneumo-Canc&eacute;rologie (GFPC) Protocol 95-1. Ann Oncol 2001; 12:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/13/217/abstract/54\">",
"      Azar JM, Schneider BP, Einhorn LH. Is the blood-brain barrier relevant in metastatic germ cell tumor? Int J Radiat Oncol Biol Phys 2007; 69:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/13/217/abstract/55\">",
"      Sundermeyer ML, Meropol NJ, Rogatko A, et al. Changing patterns of bone and brain metastases in patients with colorectal cancer. Clin Colorectal Cancer 2005; 5:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/13/217/abstract/56\">",
"      Pectasides D, Pectasides M, Economopoulos T. Brain metastases from epithelial ovarian cancer: a review of the literature. Oncologist 2006; 11:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/13/217/abstract/57\">",
"      Tay SK, Rajesh H. Brain metastases from epithelial ovarian cancer. Int J Gynecol Cancer 2005; 15:824.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5197 Version 20.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-213.134.24.46-82D89F4E57-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_13_217=[""].join("\n");
var outline_f0_13_217=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H20\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      FACTORS AFFECTING RESPONSIVENESS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Blood brain barrier",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Chemosensitivity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      SMALL CELL LUNG CANCER",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      NON-SMALL CELL LUNG CANCER",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Systemic therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Cytotoxic chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Targeted agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Chemotherapy plus RT",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Temozolomide",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Other agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17007278\">",
"      Summary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      BREAST CANCER",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      MELANOMA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      GERM CELL TUMORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      GESTATIONAL TROPHOBLASTIC DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      NON-HODGKINS LYMPHOMA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      OTHER TUMORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      RISK OF CNS HEMORRHAGE WITH ANTIANGIOGENIC AGENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/13/19674?source=related_link\">",
"      Experimental treatment approaches for malignant gliomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/39/6778?source=related_link\">",
"      First-line chemotherapy for patients with extensive stage small cell lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/15/42234?source=related_link\">",
"      Gestational trophoblastic neoplasia: Staging and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/63/24568?source=related_link\">",
"      Initial risk-stratified treatment for advanced testicular germ cell tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/54/34666?source=related_link\">",
"      Initial systemic chemotherapy for advanced non-small cell lung cancer without an epidermal growth factor receptor mutation or the ALK fusion oncogene",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/4/31816?source=related_link\">",
"      Initial systemic therapy for advanced non-small cell lung cancer with a mutation in the epidermal growth factor receptor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/0/19464?source=related_link\">",
"      Management of brain metastases in breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/63/39927?source=related_link\">",
"      Management of brain metastases in melanoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/26/39335?source=related_link\">",
"      Management of vasogenic edema in patients with primary and metastatic brain tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/58/6057?source=related_link\">",
"      Overview of the clinical manifestations, diagnosis, and management of patients with brain metastases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/7/13432?source=related_link\">",
"      Overview of the treatment of testicular germ cell tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/17/39194?source=related_link\">",
"      Secondary involvement of the central nervous system by non-Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/54/43882?source=related_link\">",
"      Toxicity of molecularly targeted antiangiogenic agents: Non-cardiovascular effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/35/44601?source=related_link\">",
"      Treatment of brain metastases in favorable prognosis patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/40/36486?source=related_link\">",
"      Treatment of brain metastases in poor prognosis patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/53/26458?source=related_link\">",
"      Treatment of leptomeningeal metastases (carcinomatous meningitis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/5/4183?source=related_link\">",
"      Treatment of refractory and relapsed small cell lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/56/2954?source=related_link\">",
"      Treatment of relapsed and refractory testicular germ cell tumors",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f0_13_218="Extravasation injury from chemotherapy and other non-neoplastic vesicants";
var content_f0_13_218=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Extravasation injury from chemotherapy and other non-neoplastic vesicants",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/13/218/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/13/218/contributors\">",
"     Aimee S Payne, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/13/218/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/13/218/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/13/218/contributors\">",
"     Reed E Drews, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/13/218/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/13/218/contributors\">",
"     Michael E Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?0/13/218/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 18, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Extravasation refers to the escape of a drug into the extravascular space, either by leakage from a vessel or by direct infiltration [",
"    <a class=\"abstract\" href=\"UTD.htm?0/13/218/abstract/1\">",
"     1",
"    </a>",
"    ]. Although many drugs are irritating when they are introduced into extravascular tissues, extravasation of a vesicant drug has the potential to cause tissue damage with severe",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    lasting injury. Although the most well known vesicants are cytotoxic chemotherapy drugs (",
"    <a class=\"graphic graphic_table graphicRef67517 \" href=\"UTD.htm?5/53/5981\">",
"     table 1",
"    </a>",
"    ), several non-antineoplastic drugs also have vesicant properties (",
"    <a class=\"graphic graphic_table graphicRef86804 \" href=\"UTD.htm?25/63/26622\">",
"     table 2",
"    </a>",
"    ). &nbsp;",
"   </p>",
"   <p>",
"    The incidence, risk factors, clinical presentation, pathogenesis, prevention, and management of extravasation injury from chemotherapy and non-antineoplastic vesicants are reviewed here, with a focus on chemotherapy extravasation injury. Other cutaneous complications of chemotherapy and venous irritation (chemical phlebitis) that occurs with drug administration into an intact vein (as is seen predominantly with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/59/953?source=see_link\">",
"     vinorelbine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/27/4536?source=see_link\">",
"     epirubicin",
"    </a>",
"    ) are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/7/36986?source=see_link\">",
"     \"Cutaneous complications of conventional chemotherapy agents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1420806\">",
"    <span class=\"h1\">",
"     INCIDENCE AND RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among patients receiving chemotherapy, vesicant extravasations are rare occurrences, although the true incidence is unclear since there is no central reporting mechanism. In a 1979 study of 139 patients receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    via peripheral vein, nine (6.5 percent) developed an extravasation injury [",
"    <a class=\"abstract\" href=\"UTD.htm?0/13/218/abstract/2\">",
"     2",
"    </a>",
"    ]. More recently, data from MD Anderson Cancer Center indicates that rates of extravasation injury (as determined by referral patterns to a plastic surgery clinic) declined over a 15-year period, from 0.1 to 0.01 percent based upon individual doses of chemotherapy administered [",
"    <a class=\"abstract\" href=\"UTD.htm?0/13/218/abstract/3\">",
"     3",
"    </a>",
"    ]. However, this series only includes patients who were referred to plastic surgery rather than all extravasations, while the denominator includes all individual doses of chemotherapy delivered at MD Anderson over the 6-year study period. As such, this rate probably represents an underestimation of the true incidence of chemotherapy extravasation injury.",
"   </p>",
"   <p>",
"    Infusional administration of vesicant antineoplastic agents is frequently done through a central venous access device (CVAD) to minimize the likelihood of subcutaneous extravasation. While the risk of chemotherapy extravasation through a CVAD is small, it is not zero and may be due to injection technique or device failure:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a single center report of 376 patients receiving high-dose chemotherapy and peripheral blood stem cell transplantation through a CVAD over a five-year period, there was one case of extravasation (0.26 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?0/13/218/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Another series noted three extravasations in 225 CVADs implanted in 217 patients over an 11-year period (1.3 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?0/13/218/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A third report noted 15 cases of drug extravasation among 815 consecutive cancer patients who received chemotherapy with a totally implantable venous access port system over a one-year period (2 percent), not all of whom were receiving vesicants [",
"      <a class=\"abstract\" href=\"UTD.htm?0/13/218/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The incidence of extravasation among individuals receiving non-neoplastic vesicant medications is unknown.",
"   </p>",
"   <p>",
"    Every patient who receives a vesicant is at risk for extravasation. Risk factors for extravasation from a peripheral vein include [",
"    <a class=\"abstract\" href=\"UTD.htm?0/13/218/abstract/7-9\">",
"     7-9",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Small",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      fragile veins, or limited vein availability because of lymph node dissection, lymphedema, or limb removal",
"     </li>",
"     <li>",
"      Obesity, which obscures veins from view and palpation",
"     </li>",
"     <li>",
"      Multiple previous venipunctures",
"     </li>",
"     <li>",
"      Disseminated skin disease (eg, eczema, psoriasis)",
"     </li>",
"     <li>",
"      Patient movement",
"     </li>",
"     <li>",
"      Sensory deficits that impair a patient&rsquo;s ability to detect a change in sensation at the site of chemotherapy administration (eg, paralysis, prior stroke, sedation, somnolence, impaired cognition, impaired mental status)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Risk factors for extravasation from a CVAD include [",
"    <a class=\"abstract\" href=\"UTD.htm?0/13/218/abstract/8,10,11\">",
"     8,10,11",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Difficulty encountered during insertion of the device, such as probing or inability to advance the guidewire or catheter. Catheters can also become inadvertently sliced, pierced, or nicked before or during insertion.",
"     </li>",
"     <li>",
"      Device misplacement, with the catheter tip placed outside of the venous system instead of the superior vena cava.",
"     </li>",
"     <li>",
"      Catheter migration from the vein into the tissue.",
"     </li>",
"     <li>",
"      Long dwell time (6 months or longer); soft catheter materials are prone to weakening and &ldquo;pinch off&rdquo; syndrome which occur when the catheter is compressed between the clavicle and the first or second rib.",
"     </li>",
"     <li>",
"      The presence of a fibrin sheath or thrombus at the catheter tip, which may cause vesicant chemotherapy to backtrack along the catheter and leak from the vein at the venotomy site.",
"     </li>",
"     <li>",
"      A deeply implanted port, which increases the risk that a non-coring needle will be of insufficient length to be correctly positioned into the port septum, or that patient movement will cause &ldquo;rocking&rdquo; of the needle within the port septum.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     IRRITANTS VERSUS VESICANT DRUGS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9997343\">",
"    <span class=\"h2\">",
"     Antineoplastic agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cytotoxic drugs are classified as irritants or vesicants based upon their potential for local toxicity (",
"    <a class=\"graphic graphic_table graphicRef67517 \" href=\"UTD.htm?5/53/5981\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An irritant drug causes an inflammatory reaction, with aching, burning, tightness, pain, and phlebitis at the needle insertion site or along the vein. Clinical signs include warmth, erythema, and tenderness in the extravasated area, but there is no tissue sloughing or necrosis. Symptoms are usually of short duration, and there are no long-lasting sequelae.",
"     </li>",
"     <li>",
"      Extravasation of a vesicant drug has the potential to cause tissue necrosis with a more severe",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      lasting injury. Vesicant extravasation may result in loss of the full thickness of the skin and, if severe, underlying structures. Among cytotoxic chemotherapy agents that cause extravasation injury, the anthracyclines are among the most important, both because of their widespread use in various chemotherapy regimens and because of their ability to produce severe tissue necrosis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The distinction between irritant and vesicant chemotherapy drugs is not absolute. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There is are reports of tissue injury from an extravasation of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/11/2233?source=see_link\">",
"       oxaliplatin",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?0/13/218/abstract/12,13\">",
"       12,13",
"      </a>",
"      ], although another series of 11 patients showed no tissue destruction [",
"      <a class=\"abstract\" href=\"UTD.htm?0/13/218/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Most injection site reactions following extravasation of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"       paclitaxel",
"      </a>",
"      consist of redness, tenderness, and swelling, but there are case reports that document necrosis and skin exfoliation [",
"      <a class=\"abstract\" href=\"UTD.htm?0/13/218/abstract/15-18\">",
"       15-18",
"      </a>",
"      ]. Only rarely are long-term sequelae reported, such as ulceration requiring surgical intervention [",
"      <a class=\"abstract\" href=\"UTD.htm?0/13/218/abstract/19\">",
"       19",
"      </a>",
"      ]. In a compilation of 35 reported cases of paclitaxel extravasation, only three developed ulceration, two requiring skin closure [",
"      <a class=\"abstract\" href=\"UTD.htm?0/13/218/abstract/15\">",
"       15",
"      </a>",
"      ]. While most references classify paclitaxel as an irritant drug, the Oncology Nursing Society (ONS) classifies it as a vesicant [",
"      <a class=\"abstract\" href=\"UTD.htm?0/13/218/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Similarly,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/31/37368?source=see_link\">",
"       mitoxantrone",
"      </a>",
"      , usually classified as an irritant, has been reported to cause skin necrosis requiring surgical debridement and skin grafting [",
"      <a class=\"abstract\" href=\"UTD.htm?0/13/218/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/20/32071?source=see_link\">",
"       Bendamustine",
"      </a>",
"      is usually classified as an irritant, but postmarketing surveillance has identified extravasations causing erythema, marked swelling and pain; the manufacturer recommends that extravasation be avoided [",
"      <a class=\"abstract\" href=\"UTD.htm?0/13/218/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In such cases, the extent of tissue injury may be a function of the amount of drug extravasated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9997351\">",
"    <span class=\"h2\">",
"     Non-antineoplastic agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although extravasation from vesicants is best described with antineoplastic agents, a number of other non-antineoplastic drugs can also act as vesicants or irritants if they extravasate into the subcutaneous tissues (",
"    <a class=\"graphic graphic_table graphicRef86804 \" href=\"UTD.htm?25/63/26622\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/13/218/abstract/23-26\">",
"     23-26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early symptoms and signs of extravasation injury from a vesicant are often subtle. They usually appear immediately after the extravasation but can be delayed for days to weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?0/13/218/abstract/23\">",
"     23",
"    </a>",
"    ]. Initially, there is local burning or tingling at the infusion site, mild erythema, pruritus, and swelling. Within two to three days, increased erythema, pain, brawny discoloration, induration, dry desquamation,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    blistering may appear [",
"    <a class=\"abstract\" href=\"UTD.htm?0/13/218/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    With small volume extravasations, symptoms may disappear over the next several weeks. With more extensive infiltrations, necrosis, eschar formation, and ulceration with raised, red, painful edges and a yellow necrotic base may appear over several weeks.",
"   </p>",
"   <p>",
"    Vesicant-induced ulcerations lack granulation tissue and have little epithelial ingrowth. While very small ulcers typically heal gradually, larger lesions tend to persist, gradually expanding over time. If left untreated, underlying tendons, nerves, and vessels may become involved, leading to the possible sequelae of nerve compression syndromes, permanent joint stiffness, contractures, and neurologic dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?0/13/218/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There have been reports of an extravasation recall phenomenon, where previous sites of extravasation of a vesicant drug become inflamed upon re-exposure of the patient to the same drug administered at a remote IV site. This phenomenon has been reported with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?0/13/218/abstract/28-30\">",
"     28-30",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?0/13/218/abstract/31,32\">",
"     31,32",
"    </a>",
"    ], and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/27/4536?source=see_link\">",
"     epirubicin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?0/13/218/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H75722605\">",
"    <span class=\"h2\">",
"     Central venous access device extravasation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Extravasation of chemotherapy agents administered through a central venous access device (CVAD) is a rare complication; in one series of 815 patients, the incidence was 0.24 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?0/13/218/abstract/6\">",
"     6",
"    </a>",
"    ]. The extravasated solution may accumulate in the mediastinum, pleura, or in the subcutaneous tissues of the chest or neck. The predominant symptom is thoracic pain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The best approach to extravasation injury is prevention [",
"    <a class=\"abstract\" href=\"UTD.htm?0/13/218/abstract/10\">",
"     10",
"    </a>",
"    ]. Guidelines for prevention of chemotherapy extravasation are available from the Oncology Nursing Society and the European Oncology Nurses Society [",
"    <a class=\"abstract\" href=\"UTD.htm?0/13/218/abstract/20,34\">",
"     20,34",
"    </a>",
"    ]. Several simple precautions can minimize the risk of extravasation:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For peripheral infusions of chemotherapy, the IV line should be recently started, and the vein selected should be large and intact, with good blood return established prior to starting the infusion.",
"     </li>",
"     <li>",
"      Infusion sites should be selected in the following order of preference: forearm (basilic, cephalic, and median antebrachial), dorsum of hand, wrist, antecubital fossae.",
"     </li>",
"     <li>",
"      Sites with sclerosis, thrombosis, or scar formation should be avoided, as should limbs with impaired circulation. Although controversial, most experts do not feel that the avoidance of IV lines on the ipsilateral side is necessary or beneficial in a woman who has undergone mastectomy for breast cancer, as long as lymphedema is absent. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/1/33817?source=see_link\">",
"       \"Prevention and treatment of lymphedema\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The butterfly needle or plastic cannula should be secured to the skin with tape. Taping of the entry site itself should be avoided so that the area can be examined. Instead, once the hub of the cannula or butterfly needle is secured to the skin with tape, a clear dressing such as Tegaderm is usually applied to cover the skin entry site.",
"     </li>",
"     <li>",
"      The patency of the IV line should be verified just prior to drug infusion by flushing with 5 to 10 mL of isotonic saline or a 5 percent dextrose solution.",
"     </li>",
"     <li>",
"      Instruct the patient to notify a clinician immediately if he or she experiences any pain, leaking, or other changes in sensation at the infusion site. For patients with central venous catheters, this may include chest pain or dyspnea from pleural effusion if the tip should penetrate the superior vena cava.",
"     </li>",
"     <li>",
"      The chemotherapeutic agent, appropriately diluted, should be infused through the side arm of the freely-flowing IV with isotonic saline or 5 percent dextrose. During the infusion, patients should be closely monitored for pain (often described as mild to severe burning radiating along the vein), and the site inspected for erythema or swelling [",
"      <a class=\"abstract\" href=\"UTD.htm?0/13/218/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Use of a central venous catheter for infusion of vesicant drugs provides reliable venous access, high flow rates and rapid drug dilution. However, these vascular access devices are subject to a number of complications, including drug extravasation. The catheter tip may not be properly positioned in the superior vena cava or right atrium, it may migrate out of position, the needle may be improperly inserted into the injection port, or the catheter itself may be punctured or rupture [",
"      <a class=\"abstract\" href=\"UTD.htm?0/13/218/abstract/35\">",
"       35",
"      </a>",
"      ]. One report found a 6.5 percent rate of extravasation from subcutaneous ports, a value that is similar to that reported for peripheral lines [",
"      <a class=\"abstract\" href=\"UTD.htm?0/13/218/abstract/36\">",
"       36",
"      </a>",
"      ]. The position of a catheter following surgical placement should be confirmed radiographically prior to drug administration. In addition, if there are any complaints of pain, even without soft tissue swelling, or the lack of ability to draw blood or infuse a flush solution, there is a need to reconfirm the positioning of the catheter prior to continuing with the chemotherapy infusion. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Information regarding the treatment of chemotherapy extravasation is based upon animal models, anecdotal case reports, and a limited number of small uncontrolled studies. The efficacy of any specific approach has never been proven in controlled studies [",
"    <a class=\"abstract\" href=\"UTD.htm?0/13/218/abstract/37\">",
"     37",
"    </a>",
"    ]. Furthermore, evaluation of the published data in humans is difficult due to variability in methods and treatment endpoints, and the confounding influence of nonpharmacologic therapy (ie, the application of cold or heat).",
"   </p>",
"   <p>",
"    Guidelines for management of chemotherapy extravasation are available from the Oncology Nursing Society (ONS) and the European Oncology Nurses Society (EONS) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/13/218/abstract/20,34\">",
"     20,34",
"    </a>",
"    ]. An overview of our recommended approach to the management of chemotherapy extravasations, which follows the general guidelines of the ONS and EONS, is presented in the table (",
"    <a class=\"graphic graphic_table graphicRef67155 \" href=\"UTD.htm?25/57/26525\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Initial management",
"    </span>",
"    &nbsp;&mdash;&nbsp;When extravasation of an irritant or vesicant drug is suspected, the following initial management is recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?0/13/218/abstract/20,34,38,39\">",
"     20,34,38,39",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Stop the infusion immediately. Do not flush the line, and avoid applying pressure to the extravasated site.",
"     </li>",
"     <li>",
"      Elevate the affected extremity.",
"     </li>",
"     <li>",
"      The",
"      <span class=\"nowrap\">",
"       catheter/needle",
"      </span>",
"      should",
"      <strong>",
"       not",
"      </strong>",
"      be removed immediately. Instead, it should be left in place to attempt to aspirate fluid from the extravasated area and to facilitate the administration of an antidote to the local area, if appropriate (see below).",
"     </li>",
"     <li>",
"      If an antidote will not be injected into the extravasation site, the",
"      <span class=\"nowrap\">",
"       catheter/needle",
"      </span>",
"      can be removed after attempted aspiration of the subcutaneous tissues.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Application of heat or cold",
"    </span>",
"    &nbsp;&mdash;&nbsp;Topical application of ice or cold packs is recommended for extravasation of all vesicant or irritant drugs",
"    <strong>",
"     except",
"    </strong>",
"    the vinca alkaloids (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/3/4152?source=see_link\">",
"     vinblastine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/59/953?source=see_link\">",
"     vinorelbine",
"    </a>",
"    ) and epipodophyllotoxins such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    . Intermittent cooling is thought to cause vasoconstriction, thereby diminishing the spread of the drug and the extent of the local injury [",
"    <a class=\"abstract\" href=\"UTD.htm?0/13/218/abstract/40\">",
"     40",
"    </a>",
"    ]. Cold compresses also reduce local inflammation and pain.",
"   </p>",
"   <p>",
"    Efficacy of cold application was suggested in a series of 175 patients with extravasation of a variety of chemotherapeutic agents, in whom close to 90 percent of those treated with ice alone (15 minutes four times daily for three days) required no further therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?0/13/218/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Application of ice is",
"    <strong>",
"     contraindicated",
"    </strong>",
"    for extravasations of vinca alkaloids or epipodophyllotoxins, as cold worsens the ulceration caused by these drugs, at least in animal models [",
"    <a class=\"abstract\" href=\"UTD.htm?0/13/218/abstract/40,42\">",
"     40,42",
"    </a>",
"    ]. Instead, the application of heat is generally recommended for these agents, although most of the available data are derived from animal studies rather than clinical reports. Local heating is thought to result in localized vasodilation and increased blood flow, thereby enhancing drug removal [",
"    <a class=\"abstract\" href=\"UTD.htm?0/13/218/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The role of heat versus cold with taxanes is less clear:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"       paclitaxel",
"      </a>",
"      extravasations, some guidelines suggest the application of ice [",
"      <a class=\"abstract\" href=\"UTD.htm?0/13/218/abstract/15,20\">",
"       15,20",
"      </a>",
"      ], although EONS guidelines suggest application of heat in this setting, since the taxanes, like the vinca alkaloids, are non-DNA binding agents and the general strategy for these types of extravasations is to dilute and diffuse [",
"      <a class=\"abstract\" href=\"UTD.htm?0/13/218/abstract/34\">",
"       34",
"      </a>",
"      ]. Aside from extravasation recall phenomena, long-term effects of paclitaxel extravasation are minimal and usually entail mild fibrosis around the extravasation site.",
"     </li>",
"     <li>",
"      Skin toxicity, including desquamation following accidental extravasation, is more frequent with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/59/41913?source=see_link\">",
"       docetaxel",
"      </a>",
"      than",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"       paclitaxel",
"      </a>",
"      , although serious long-term sequelae have not been described. The relative benefit of topical cooling for docetaxel extravasations is less clear than for paclitaxel; some (including the EONS) suggest that heat rather than cold be applied in such cases [",
"      <a class=\"abstract\" href=\"UTD.htm?0/13/218/abstract/34,43\">",
"       34,43",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Specific antidotes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Specific antidotes have been recommended to prevent necrosis and ulceration following extravasation of certain drugs (",
"    <a class=\"graphic graphic_table graphicRef67155 \" href=\"UTD.htm?25/57/26525\">",
"     table 3",
"    </a>",
"    ). These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Local injection of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/18/17700?source=see_link\">",
"       sodium thiosulfate",
"      </a>",
"      for extravasations of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/57/40853?source=see_link\">",
"       mechlorethamine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/49/4887?source=see_link\">",
"       dacarbazine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"     </li>",
"     <li>",
"      Topical application of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/22/33123?source=see_link\">",
"       dimethylsulfoxide",
"      </a>",
"      (DMSO) for anthracycline extravasation",
"     </li>",
"     <li>",
"      A single subcutaneous injection of DMSO for",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/16/38144?source=see_link\">",
"       mitomycin",
"      </a>",
"      extravasation, followed by topical application [",
"      <a class=\"abstract\" href=\"UTD.htm?0/13/218/abstract/7\">",
"       7",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Local injection of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/33/42512?source=see_link\">",
"       hyaluronidase",
"      </a>",
"      has been recommended for extravasations of vinca alkaloids,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"       paclitaxel",
"      </a>",
"      , epipodophyllotoxins, and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/25/38297?source=see_link\">",
"       ifosfamide",
"      </a>",
"     </li>",
"     <li>",
"      Systemic administration of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/28/30150?source=see_link\">",
"       dexrazoxane",
"      </a>",
"      following anthracycline extravasation",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    None of these treatments has been validated in randomized trials, and there is no consensus on the proper use of these agents.",
"   </p>",
"   <p>",
"    For other drugs (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/52/41798?source=see_link\">",
"     trabectedin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?0/13/218/abstract/44\">",
"     44",
"    </a>",
"    ]), there are no specific published antidotes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Sodium thiosulfate",
"    </span>",
"    &nbsp;&mdash;&nbsp;Local injection of a freshly prepared 4 percent",
"    <span class=\"nowrap\">",
"     (1/6",
"    </span>",
"    Molar) or 2 percent solution of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/18/17700?source=see_link\">",
"     sodium thiosulfate",
"    </a>",
"    (2 mL for each mg thought to be extravasated) is recommended for the treatment of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/57/40853?source=see_link\">",
"     mechlorethamine",
"    </a>",
"    (nitrogen mustard) extravasations, as well as for large volume extravasation of concentrated",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/49/4887?source=see_link\">",
"     dacarbazine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    &nbsp;(",
"    <a class=\"graphic graphic_table graphicRef67155 \" href=\"UTD.htm?25/57/26525\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/13/218/abstract/20,39,45\">",
"     20,39,45",
"    </a>",
"    ]. The solution is injected subcutaneously into the extravasated site using a separate 25 gauge or smaller needle.",
"   </p>",
"   <p>",
"    To make a 4 percent solution:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If using 10 percent",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/18/17700?source=see_link\">",
"       sodium thiosulfate",
"      </a>",
"      , mix 4 mL with 6 mL sterile water for injection.",
"     </li>",
"     <li>",
"      If using 25 percent",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/18/17700?source=see_link\">",
"       sodium thiosulfate",
"      </a>",
"      , mix 1.6 mL with 8.4 mL sterile water for injection.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The recommendation for use of thiosulfate is based largely on in vitro data demonstrating an interaction of thiosulfate with both",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/57/40853?source=see_link\">",
"     mechlorethamine",
"    </a>",
"    , and in vivo animal data demonstrating the ability of thiosulfate to inactivate mechlorethamine [",
"    <a class=\"abstract\" href=\"UTD.htm?0/13/218/abstract/46-50\">",
"     46-50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical benefit of thiosulfate in patients with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/57/40853?source=see_link\">",
"     mechlorethamine",
"    </a>",
"    extravasation is poorly documented, with one report demonstrating protection from ulceration in a single patient who received an inadvertent intramuscular injection [",
"    <a class=\"abstract\" href=\"UTD.htm?0/13/218/abstract/51\">",
"     51",
"    </a>",
"    ]. Nevertheless, both the ONS and EONS recommend the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/18/17700?source=see_link\">",
"     sodium thiosulfate",
"    </a>",
"    for mechlorethamine extravasation despite the lack of conclusive evidence as to benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?0/13/218/abstract/20,34\">",
"     20,34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/18/17700?source=see_link\">",
"     sodium thiosulfate",
"    </a>",
"    has also been suggested for extravasations of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/20/32071?source=see_link\">",
"     bendamustine",
"    </a>",
"    (a",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/57/40853?source=see_link\">",
"     mechlorethamine",
"    </a>",
"    derivative that usually acts as an irritant but can cause local tissue injury if extravasated) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/13/218/abstract/8\">",
"     8",
"    </a>",
"    ]. However, neither the ONS or EONS has addressed the issue of sodium thiosulfate with this drug [",
"    <a class=\"abstract\" href=\"UTD.htm?0/13/218/abstract/20,34\">",
"     20,34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Clinical efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/18/17700?source=see_link\">",
"     sodium thiosulfate",
"    </a>",
"    in patients with extravasation from other agents was suggested in a series of 63 patients who had received",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/27/4536?source=see_link\">",
"     epirubicin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/3/4152?source=see_link\">",
"     vinblastine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/16/38144?source=see_link\">",
"     mitomycin",
"    </a>",
"    C [",
"    <a class=\"abstract\" href=\"UTD.htm?0/13/218/abstract/45\">",
"     45",
"    </a>",
"    ]. One-half were treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/49/32528?source=see_link\">",
"     hydrocortisone",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    (see below) alone while the remainder also received sodium thiosulfate (2 percent solution injected subcutaneously). No patient in either group developed skin ulceration or required surgery. The mean healing time for the group receiving thiosulfate was one half that of the other group, although the lack of randomization in treatment assignment renders this result inconclusive.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Hyaluronidase",
"    </span>",
"    &nbsp;&mdash;&nbsp;The proteolytic enzyme",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/33/42512?source=see_link\">",
"     hyaluronidase",
"    </a>",
"    promotes the diffusion of subcutaneously injected solutions by hydrolyzing hyaluronic acid, one of the chief ingredients of the connective tissue stroma. It is postulated that this creates a wider surface for dilution and aspiration of the drug.",
"   </p>",
"   <p>",
"    Based upon small clinical reports, local infiltration with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/33/42512?source=see_link\">",
"     hyaluronidase",
"    </a>",
"    had been recommended for extravasations due to antineoplastic agents such as vinca alkaloids,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    , epipodophyllotoxins, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/25/38297?source=see_link\">",
"     ifosfamide",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?0/13/218/abstract/15,20,34\">",
"     15,20,34",
"    </a>",
"    ]. In addition, single case reports support potential benefit with extravasations from",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?0/13/218/abstract/52\">",
"     52",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/36/1608?source=see_link\">",
"     nafcillin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?0/13/218/abstract/53\">",
"     53",
"    </a>",
"    ] and other compounds such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/42/3752?source=see_link\">",
"     mannitol",
"    </a>",
"    and high concentrations of dextrose [",
"    <a class=\"abstract\" href=\"UTD.htm?0/13/218/abstract/54-57\">",
"     54-57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A preparation of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/33/42512?source=see_link\">",
"     hyaluronidase",
"    </a>",
"    is commercially available but has not been approved for this indication [",
"    <a class=\"abstract\" href=\"UTD.htm?0/13/218/abstract/58\">",
"     58",
"    </a>",
"    ]. The recommended dose is 1 mL (150 units), infiltrated subcutaneously, as five separate injections of 0.2 mL each, into the extravasated site using a separate 25 gauge or smaller needle.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     DMSO",
"    </span>",
"    &nbsp;&mdash;&nbsp;Topical application of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/22/33123?source=see_link\">",
"     dimethylsulfoxide",
"    </a>",
"    (DMSO) has been recommended by some groups (including the EONS but not ONS) for anthracycline or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/16/38144?source=see_link\">",
"     mitomycin",
"    </a>",
"    extravasation [",
"    <a class=\"abstract\" href=\"UTD.htm?0/13/218/abstract/20,34,39\">",
"     20,34,39",
"    </a>",
"    ]. For extravasation with mitomycin, one source recommends subcutaneous injection of DMSO immediately following extravasation, followed by topical application [",
"    <a class=\"abstract\" href=\"UTD.htm?0/13/218/abstract/7\">",
"     7",
"    </a>",
"    ]. The evidence supporting the use of DMSO comes from at least two observational studies in patients with chemotherapy extravasations.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the largest series, 144 patients with chemotherapy extravasation from a variety of drugs received topical DMSO (application of a 99 percent solution every eight hours for seven days) plus local cooling therapy (60 minutes every eight hours for three days) [",
"      <a class=\"abstract\" href=\"UTD.htm?0/13/218/abstract/59\">",
"       59",
"      </a>",
"      ]. The authors reported complete recovery within one week in 103 patients (71 percent), while 22 others recovered with more prolonged DMSO therapy (total success rate 87 percent). Ulceration developed in a sole patient with an",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/27/4536?source=see_link\">",
"       epirubicin",
"      </a>",
"      extravasation. Interpretation of these results is difficult because of the combined use of both DMSO and topical cooling. Furthermore, only 62 extravasations were due to known vesicants (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/16/38144?source=see_link\">",
"       mitomycin",
"      </a>",
"      or epirubicin), while the remainder involved irritant rather than vesicant drugs (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/25/38297?source=see_link\">",
"       ifosfamide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/31/37368?source=see_link\">",
"       mitoxantrone",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Benefit for DMSO independent of cold application in patients with anthracycline extravasation was suggested in a prospective series, in which none of 20 patients who received topical DMSO (99 percent solution every six hours for 14 days) developed ulceration or required surgical management [",
"      <a class=\"abstract\" href=\"UTD.htm?0/13/218/abstract/60\">",
"       60",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The mechanism underlying benefit from DMSO is uncertain. DMSO has activity as a free radical scavenger, and at least some data support the view that tissue damage from vesicants (particularly anthracyclines) is due to the formation of hydroxyl free radicals [",
"    <a class=\"abstract\" href=\"UTD.htm?0/13/218/abstract/61,62\">",
"     61,62",
"    </a>",
"    ]. The two studies cited above both used a DMSO concentration of &gt;90 percent, which is not available in the United States. The only available preparation is a 50 percent solution, which is marketed for intravesical use. Guidelines for extravasation management from the Oncology Nursing Society (ONS) do not include DMSO, and even the manufacturers' package labeling information fails to recommend its use for anthracycline or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/16/38144?source=see_link\">",
"     mitomycin",
"    </a>",
"    extravasations. Therefore DMSO is not included in the recommended treatments in the following table (",
"    <a class=\"graphic graphic_table graphicRef67155 \" href=\"UTD.htm?25/57/26525\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Dexrazoxane",
"    </span>",
"    &nbsp;&mdash;&nbsp;Benefit for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/28/30150?source=see_link\">",
"     dexrazoxane",
"    </a>",
"    after anthracycline extravasation was initially suggested in animal studies and isolated case reports [",
"    <a class=\"abstract\" href=\"UTD.htm?0/13/218/abstract/63-66\">",
"     63-66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/28/30150?source=see_link\">",
"     Dexrazoxane",
"    </a>",
"    was subsequently evaluated in two prospective nonrandomized multicenter studies involving 80 patients with presumed anthracycline extravasations [",
"    <a class=\"abstract\" href=\"UTD.htm?0/13/218/abstract/67\">",
"     67",
"    </a>",
"    ]. Dexrazoxane was administered intravenously as three one- to two-hour infusions through a different venous access location, with the first dose given within six hours of the actual extravasation, and subsequent doses administered 24 and 48 hours after extravasation. The first and second doses were 1000",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    and the third dose was 500",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    up to maximum total doses of 2000, 2000, and 1000 mg, respectively.",
"   </p>",
"   <p>",
"    Extravasation was confirmed by fluorescence microscopy of a biopsy specimen in 54 cases. Only one patient (2 percent) who received therapy within six hours after the event required surgical debridement. The most frequent sequelae of the extravasations were mild pain and sensory disturbances (19 and 17 percent, respectively). Chemotherapy was able to be continued without interruption in 71 percent of cases.",
"   </p>",
"   <p>",
"    Based upon these results,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/28/30150?source=see_link\">",
"     dexrazoxane",
"    </a>",
"    has been approved by both the European Agency for the Evaluation of Medicinal Products (EMA) and the United States Food and Drug Administration for the treatment of anthracycline extravasation injury.",
"   </p>",
"   <p>",
"    Extravasation of liposomal anthracycline preparations (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/15/43254?source=see_link\">",
"     daunorubicin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    ) is generally not associated with necrotic injury [",
"    <a class=\"abstract\" href=\"UTD.htm?0/13/218/abstract/68,69\">",
"     68,69",
"    </a>",
"    ]. Application of ice alone to reduce local inflammation (and avoidance of DMSO) is recommended (",
"    <a class=\"graphic graphic_table graphicRef67155 \" href=\"UTD.htm?25/57/26525\">",
"     table 3",
"    </a>",
"    ). However, for the rare patient who develops symptomatic extravasation of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/13/10458?source=see_link\">",
"     liposomal doxorubicin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/28/30150?source=see_link\">",
"     dexrazoxane",
"    </a>",
"    may be beneficial [",
"    <a class=\"abstract\" href=\"UTD.htm?0/13/218/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Corticosteroids",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with anthracycline extravasation, systemic, subcutaneous, and intradermal administration of corticosteroids at the extravasation site have all been recommended, although whether there is benefit for this approach is unclear. Interpretation of the published literature is confounded by variability in dose and duration of therapy, route of administration, and outcome measurement [",
"    <a class=\"abstract\" href=\"UTD.htm?0/13/218/abstract/23\">",
"     23",
"    </a>",
"    ]. Corticosteroids are presumed to reduce local inflammation, although it has never been shown that tissue damage from vesicant extravasation is the result of an inflammatory process.",
"   </p>",
"   <p>",
"    The lack of consensus on the benefit of corticosteroids for anthracycline extravasation is illustrated by the fact that product labeling information from two of three suppliers of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    , as well as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/15/43254?source=see_link\">",
"     daunorubicin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/43/40630?source=see_link\">",
"     idarubicin",
"    </a>",
"    , do not recommend corticosteroids as a component of extravasation management. Recommendations from the Oncology Nursing Society (ONS) and the European Oncology Nurses Society (EONS) also do not advocate the use of corticosteroids [",
"    <a class=\"abstract\" href=\"UTD.htm?0/13/218/abstract/20,34\">",
"     20,34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One circumstance where oral corticosteroids may be of benefit is in patients who have extravasated large amounts of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    . In one series of five such patients, the early administration of high-dose oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    (8 mg twice daily for up to 14 days) appeared to have a beneficial effect on the severity and clinical course of the inflammatory reaction [",
"    <a class=\"abstract\" href=\"UTD.htm?0/13/218/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Corticosteroids may worsen the skin damage from",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    or vinca alkaloids, and they are specifically contraindicated in these situations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Surgical intervention",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonhealing ulcers resulting from an extravasation injury often require debridement and skin grafting. However, the optimal timing of surgical intervention is controversial.",
"   </p>",
"   <p>",
"    There are no uniform guidelines for the surgical treatment of extravasation injuries Guidelines from the ONS do not address indications for surgical management [",
"    <a class=\"abstract\" href=\"UTD.htm?0/13/218/abstract/20\">",
"     20",
"    </a>",
"    ]. While guidelines from the EONS recommend surgical debridement for unresolved tissue necrosis or pain lasting more than 10 days [",
"    <a class=\"abstract\" href=\"UTD.htm?0/13/218/abstract/34\">",
"     34",
"    </a>",
"    ], whether surgical intervention is indicated in the presence of normal-looking skin if the patient is complaining of persistent pain in the area is unclear. &nbsp;",
"   </p>",
"   <p>",
"    Although some clinicians suggest early surgical intervention to prevent ulceration [",
"    <a class=\"abstract\" href=\"UTD.htm?0/13/218/abstract/27\">",
"     27",
"    </a>",
"    ], a conservative approach is more often recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?0/13/218/abstract/38,71-75\">",
"     38,71-75",
"    </a>",
"    ], particularly since fewer than one-third of vesicant extravasations ultimately result in ulceration. Failure of initial conservative management with continued erythema, swelling and pain, or the presence of large areas of tissue necrosis or skin ulceration are indications for surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?0/13/218/abstract/71,76\">",
"     71,76",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Early debridement has been recommended for anthracycline extravasations, since these agents bind to fat [",
"    <a class=\"abstract\" href=\"UTD.htm?0/13/218/abstract/77\">",
"     77",
"    </a>",
"    ]. This recommendation was based upon a series of three cases in which delayed surgical care resulted in a poor functional outcome, and it predated the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/28/30150?source=see_link\">",
"     dexrazoxane",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H75722763\">",
"    <span class=\"h3\">",
"     Issues unique to central venous access device extravasation",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are only case report data regarding the evolution and management of extravasation through a CVAD. The diagnosis may be confirmed by imaging, typically with a thoracic CT.",
"   </p>",
"   <p>",
"    Management should include stopping the infusion, and aspirating through the CVAD catheter of as much of the solution as possible. If the extravasated agent is an anthracycline, intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/28/30150?source=see_link\">",
"     dexrazoxane",
"    </a>",
"    could be considered as an antidote. The utility of local antidotes (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/33/42512?source=see_link\">",
"     hyaluronidase",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/18/17700?source=see_link\">",
"     sodium thiosulfate",
"    </a>",
"    ) is unclear, and their use is not recommended in guidelines from the EONS [",
"    <a class=\"abstract\" href=\"UTD.htm?0/13/218/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A CT scan should be obtained; catheter tip migration through the superior vena cava or atrium is a surgical emergency, and requires immediate operation. If there is no evidence of suppurative mediastinitis, one would assume that the process is sterile and, therefore, conservative management is reasonable. Indications for operative intervention (debridement of all necrotic material, with the establishment of drainage and antibiotic therapy) include failure of response to",
"    <span class=\"nowrap\">",
"     conservative/supportive",
"    </span>",
"    treatment, as indicated by the development of sepsis, progression of the radiographic abnormalities concurrent with clinical deterioration, and clinical deterioration in the setting of a collection or necrotic area &ndash; even if it appears &ldquo;improved&rdquo; on radiographic imaging.",
"   </p>",
"   <p>",
"    The only data on surgical intervention for extravasation from CVAD come from published case reports [",
"    <a class=\"abstract\" href=\"UTD.htm?0/13/218/abstract/17,35,78-81\">",
"     17,35,78-81",
"    </a>",
"    ]. EONS guidelines recommend immediate surgical consultation with consideration of thoracentesis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    chest tube placement if the extravasation is into the pleura, thoracoscopy or thoracotomy for an extravasation into the mediastinum, and surgical drainage of the accumulated solution in the case of a subcutaneous fluid collection [",
"    <a class=\"abstract\" href=\"UTD.htm?0/13/218/abstract/34\">",
"     34",
"    </a>",
"    ]. However, cases of mediastinal extravasation of anthracyclines have resolved with conservative therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?0/13/218/abstract/81,82\">",
"     81,82",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Proper infusion technique is the most important component of preventing extravasation injury from chemotherapy and other non-neoplastic vesicants (see",
"      <a class=\"local\" href=\"#H5\">",
"       'Prevention'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      If an extravasation of a vesicant agent is suspected, initial management should focus on minimizing the extent of drug extravasation (see",
"      <a class=\"local\" href=\"#H7\">",
"       'Initial management'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Stop the infusion immediately. Do not flush the line, and avoid applying pressure to the extravasated site.",
"     </li>",
"     <li>",
"      Elevate the affected extremity.",
"     </li>",
"     <li>",
"      The",
"      <span class=\"nowrap\">",
"       catheter/needle",
"      </span>",
"      should",
"      <strong>",
"       not",
"      </strong>",
"      be removed immediately. Instead, it should be left in place to attempt to aspirate fluid from the extravasated area and to facilitate the administration of an antidote to the local area, if appropriate (see below).",
"     </li>",
"     <li>",
"      If an antidote will not be injected into the extravasation site, the",
"      <span class=\"nowrap\">",
"       catheter/needle",
"      </span>",
"      can be removed after attempted aspiration of the subcutaneous tissues.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For extravasations of vesicant agents other than the vinca alkaloids and epipodophyllotoxins, we suggest the topical application of cold (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      )&nbsp;(",
"      <a class=\"graphic graphic_table graphicRef67155 \" href=\"UTD.htm?25/57/26525\">",
"       table 3",
"      </a>",
"      ). For the vinca alkaloids and epipodophyllotoxins, we suggest the application of heat rather than cold (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Application of heat or cold'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For extravasation of anthracyclines that have a high likelihood of producing tissue ulceration, we recommend the systemic administration of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/28/30150?source=see_link\">",
"       dexrazoxane",
"      </a>",
"      &nbsp;(",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Liposomal anthracyclines are generally not associated with necrotic injury, and treatment with dexrazoxane is not indicated in this situation, except in the rare situation of a symptomatic extravasation. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Dexrazoxane'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For extravasations of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/11/2233?source=see_link\">",
"       oxaliplatin",
"      </a>",
"      , we suggest the administration of high doses oral corticosteroids (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      8 mg twice daily for up to 14 days) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Corticosteroids'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For extravasation of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/57/40853?source=see_link\">",
"       mechlorethamine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/20/32071?source=see_link\">",
"       bendamustine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/49/4887?source=see_link\">",
"       dacarbazine",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      , we suggest local injection of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/18/17700?source=see_link\">",
"       sodium thiosulfate",
"      </a>",
"      &nbsp;(",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Sodium thiosulfate'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For extravasations of vinca alkaloids,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"       paclitaxel",
"      </a>",
"      , epipodophyllotoxins, and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/25/38297?source=see_link\">",
"       ifosfamide",
"      </a>",
"      , we suggest local injection of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/33/42512?source=see_link\">",
"       hyaluronidase",
"      </a>",
"      &nbsp;(",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Hyaluronidase'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The optimal approach to local therapy for extravasation of non-neoplastic vesicants is unclear, and there are no guidelines. While the available data are limited to case reports with a few drugs (ie,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/36/1608?source=see_link\">",
"       nafcillin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/48/35594?source=see_link\">",
"       phenytoin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?3/42/3752?source=see_link\">",
"       mannitol",
"      </a>",
"      , high concentrations of dextrose), local injection of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/33/42512?source=see_link\">",
"       hyaluronidase",
"      </a>",
"      represents a reasonable approach.",
"     </li>",
"     <li>",
"      There are no uniform guidelines for the surgical treatment of extravasation injuries; failure of initial conservative management with continued erythema, swelling and pain or the presence of large areas of tissue necrosis or skin ulceration are indications for surgical management. For central venous access device extravasations, CT scanning and surgical consultation is indicated, although no specific plan of treatment has been supported through published studies. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Surgical intervention'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Fischer D, Knobf M, Durivage H. The Cancer Chemotherapy Handbook, Mosby, 1997. p.514.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/13/218/abstract/2\">",
"      Barlock AL, Howser DM, Hubbard SM. Nursing management of adriamycin extravasation. Am J Nurs 1979; 79:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/13/218/abstract/3\">",
"      Langstein HN, Duman H, Seelig D, et al. Retrospective study of the management of chemotherapeutic extravasation injury. Ann Plast Surg 2002; 49:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/13/218/abstract/4\">",
"      Biffi R, Pozzi S, Agazzi A, et al. Use of totally implantable central venous access ports for high-dose chemotherapy and peripheral blood stem cell transplantation: results of a monocentre series of 376 patients. Ann Oncol 2004; 15:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/13/218/abstract/5\">",
"      Yildizeli B, La&ccedil;in T, Batirel HF, Y&uuml;ksel M. Complications and management of long-term central venous access catheters and ports. J Vasc Access 2004; 5:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/13/218/abstract/6\">",
"      Narducci F, Jean-Laurent M, Boulanger L, et al. Totally implantable venous access port systems and risk factors for complications: a one-year prospective study in a cancer centre. Eur J Surg Oncol 2011; 37:913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/13/218/abstract/7\">",
"      Goolsby TV, Lombardo FA. Extravasation of chemotherapeutic agents: prevention and treatment. Semin Oncol 2006; 33:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/13/218/abstract/8\">",
"      Schulmeister L. Extravasation management: clinical update. Semin Oncol Nurs 2011; 27:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/13/218/abstract/9\">",
"      Doellman D, Hadaway L, Bowe-Geddes LA, et al. Infiltration and extravasation: update on prevention and management. J Infus Nurs 2009; 32:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/13/218/abstract/10\">",
"      Sauerland C, Engelking C, Wickham R, Corbi D. Vesicant extravasation part I: Mechanisms, pathogenesis, and nursing care to reduce risk. Oncol Nurs Forum 2006; 33:1134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/13/218/abstract/11\">",
"      Schulmeister L, Camp-Sorrell D. Chemotherapy extravasation from implanted ports. Oncol Nurs Forum 2000; 27:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/13/218/abstract/12\">",
"      Baur M, Kienzer HR, Rath T, Dittrich C. Extravasation of Oxaliplatin (Eloxatin((R))) - Clinical Course. Onkologie 2000; 23:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/13/218/abstract/13\">",
"      Foo KF, Michael M, Toner G, Zalcberg J. A case report of oxaliplatin extravasation. Ann Oncol 2003; 14:961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/13/218/abstract/14\">",
"      Kretzschmar A, Pink D, Thuss-Patience P, et al. Extravasations of oxaliplatin. J Clin Oncol 2003; 21:4068.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/13/218/abstract/15\">",
"      Stanford BL, Hardwicke F. A review of clinical experience with paclitaxel extravasations. Support Care Cancer 2003; 11:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/13/218/abstract/16\">",
"      Bicher A, Levenback C, Burke TW, et al. Infusion site soft-tissue injury after paclitaxel administration. Cancer 1995; 76:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/13/218/abstract/17\">",
"      Barutca S, Kadikoylu G, Bolaman Z, et al. Extravasation of paclitaxel into breast tissue from central catheter port. Support Care Cancer 2002; 10:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/13/218/abstract/18\">",
"      Ajani JA, Dodd LG, Daugherty K, et al. Taxol-induced soft-tissue injury secondary to extravasation: characterization by histopathology and clinical course. J Natl Cancer Inst 1994; 86:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/13/218/abstract/19\">",
"      Herrington JD, Figueroa JA. Severe necrosis due to paclitaxel extravasation. Pharmacotherapy 1997; 17:163.",
"     </a>",
"    </li>",
"    <li>",
"     Polovich M, Whitford JM, Olsen M. Chemotherapy and biotherapy guidelines and recommendations for practice, 3rd ed, Oncology Nursing Society, Pittsburgh, PA, 2009. Section V: Immediate Complications of cytotoxic therapy, p 105.  A summary of the  guidelines is available online at file://www.ons.org/about/FAQ/Clinical/#extravasation (Accessed on July 06, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/13/218/abstract/21\">",
"      Luke E. Mitoxantrone-induced extravasation. Oncol Nurs Forum 2005; 32:27.",
"     </a>",
"    </li>",
"    <li>",
"     US FDA-approved manufacturer's approved labeling available online at file://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=39d53698-57fa-7c99-fc5b-f52a55684826 (Accessed on October 16, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/13/218/abstract/23\">",
"      Susser WS, Whitaker-Worth DL, Grant-Kels JM. Mucocutaneous reactions to chemotherapy. J Am Acad Dermatol 1999; 40:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/13/218/abstract/24\">",
"      Usuki A, Funasaka Y, Oka M, Ichihashi M. Tegafur-induced photosensitivity--evaluation of provocation by UVB irradiation. Int J Dermatol 1997; 36:604.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.bardaccess.com/assets/pdfs/other/MC-0086-00_Irritants_Vesicants_QRG_Web.pdf (Accessed on October 16, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/13/218/abstract/26\">",
"      Wang CL, Cohan RH, Ellis JH, et al. Frequency, management, and outcome of extravasation of nonionic iodinated contrast medium in 69,657 intravenous injections. Radiology 2007; 243:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/13/218/abstract/27\">",
"      Loth TS, Eversmann WW Jr. Treatment methods for extravasations of chemotherapeutic agents: a comparative study. J Hand Surg Am 1986; 11:388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/13/218/abstract/28\">",
"      Shapiro J, Richardson GE. Paclitaxel-induced \"recall\" soft tissue injury occurring at the site of previous extravasation with subsequent intravenous treatment in a different limb. J Clin Oncol 1994; 12:2237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/13/218/abstract/29\">",
"      Meehan JL, Sporn JR. Case report of Taxol administration via central vein producing a recall reaction at a site of prior Taxol extravasation. J Natl Cancer Inst 1994; 86:1250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/13/218/abstract/30\">",
"      du Bois A, Kommoss FG, Pfisterer J, et al. Paclitaxel-induced \"recall\" soft tissue ulcerations occurring at the site of previous subcutaneous administration of paclitaxel in low doses. Gynecol Oncol 1996; 60:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/13/218/abstract/31\">",
"      Valencak J, Troch M, Raderer M. Cutaneous recall phenomenon at the site of previous doxorubicin extravasation after second-line chemotherapy. J Natl Cancer Inst 2007; 99:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/13/218/abstract/32\">",
"      Saini A, Berruti A, Sperone P, et al. Recall inflammatory skin reaction after use of pegylated liposomal doxorubicin in site of previous drug extravasation. Lancet Oncol 2006; 7:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/13/218/abstract/33\">",
"      Wilson J, Carder P, Gooi J, Nishikawa H. Recall phenomenon following epirubicin. Clin Oncol (R Coll Radiol) 1999; 11:424.",
"     </a>",
"    </li>",
"    <li>",
"     Perez Fidalgo JA, Garcia Fabregat L, Cervantes A, et al. Management of chemotherapy extravasation: ESMO-EONS Clinical Practice Guidelines. Ann Oncol 2012; 23(7 Suppl): vii167.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/13/218/abstract/35\">",
"      Bozkurt AK, Uzel B, Akman C, et al. Intrathoracic extravasation of antineoplastic agents: case report and systematic review. Am J Clin Oncol 2003; 26:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/13/218/abstract/36\">",
"      Brothers TE, Von Moll LK, Niederhuber JE, et al. Experience with subcutaneous infusion ports in three hundred patients. Surg Gynecol Obstet 1988; 166:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/13/218/abstract/37\">",
"      Wickham R, Engelking C, Sauerland C, Corbi D. Vesicant extravasation part II: Evidence-based management and continuing controversies. Oncol Nurs Forum 2006; 33:1143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/13/218/abstract/38\">",
"      Cox K, Stuart-Harris R, Abdini G, et al. The management of cytotoxic-drug extravasation: guide-lines drawn up by a working party for the Clinical Oncological Society of Australia. Med J Aust 1988; 148:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/13/218/abstract/39\">",
"      Albanell J, Baselga J. Systemic therapy emergencies. Semin Oncol 2000; 27:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/13/218/abstract/40\">",
"      Bertelli G. Prevention and management of extravasation of cytotoxic drugs. Drug Saf 1995; 12:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/13/218/abstract/41\">",
"      Larson DL. What is the appropriate management of tissue extravasation by antitumor agents? Plast Reconstr Surg 1985; 75:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/13/218/abstract/42\">",
"      Dorr RT, Alberts DS. Vinca alkaloid skin toxicity: antidote and drug disposition studies in the mouse. J Natl Cancer Inst 1985; 74:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/13/218/abstract/43\">",
"      Ascherman JA, Knowles SL, Attkiss K. Docetaxel (taxotere) extravasation: a report of five cases with treatment recommendations. Ann Plast Surg 2000; 45:438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/13/218/abstract/44\">",
"      Theman TA, Hartzell TL, Sinha I, et al. Recognition of a new chemotherapeutic vesicant: trabectedin (ecteinascidin-743) extravasation with skin and soft tissue damage. J Clin Oncol 2009; 27:e198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/13/218/abstract/45\">",
"      Tsavaris NB, Komitsopoulou P, Karagiaouris P, et al. Prevention of tissue necrosis due to accidental extravasation of cytostatic drugs by a conservative approach. Cancer Chemother Pharmacol 1992; 30:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/13/218/abstract/46\">",
"      BONADONNA G, KARNOFSKY DA. PROTECTION STUDIES WITH SODIUM THIOSULFATE AGAINST METHYL BIS (BETA-CHLOROETHYL)AMINE HYDROCHLORIDE (HN2) AND ITS ETHYLENIMONIUM DERIVATIVE. Clin Pharmacol Ther 1965; 6:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/13/218/abstract/47\">",
"      LAWRENCE W Jr, TAYAO MS, MAHAJAN RD, et al. SYSTEMIC THIOSULFATE PROTECTION DURING FRACTIONATED REGIONAL NITROGEN MUSTARD THERAPY. J Surg Res 1964; 4:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/13/218/abstract/48\">",
"      Dorr RT, Soble M, Alberts DS. Efficacy of sodium thiosulfate as a local antidote to mechlorethamine skin toxicity in the mouse. Cancer Chemother Pharmacol 1988; 22:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/13/218/abstract/49\">",
"      HATIBOGLU I, MIHICH E, MOORE GE, NICHOL CA. Use of sodium thiosulfate as a neutralizing agent during regional administration of nitrogen mustard: an experimental study. Ann Surg 1962; 156:994.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/13/218/abstract/50\">",
"      Dorr RT, Alberts DS, Einspahr J, et al. Experimental dacarbazine antitumor activity and skin toxicity in relation to light exposure and pharmacologic antidotes. Cancer Treat Rep 1987; 71:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/13/218/abstract/51\">",
"      Owen OE, Dellatorre DL, Van Scott EJ, Cohen MR. Accidental intramuscular injection of mechlorethamine. Cancer 1980; 45:2225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/13/218/abstract/52\">",
"      Sokol DK, Dahlmann A, Dunn DW. Hyaluronidase treatment for intravenous phenytoin extravasation. J Child Neurol 1998; 13:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/13/218/abstract/53\">",
"      Zenk KE, Dungy CI, Greene GR. Nafcillin extravasation injury. Use of hyaluronidase as an antidote. Am J Dis Child 1981; 135:1113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/13/218/abstract/54\">",
"      Bertelli G, Dini D, Forno GB, et al. Hyaluronidase as an antidote to extravasation of Vinca alkaloids: clinical results. J Cancer Res Clin Oncol 1994; 120:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/13/218/abstract/55\">",
"      Cicchetti S, Jemec B, Gault DT. Two case reports of vinorelbine extravasation: management and review of the literature. Tumori 2000; 86:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/13/218/abstract/56\">",
"      Kumar MM, Sprung J. The use of hyaluronidase to treat mannitol extravasation. Anesth Analg 2003; 97:1199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/13/218/abstract/57\">",
"      Wiegand R, Brown J. Hyaluronidase for the management of dextrose extravasation. Am J Emerg Med 2010; 28:257.e1.",
"     </a>",
"    </li>",
"    <li>",
"     U.S. Food and Drug Administration. www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Overview&amp;DrugName=VITRASE (Accessed on July 18, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/13/218/abstract/59\">",
"      Bertelli G, Gozza A, Forno GB, et al. Topical dimethylsulfoxide for the prevention of soft tissue injury after extravasation of vesicant cytotoxic drugs: a prospective clinical study. J Clin Oncol 1995; 13:2851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/13/218/abstract/60\">",
"      Olver IN, Aisner J, Hament A, et al. A prospective study of topical dimethyl sulfoxide for treating anthracycline extravasation. J Clin Oncol 1988; 6:1732.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/13/218/abstract/61\">",
"      Monstrey SJ, Mullick P, Narayanan K, Ramasastry SS. Hyperbaric oxygen therapy and free radical production: an experimental study in doxorubicin (Adriamycin) extravasation injuries. Ann Plast Surg 1997; 38:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/13/218/abstract/62\">",
"      Averbuch SD, Boldt M, Gaudiano G, et al. Experimental chemotherapy-induced skin necrosis in swine. Mechanistic studies of anthracycline antibiotic toxicity and protection with a radical dimer compound. J Clin Invest 1988; 81:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/13/218/abstract/63\">",
"      Langer SW, Sehested M, Jensen PB. Dexrazoxane is a potent and specific inhibitor of anthracycline induced subcutaneous lesions in mice. Ann Oncol 2001; 12:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/13/218/abstract/64\">",
"      Jensen JN, Lock-Andersen J, Langer SW, Mejer J. Dexrazoxane-a promising antidote in the treatment of accidental extravasation of anthracyclines. Scand J Plast Reconstr Surg Hand Surg 2003; 37:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/13/218/abstract/65\">",
"      Langer SW, Sehested M, Jensen PB. Treatment of anthracycline extravasation with dexrazoxane. Clin Cancer Res 2000; 6:3680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/13/218/abstract/66\">",
"      Langer SW, Sehested M, Jensen PB, et al. Dexrazoxane in anthracycline extravasation. J Clin Oncol 2000; 18:3064.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/13/218/abstract/67\">",
"      Mouridsen HT, Langer SW, Buter J, et al. Treatment of anthracycline extravasation with Savene (dexrazoxane): results from two prospective clinical multicentre studies. Ann Oncol 2007; 18:546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/13/218/abstract/68\">",
"      Madhavan S, Northfelt DW. Lack of vesicant injury following extravasation of liposomal doxorubicin. J Natl Cancer Inst 1995; 87:1556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/13/218/abstract/69\">",
"      Curtit E, Chaigneau L, Pauchot J, et al. Extravasation of liposomal doxorubicin induces irritant reaction without vesicant injury. Anticancer Res 2012; 32:1481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/13/218/abstract/70\">",
"      Vos FY, Lesterhuis WJ, Br&uuml;ggemann RJ, Graaf WT. Recovery of symptomatic extravasation of liposomal doxorubicin after dexrazoxane treatment. Anticancer Drugs 2012; 23:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/13/218/abstract/71\">",
"      Larson DL. Treatment of tissue extravasation by antitumor agents. Cancer 1982; 49:1796.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/13/218/abstract/72\">",
"      Rudolph R, Larson DL. Etiology and treatment of chemotherapeutic agent extravasation injuries: a review. J Clin Oncol 1987; 5:1116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/13/218/abstract/73\">",
"      Boyle DM, Engelking C. Vesicant extravasation: myths and realities. Oncol Nurs Forum 1995; 22:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/13/218/abstract/74\">",
"      Scuderi N, Onesti MG. Antitumor agents: extravasation, management, and surgical treatment. Ann Plast Surg 1994; 32:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/13/218/abstract/75\">",
"      Heckler FR. Current thoughts on extravasation injuries. Clin Plast Surg 1989; 16:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/13/218/abstract/76\">",
"      Dorr RT. Antidotes to vesicant chemotherapy extravasations. Blood Rev 1990; 4:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/13/218/abstract/77\">",
"      Heitmann C, Durmus C, Ingianni G. Surgical management after doxorubicin and epirubicin extravasation. J Hand Surg Br 1998; 23:666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/13/218/abstract/78\">",
"      Uges JW, Vollaard AM, Wilms EB, Brouwer RE. Intrapleural extravasation of epirubicin, 5-fluouracil, and cyclophosphamide, treated with dexrazoxane. Int J Clin Oncol 2006; 11:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/13/218/abstract/79\">",
"      D&uuml;hrsen U, Heinrichs V, Beecken WD, et al. Local and systemic sequelae of mediastinal daunorubicin extravasation in a patient with acute myelomonocytic leukemia. Ann Oncol 1997; 8:1167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/13/218/abstract/80\">",
"      Anderson CM, Walters RS, Hortobagyi GN. Mediastinitis related to probable central vinblastine extravasation in a woman undergoing adjuvant chemotherapy for early breast cancer. Am J Clin Oncol 1996; 19:566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/13/218/abstract/81\">",
"      Rodier JM, Malbec L, Lauraine EP, et al. Mediastinal infusion of epirubicin and 5-fluorouracil. A complication of totally implantable central venous systems. Report of a case. J Cancer Res Clin Oncol 1996; 122:566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/13/218/abstract/82\">",
"      Quintanar Verd&uacute;guez T, Blanco Jarava A, Mart&iacute;nez-Barbeito MB, et al. Mediastinal extravasation of doxorubicin. Clin Transl Oncol 2008; 10:128.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2797 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-122.72.76.133-FE8AB3007C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_13_218=[""].join("\n");
var outline_f0_13_218=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1420806\">",
"      INCIDENCE AND RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      IRRITANTS VERSUS VESICANT DRUGS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9997343\">",
"      Antineoplastic agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9997351\">",
"      Non-antineoplastic agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H75722605\">",
"      Central venous access device extravasation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Initial management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Application of heat or cold",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Specific antidotes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Sodium thiosulfate",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Hyaluronidase",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - DMSO",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Dexrazoxane",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Corticosteroids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Surgical intervention",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H75722763\">",
"      - Issues unique to central venous access device extravasation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/2797\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2797|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?5/53/5981\" title=\"table 1\">",
"      Antineoplastic drugs that act as vesicants or irritants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?25/63/26622\" title=\"table 2\">",
"      Non-antineoplastic drugs that act as vesicants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?25/57/26525\" title=\"table 3\">",
"      Rx cytotoxic drug extravasation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/7/36986?source=related_link\">",
"      Cutaneous complications of conventional chemotherapy agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/1/33817?source=related_link\">",
"      Prevention and treatment of lymphedema",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f0_13_219="Confirmed targets autoantibodies T1 DM";
var content_f0_13_219=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F69086&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F69086&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Confirmed targets of autoantibodies in type 1 diabetes of man",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Insulin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Glutamic acid decarboxylase",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Insulinoma associated antigens 2 (alpha and beta)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        ZnT8 (zinc transporter)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_13_219=[""].join("\n");
var outline_f0_13_219=null;
var title_f0_13_220="Contributors major depression";
var content_f0_13_220=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F52373&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F52373&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    General medical conditions causing or contributing to major depression ('Secondary Depression')",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Drugs and Poisons",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Alcohol, beta blockers, steroids, opiates, barbiturates, withdrawal from cocaine and  amphetamines, heavy metal poisoning, cholinesterase inhibitors, cimetidine, chemotherapy agents",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Metabolic/Endocrine",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Hyper and hypothyroidism, severe anemia, hyperparathyroidism, hypokalemia, hyponatremia, Cushing's disease, Addison's disease, uremia, hypopituitarism, porphyria, Wilson's Disease, Wernicke-Korsakoff's syndrome",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Infectious Diseases",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Tuberculosis, Epstein-Barr infection, HIV, pneumonia, postinfluenza, tertiary syphilis, encephalitis, and post-encephalitic states",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Neurodegenerative and Demyelinating Diseases",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Alzheimer disease, multiple sclerosis, Parkinson disease, Huntington's disease",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Other Neurologic",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Subdural hematoma, normal pressure hydrocephalus, strokes, post-traumatic brain injury syndromes, cerebral tumors",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Neoplasia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Carcinomatosis, cancers of the pancreas, lung, breast, and others",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Others",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Systemic lupus erythematosus, other collagen vascular disorders, other chronic inflammatory or auto-immune disorders, heart failure",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Privitera, MR, Lyness, JM. Depression. In: The Practice of Geriatrics, 4th ed, Duthie, E Jr, Katz, PR, Malone, ML (Eds), W.B. Saunders, 2007. Copyright &copy; 2007 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_13_220=[""].join("\n");
var outline_f0_13_220=null;
var title_f0_13_221="Ingredient label terms for tree nut";
var content_f0_13_221=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F56449&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F56449&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    How to read an ingredient label for a tree nut-free diet",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Avoid foods that contain nuts or any of these ingredients:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Almond",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Artificial nuts",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Beechnut",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Brazil nut",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Butternut",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cashew",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chestnut",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chinquapin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Coconut",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Filbert/hazelnut",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gianduja (a chocolate-nut mixture)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ginkgo nut",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hickory nut",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Litchi/lichee/lychee nut",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Macadamia nut",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Marzipan/almond paste",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nangai nut",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Natural nut extract (eg, almond, walnut)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nut butters (eg, cashew butter)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nut meal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nut meat",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nut paste (eg, almond paste)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nut pieces",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pecan",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pesto",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pili nut",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pine nut (also referred to as Indian, pignoli, pig&ntilde;olia, pignon, pi&ntilde;on, and pinyon nut)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pistachio",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Praline",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Shea nut",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Walnut",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Tree nuts are sometimes found in the following:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Black walnut hull extract (flavoring)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Natural nut extract",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nut distillates/alcoholic extracts",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nut oils (eg, walnut oil, almond oil)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Walnut hull extract (flavoring)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Keep the following in mind:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Mortadella may contain pistachios.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; There is no evidence that coconut oil and shea nut oil/butter are allergenic.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Many experts advise patients allergic to tree nuts to avoid peanuts as well.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Talk to your doctor if you find other nuts not listed here.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    All FDA-regulated manufactured food products that contain a tree nut as an ingredient are required by US law to list the specific tree nut on the product label.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Copyright &copy; 2010 The Food Allergy &amp; Anaphylaxis Network. Used with permission.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_13_221=[""].join("\n");
var outline_f0_13_221=null;
var title_f0_13_222="Comb chemo rhabdomyosarcoma";
var content_f0_13_222=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F53178&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F53178&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Current standard chemotherapy regimens for newly diagnosed patients with rhabdomyosarcoma",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Prognosis group*",
"       </td>",
"       <td class=\"subtitle1\">",
"        Definition",
"       </td>",
"       <td class=\"subtitle1\">",
"        Regimen",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dose",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td class=\"subtitle1\">",
"        Schedule",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"3\">",
"        Low risk - Excellent prognosis",
"       </td>",
"       <td class=\"sublist1_start\" rowspan=\"3\">",
"        <p>",
"         Embryonal tumors:",
"        </p>",
"        <p>",
"         - Stage 1 Group I",
"        </p>",
"        <p>",
"         - Stage 1 Group II",
"        </p>",
"        <p>",
"         - Stage 1 Group III orbital",
"        </p>",
"        <p>",
"         - Stage 2 Group I/II",
"        </p>",
"       </td>",
"       <td class=\"sublist1_start\" colspan=\"3\">",
"        VA x one year",
"        <sup>",
"         [1]",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Vincristine",
"       </td>",
"       <td class=\"sublist_other\">",
"        1.5 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        (max 2 mg)",
"       </td>",
"       <td class=\"sublist_other\">",
"        Weekly during weeks 0-8, 12-20, 24-32, 36-44",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Dactinomycin",
"       </td>",
"       <td class=\"sublist_other\">",
"        0.045 mg/kg (max 2.5 mg)",
"       </td>",
"       <td class=\"sublist_other\">",
"        Every three weeks during weeks 0 through 45",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"4\">",
"        Low risk - Good prognosis",
"       </td>",
"       <td class=\"sublist1_start\" rowspan=\"4\">",
"        <p>",
"         Embryonal tumors:",
"        </p>",
"        <p>",
"         - Stage 1 Group III non orbit",
"        </p>",
"        <p>",
"         - Stage 3 Group I/II",
"        </p>",
"       </td>",
"       <td class=\"sublist1_start\" colspan=\"3\">",
"        VAC x one year",
"        <sup>",
"         &Delta;",
"        </sup>",
"        <sup>",
"         [1,2]",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Vincristine",
"       </td>",
"       <td class=\"sublist_other\">",
"        1.5 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        (max 2 mg)",
"       </td>",
"       <td class=\"sublist_other\">",
"        Weekly during weeks 0-8, 12-20, 24-32, 36-44",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Dactinomycin",
"       </td>",
"       <td class=\"sublist_other\">",
"        0.045 mg/kg (max 2.5 mg)",
"       </td>",
"       <td class=\"sublist_other\">",
"        Every three weeks during weeks 0 through 45",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Cyclophosphamide",
"       </td>",
"       <td class=\"sublist_other\">",
"        1200 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        with MESNA and hematopoietic growth factor support",
"       </td>",
"       <td class=\"sublist_other\">",
"        Every three weeks during weeks 0 through 42",
"        <sup>",
"         &sect;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"4\">",
"        Intermediate risk - Good prognosis",
"       </td>",
"       <td class=\"sublist1_start\" rowspan=\"4\">",
"        <p>",
"         Embryonal tumors:",
"        </p>",
"        <p>",
"         - Stage 2, 3 Group III",
"        </p>",
"        <p>",
"         - Metastatic disease, age &lt;10",
"        </p>",
"        <p>",
"         - Aveolar tumors",
"        </p>",
"        <p>",
"         - Group I-III",
"        </p>",
"       </td>",
"       <td class=\"sublist1_start\" colspan=\"3\">",
"        VAC x one year",
"        <sup>",
"         [3]",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Vincristine",
"       </td>",
"       <td class=\"sublist_other\">",
"        1.5 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        (max 2 mg)",
"       </td>",
"       <td class=\"sublist_other\">",
"        Weekly during weeks 0-13, 16, 19-25, 28, 31-37, and 40",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Dactinomycin",
"       </td>",
"       <td class=\"sublist_other\">",
"        0.045 mg/kg (max 2.5 mg)",
"       </td>",
"       <td class=\"sublist_other\">",
"        Day 1 every three weeks during weeks 0 through 40",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Cyclophosphamide",
"       </td>",
"       <td class=\"sublist_other\">",
"        1200 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        with MESNA and hematopoietic growth factor support",
"       </td>",
"       <td class=\"sublist_other\">",
"        Day 1 every three weeks during weeks 0 through 40",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"4\">",
"        High risk - Poor prognosis",
"       </td>",
"       <td rowspan=\"4\">",
"        <p>",
"         Embryonal tumors:",
"        </p>",
"        <p>",
"         - Metastatic disease, age &gt;10",
"        </p>",
"        <p>",
"         - Aveolar tumors",
"        </p>",
"        <p>",
"         - Metastatic disease, any age",
"        </p>",
"       </td>",
"       <td class=\"sublist1_start\" colspan=\"3\">",
"        VAC x one year",
"        <sup>",
"         [3]",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Vincristine",
"       </td>",
"       <td class=\"sublist_other\">",
"        1.5 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        (max 2 mg)",
"       </td>",
"       <td class=\"sublist_other\">",
"        Weekly during weeks 0-13, 16, 19-25, 28, 31-37, and 40",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Dactinomycin",
"       </td>",
"       <td class=\"sublist_other\">",
"        0.045 mg/kg (max 2.5 mg)",
"       </td>",
"       <td class=\"sublist_other\">",
"        Day 1 every three weeks during weeks 0 through 40",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Cyclophosphamide",
"       </td>",
"       <td class=\"sublist_other\">",
"        1200 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        with MESNA and hematopoietic growth factor support",
"       </td>",
"       <td class=\"sublist_other\">",
"        Day 1 every three weeks during weeks 0 through 40",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    A pediatric oncologist with expertise in the soft tissue sarcoma field should be contacted for current standard therapy schemas.",
"    <div class=\"footnotes\">",
"     * See table titled \"Rhabdomyosarcoma prognostic stratification and standard treatment assignment\" for prognosis group definitions.",
"     <br>",
"      <span class=\"bullet\">",
"       &bull;",
"      </span>",
"      Doses are for adults and children over the age of three. Dose reductions are necessary for younger children.",
"      <br>",
"       &Delta; Lower doses of cyclophosphamide than were used in protocol D9602 (1200 mg/m",
"       <sup>",
"        2",
"       </sup>",
"       versus 2200 mg/m",
"       <sup>",
"        2",
"       </sup>",
"       ) supported by data from ARST 0331",
"       <sup>",
"        [2]",
"       </sup>",
"       .",
"       <br>",
"        <span class=\"lozenge\">",
"         &loz;",
"        </span>",
"        Omit dactinomycin on week 6 for patients beginning RT at week 3; weeks 15 and 18 for patients beginning RT at week 12; and weeks 30 and 33 for patients beginning RT at week 28.",
"        <br>",
"         &sect; No chemotherapy on week 21; on weeks 33 and 45, only dactinomycin is given.",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br>",
"      <ol>",
"       <li>",
"        J Clin Oncol 2011; 29:1312.",
"       </li>",
"       <li>",
"        J Clin Oncol 2011; 29:5895 (abstract 9516).",
"       </li>",
"       <li>",
"        VAC doses as used in the current Children's Oncology Group (COG) protocol for intermediate risk disease, ARST0531 (NCT00354835, file://cancer.gov/clinicaltrials/search/view?cdrid=487560&amp;version=healthprofessional).",
"       </li>",
"      </ol>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_13_222=[""].join("\n");
var outline_f0_13_222=null;
var title_f0_13_223="Ileocolic anastomosis and linear cutting stapler";
var content_f0_13_223=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F71016&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F71016&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Ileocolic functional end-to-end anastomosis and linear cutting stapler",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 377px; height: 370px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_13_223=[""].join("\n");
var outline_f0_13_223=null;
